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Abstract
Molecular self-assembly describes the assembly of molecular components into complex,
supramolecular structures governed by weak, non-covalent interactions. In recent years,
molecular self-assembly has been used extensively as a means of creating materials and devices
with well-controlled, nanometer-scale architectural features. In this thesis, molecular self-
assembly is used as a tool for the fabrication of both gene and drug delivery systems which, by
virtue of their well-controlled architectural features, possess advantageous properties relative to
traditional materials used in these applications.
The first part of this thesis describes the solution-phase self-assembly of a new family of
linear-dendritic "hybrid" polymers with plasmid DNA for applications in gene therapy. It begins
with an overview of the design of next-generation, non-viral gene delivery systems and continues
through the synthesis and validation of hybrid polymer systems, which possess modular
functionalities for DNA binding, endosomal escape, steric stabilization, and tissue targeting.
This part of the thesis concludes with applications of these systems to two areas of clinical
interest: DNA vaccination and tumor targeted gene therapy.
The second part of this thesis describes the directed self-assembly of polymeric thin films
which are capable of degrading in response to either passive or active stimuli to release their
contents. It begins with a description of passive release thin films which degrade by basic
hydrolysis to release precise quantities of model drug compounds. These systems can be
engineered to release their contents on time scales ranging from hours to weeks and can also be
designed to release multiple drugs either in series or in parallel. Later, field-activated thin films
which release their contents in response to an external, electrical stimulus are described and
characterized in detail. Together, these approaches combine rapid and inexpensive processing,
the ability to conformally coat any surface regardless of composition, size, or shape, and the
ability to release multi-drug or multi-dose schedules, and as such they may find applications in a
range of areas.
Thesis Supervisor: Paula T. Hammond
Bayer Professor of Chemical Engineering
Thesis Supervisor: Robert S. Langer
Institute Professor
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Chapter 1: Molecular self-assembly
1.1 Introduction
Self-assembly can be defined as the autonomous organization of discrete components
into structures or patterns without human intervention. ' 1,2 This general phenomenon occurs on
length scales ranging from molecular (i.e. crystals, vesicles) to planetary (i.e. weather systems)
and can be driven by a wide range of different physical interactions. In some cases, self-
assembly behavior can be governed entirely by properties such as the shape, size, charge, surface
characteristics, and polarity of constituent components; in other cases, external forces and fields
can also play a role. 1' 2 In recent years, self-assembly has been a topic of significant scientific
interest because of its pervasive role in nature and its expanding utility as a tool for developing
new technologies. -5
In nature, examples of the abundant materials and systems which exhibit self-assembly
behavior include atomic or molecular crystals2' 6, multi-protein complexes (i.e. organelles,
viruses), lipid membranes , bacterial colonies , and complex weather patterns 1,2 (Figure 1.1).
The interactions governing self-assembly processes in nature vary with respect to length scale.
Small-scale molecular self-assembly of crystals or protein complexes, for example, is governed
primarily by non-covalent interactions such as van der Waals forces, electrostatics, hydrophobic
interactions, hydrogen and coordination bonds. Self-assembly of larger components such as
macroscopic objects can also include gravitational attraction, external electromagnetic fields, and
magnetic, capillary, and entropic interactions.1, 2
(a) (b) (c)
(d) (e)
Figure 1.1. Examples of naturally-occurring materials and systems based on self-assembly.
(a) Crystalline calcite microlenses from brittlestars9; (b) Crystal structure of a ribosomelo;
(c) Micrograph of an individual influenza particle'; (d) A colony of Bacillus subtilis' 2;
(e) A school of fish'
1.2 Synthetic materials and devices based on self-assembly
Driven by an increasing need to produce materials and devices with small-scale, well-
controlled, and highly functional architectural features, engineers and scientists have begun to
use self-assembly as a powerful fabrication tool.1-5 Figure 1.2 provides examples of novel
materials constructed using the principles of engineering self-assembly, including nanoscale
tubes, fibers, and origami-like shapes as well as microscale folded polyhedra and arrayed or
aggregated colloids.
13-17
(a) (b) (c)
(d) (e) (f)
Figure 1.2. Examples of engineered materials based on self-assembly.
(a) Self-assembled peptide-amphiphile nanofibers'3 ; (b,c) Two-dimensional self-assembly of
DNA "origami" to form complex two-dimensional shapes 4; (d) Micrometer-scale folded
polyhedra15 ; (e) Templated patterning of colloids on a surface16 ; (f) Self-assembly of
colloids onto the interface of an emulsion droplet.17
Perhaps the most common approach to the design and fabrication of new materials based
on self-assembly involves so-called "molecular" self-assembly. As the name implies, molecular
self-assembly is the assembly of molecular components into complex, supramolecular
structures.1, 2, 4 This process is usually governed by weak, non-covalent interactions between
molecular components. The most significant (and common) applications of molecular self-
assembly involve the fabrication of small-scale, ordered structures whose sizes fall between
those that can be synthesized using traditional chemistry (individual molecules) and those that
ttl-
can be manipulated by conventional manufacturing (micrometer to millimeter length scales).
Unlike other approaches, self-assembly offers a clear route for assembling individual
components into functional ensembles whose sizes range from nano- to micrometers. Molecular
self-assembly frequently occurs both in solution and at interfaces (i.e. liquid-liquid, solid-liquid,
etc.), and in recent years has yielded a host of interesting new materials such as gels, thin films,
periodic two- and three-dimensional structures, and nanoscale wires, fibers, particles, and
devices.1-5
1.3 Gene and drug delivery systems based on molecular self-
assembly
The objective of the research described in this thesis is to use molecular self-assembly as
a tool to fabricate gene and drug delivery systems with controlled architectural features and, as a
consequence, new and advantageous properties. The first part of this thesis (Chapters 2-5)
describes the solution-phase self-assembly of a new family of linear-dendritic "hybrid" polymers
with plasmid DNA for applications in gene therapy. Chapters 2-3 describe the design,
fabrication, and in vitro validation of these systems, and Chapters 4-5 explore their application to
two distinct areas of interest in clinical medicine: DNA vaccination and tumor-targeted gene
therapy. The second part of this thesis (Chapters 6-9) describes the directed self-assembly of
polymeric thin films at a solid-liquid interface. The focus of this work, which is based on the
layer-by-layer (LbL) deposition technique, is to construct nanoscale polymeric architectures
capable of degrading in response to various stimuli to release their contents. In Chapter 6, an
overview of the LbL technique is offered. Chapters 7-8 describe the design, fabrication, and
testing of hydrolytically degradable thin films for the controlled release of one or more species.
Chapter 9 describes an alternative approach to the fabrication of degradable LbL structures based
on electroactive nanoparticles which trigger film degradation and drug release in response to an
electrical stimulus. Finally, Chapter 10 will provide a summary and recommendations for future
work based on findings in both parts of this thesis.
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Chapter 2: Designing systems for non-viral gene delivery
2.1 Gene therapy
Gene therapy is conventionally defined as the treatment of disease by introducing
exogenous genes, gene segments, or oligonucleotides to appropriate cells.1, 2 As such, gene
therapy aims for the transient or prolonged expression of a therapeutic or corrective gene product
in a target cell population. A range of therapeutic approaches for gene therapy have been
suggested, and include the expression of replacement genes for single genetic disorders,
apoptosis genes to prompt cell "suicide," protective genes for the production of proteins with
therapeutic utility (i.e., antiviral or antibacterial), and stimulatory genes for the elicitation of a
protective immune response (i.e., DNA vaccines).1, 2 Further, as our understanding of the genetic
and molecular basis of human disease continues to grow, the range of potential applications for
gene therapies will follow. Currently, clinical gene therapy trials are underway for illnesses
ranging from infectious 3 and cardiovascular4 diseases to cancer (see Table 2.1).5, 6 Ultimately, it
has been suggested that virtually all human diseases could one day be amenable to some form of
treatment using gene therapies.1, 2
Table 2.1. Gene therapy clinical trials by indication.
Reproduced with permission from [6].
Cancer diseases 67% (n=842)
* Vascular diseases 9% (n= 113)
* Monogenic diseases 8.4% (n=-106)
* Infectious diseases 6.4% (n=81)
Gene marking 4% {n=50)
Other diseases 3.7% (n=47)
Healthy volunteers 1.7% (n=21)
The Journal of Gene Medicine, i 2007 Jo)n Wiley and SoP s Ltd wwi wil-y cAk/genrmed/dinical
2.2 The gene delivery problem
Despite the great promise of gene therapy as a therapeutic strategy, no gene therapy
protocols have been approved by the US FDA for use in clinical settings.6-9 The most important
factor limiting the clinical application of gene therapy protocols is the lack of gene delivery
systems which are both safe and effective.7-9 Traditionally, two broad classes of delivery
vehicles ('vectors') have been used: viral and non-viral. Table 2.2 shows a breakdown of
worldwide clinical trials for gene therapies organized by delivery vector.6
Table 2.2. Gene therapy clinical trials by delivery vector.
Reproduced with permission from [6].
Adenovirus 26% (n=322)
* Retrovirus 23% (n=293)
* Naked/Plasmid DNA 18% (n=230)
* Lipofection 7.9% (n=99)
* Vaccinia virus 7% (n=88)
* Poxvirus 6.8% (n=85)
Adeno-associated virus 3.7% (n=46)
* Herpes simplex virus 3.4% (n=43)
* RNA transfer 1.3% (n= 16)
* Others 2.4% (n=31)
* Unknown 2.9% (n=36)
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2.2.1 Viral Gene Delivery Vectors
Viral vectors possess highly evolved functions for overcoming the various barriers to
gene transfer, and as a result typically yield high levels of both delivery and expression
(frequently greater than 90% for each). As a result, viruses have become the most common
vectors used in gene therapy research and clinical trials.6 Among the over 600 current clinical
trials, about 70% use recombinant viral vectors, including retroviruses, lentiviruses, adeno- and
adeno-associated viruses, herpes simplex, and combinations thereof.6' 10-16 However, viruses
have significant restrictions, including immunogenicity, high risk of insertional mutagenesis,
restricted cell targeting abilities, limited DNA carrying capacity, production problems, and high
cost. Collectively, these restrictions make current viral vectors unsuitable for clinical use.7-9
2.2.2 Non-Viral Gene Delivery Vectors
The term "non-viral" gene delivery system encompasses the wide range of approaches
that have been used to deliver nucleotide-based therapeutics without using viruses. Under this
heading, a suite of electrical17 and mechanicall8-21 methods have been explored; however, the
most common and versatile methods for overcoming the various biological barriers to gene
transfer without the deleterious side effects of viral vectors are through the use of chemical
methods. 9 The interest surrounding chemical gene delivery systems is based on the fact that they
are generally safer than their viral counterparts and allow for precise synthetic manipulation and
control. 7-9 The following paragraphs detail, in a historical context, the development of the most
significant non-viral gene delivery systems used to date, including cationic lipids, proteins, and
synthetic polymers.
As early as the 1950s, cationic proteins were used in high salt concentrations to condense
DNA for transfer into cells. Not long after, 2-(diethylamino) ether (DEAE)-dextran and calcium
phosphate were used for similar applications. While still used in laboratory in vitro
transfections, these chemical systems are cytotoxic, unstable under physiological conditions, and
inefficient delivery systems in vivo.9' 22, 23
A second wave of non-viral vectors came to prominence in the 1980s, most notably with
the development of Lipofectin, an artificial, cationic lipid-based system, in 1987. Later work
with these materials yielded systems based on cationic and neutral liposomes, combinations of
lipids with peptides and polymeric systems, and other lipid-based systems. Lipid-based systems
were among the first chemicals used in in vivo studies, and in fact are still used in on-going
studies today; however, they have thus far been limited by significant drawbacks involving in
vivo stability and toxicity.
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A few years later, peptide- and protein-based methods gained significant interest in the
non-viral arena, particularly because they allow for precise control over molecular weight and
chemical composition and can be readily functionalized with peptide-based functional domains
such as targeting ligands, membrane destabilizing peptides, and nuclear localization sequences.
For example, poly-L-lysine (PLL)-based systems were used extensively in early studies in this
area. 28 More recently, synthetic modifications to PLL-based systems have shown that significant
transfection enhancements can be achieved using conjugated ligands for cell targeting or
endosomal disruptive elements for cytoplasmic release.2 ,' 30 In addition to PLL-based systems,
other peptides such as short derivatives of human histone or protamine, poly-L-ornithines31,
elements of DNA viruses ("pseudocapsids"), and engineered proteins have also gained
significant interest and merit further investigation. 32
While liposome-based vectors have matured to the point of widespread application in
clinical trials, polymeric vectors (polyplexes) have lagged behind. This seems paradoxical, as
polyplexes were used in the laboratory for insertion of exogenous DNA long before the use of
lipoplexes. 33 However, it was not until the advent of polyethylenimine (PEI)-based vectors that
synthetic polymers were recognized as useful materials for non-viral gene delivery
applications. 34  PEI exhibited transfection efficiencies far exceeding other polyplex-based
systems, primarily owing to the endosomal buffering capacity of secondary amines along its
backbone. Numerous studies on second-generation PEIs have elucidated important design
principles for synthetic vector design, for example, the importance of the proton sponge
mechanism in orchestrating endosomal escape, the effect of cell-specific targeting via conjugated
ligands, the effect of molecular weight and cross-link density on toxicity, and the effect of charge
density on transfection. 35-42 Further, these systems represent some of the most efficient
transfecting systems to date. In addition to first- and second-generation PEI-based systems,
other linear polymeric systems have been explored as delivery vectors, including natural
polymers gelatin and chitosan, methylacrylate/methacrylamide polymers, P-cyclodextrin-
containing polymers, and poly (P amino esters).9' 43-45
Finally, hyperbranched and dendritic macromolecules have also been a source of great
interest for gene delivery applications, primarily because they can be synthesized with great
control over molecular architecture and functionality as well as high levels of endosomal
buffering capacity. Among the most frequently explored dendritic systems are cationic poly
(amidoamine)s (PAMAM), which have been shown to complex DNA into small, toroidal
particles, inhibit nuclease degradation, and promote endosomal release and transfection in vitro
(with transfection enhancements of 10-100% relative to lipid-based reagents).46' 47 In addition to
PAMAM, other dendritic systems (e.g., PLL dendrimers) and their conjugates have also been
explored, albeit in a much smaller capacity. 48
2.2.3 Designing a New Non-Viral Gene Delivery System
The focus of the work described in this thesis on the topic of gene delivery involves the
development of a new class of delivery agents for in vivo applications. We chose to focus on
non-viral, chemical delivery systems for the following reasons: (1) chemical structures are
synthetically versatile, and as such, elements imparting various functionalities (i.e. tissue
targeting, steric stabilization, etc.) can be easily added and/or modified; (2) chemical delivery
systems can transport much larger DNA payloads than their viral counterparts; and (3) chemical
delivery systems are generally safer than their viral counterparts (for example, they can be made
from biocompatible building blocks and pose little risk for adverse immune responses or
insertional mutagenesis). In order to design a gene delivery system with improved properties,
however, we first had to consider the major barriers limiting efficient gene delivery in vivo. The
following section provides an overview of these extracellular and intracellular barriers along
with corresponding strategies that have been developed to overcoming them.
2.3 Overcoming extra- and intracellular barriers to efficient gene
delivery using non-viral delivery systems
2.3.1 Extracellular Barriers
Extracellular barriers to systemic delivery of DNA are those that can be encountered
between the site of administration and the surface of the cellular target of interest. Synthetic
vectors must be able to charge neutralize and condense DNA into small, discrete particles (< 200
nm), avoid both self and non-self interactions, cause low systemic toxicity, minimize interactions
with plasma proteins, evade the adaptive immune system, and selectively target specific cell
populations.9, 43 Figure 2.1 provides an overview of these extracellular barriers.
* DNA condensation and
. ,protection
* Colloidal stability
* Immune response
* Toxicity
= site of administration
4= target site(s)
Figure 2.1. Extracellular barriers to systemic gene delivery.
Neutralization of DNA's negative charge to form condensed particles is required in order
to create discrete, small particles capable of internalization by somatic cells. It is important that
polyplexes be small (typically less than 200 nm) because larger particles are poorly internalized
by many cells and tissues and are often rapidly removed from circulation by the
reticuloendothelial system (RES). Further, polyplexes should have a near-neutral surface charge,
as highly charged particles commonly exhibit non-specific interactions with the extracellular
matrix, cell membranes in non-target tissues, and plasma proteins, and are quickly removed from
circulation via the phagocytotic pathway.43
DNA condensation and charge neutralization can be accomplished by the addition of
multivalent cations (i.e., polyamines, positively-charged polymers, and peptides) which
electrostatically condense DNA into rod-like, spheroidal, or toroidal nanoparticles. While
charge, binding affinity, and size of polyplexes are all generally controllable experimental
variables, there currently exists no optimum set of conditions for transfection. Instead, a system-
specific optimization of these parameters is generally required.43' 45, 49, 50
Avoidance of self and non-self interactions (i.e., aggregation and absorption by non-
target tissues, respectively) as well as significant increases in circulation time can be achieved by
incorporating linear, flexible, hydrophilic polymers such as poly (ethylene glycol) (PEG) into
polyplex formulations. See Figure 2.2. 44, 51, 52 PEG is known to sterically stabilize polyplexes
and other colloidal species by creating a hydrated "brush" layer on the particle surface which can
both sterically inhibit aggregation and also limit immune surveillance, permitting long
circulation times.
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Figure 2.2. Effect of polyethylene glycol on plasma half-life.
Plasma concentration of subcutaneously injected interferon (IFN) versus time without (a)
or with (b) polyethylene glycol (PEG) conjugation. Reproduced with permission from [52].
Toxicity is generally a polymer-specific phenomenon. However, it has been shown in
first generation synthetic vectors such as polyethylenimine (PEI)53, chitosan54, and f3-
cyclodextrin-containing polymers55 to be proportional to polymer molecular weight and charge
density. Further, many newer synthetic systems such as dendrimers56, networked5 7 and
degradable polymers5s-61, and various PEGylated systems44' 51, 52 demonstrate far less toxicity
than first generation vectors. In sum, toxicity can generally be controlled by judicious choice of
condensing polymer species and may also be minimized by incorporation of PEG.
Receptor-mediated endocytosis is one of a handful of mechanisms by which cells
specifically internalize certain materials from their surroundings. Importantly, it is perhaps the
most versatile and common method by which directed uptake of therapeutic materials can be
targeted to specific cell populations. 43 44, 62, 63 The steps in this process include the following:
(a) binding of the particle (by specific molecular recognition) to a cell surface receptor, (b)
clathrin-mediated vesicle formation, (c) clathrin depolymerization and uncoating of the
internalized vesicle to form the early endosome, (d) ATP-powered influx of protons and
subsequent pH decrease and ligand release, (e) recycling of plasma membrane receptors to the
cell surface, and (f) trafficking of the late endosome to the lysosome for degradation of the
internalized particle. 62
Taking advantage of the receptor-meditated endocytic pathway can allow for selective
targeting of ligand functionalized therapeutics (or carriers) to specific cells, a process which can
both enhance therapeutic efficacy and decrease undesired side effects. Examples of ligands that
have been used in targeted delivery applications are provided in Table 2.3, below.
Table 2.3. Common ligands for receptor-mediated endocytosis
Ligand Target Cell Type
Galactose Hepatocyte 64, 65
Mannose Macrophage, Dendritic cells 39, 66 , 
67
aDEC-205 Dendritic cells68
Folate Cancer (various) 44' 69
Transferrin Cancer (various) 70
Epidermal Growth Factor Cancer (various) 71
Antibodies Various72
Aptamers Various 73
Short Peptides Various 74, 7
5
Small molecules Various 76
In addition to receptor-mediated endocytosis, a range of additional, passive routes have
also been utilized for the selective targeting of therapeutics to certain cell types. For example,
non-specific adsorptive endocytosis has been cited as a mechanism by which certain polyplexes
with residual positive charge and no bound ligand enter cells. In this process, the polyplexes
interact with negatively charged proteoglycans of the cell membrane, a process that leads to
membrane binding and internalization. However, this non-specific mechanism has several in
vivo drawbacks, as it also favors opsonization by negatively charged blood proteins, premature
blood clearance, and accumulation in "first-pass" organs such as the liver, lung, and spleen.77
The phagocytotic pathway has been utilized for the selective targeting of therapeutics to antigen-
presenting cells of the immune system, but is not useful for other somatic cell types. 78 Finally,
the enhanced permeability and retention effect (EPR), wherein therapeutics passively enter
cancer cells by diffusion out of leaky angiogenic vasculature, is mediated by the presence of a
polyplex component that enhances circulation time (i.e., PEG) and has been shown to be
effective in the treatment of some malignant tumors. 44' 79
2.3.2 Intracellular Barriers
Intracellular barriers to transfection include all those between the point of internalization
by the target host cell and the expression of gene products. Steps in this process include cellular
uptake (for example, by receptor-mediated endocytosis), endosomal escape, nuclear transport,
and vector unpackaging. 9 ' 44 See Figure 2.3.
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Figure 2.3. Intracellular barriers to targeted gene delivery.
Upon internalization by endocytosis, a polyplex is enveloped in an intracellular vesicle
called an endosome. Over time, the pH of the endosome is lowered before it eventually fuses
with a second vesicle called a lysosome, where its contents undergo hydrolytic and enzymatic
degradation. Importantly, in order for an internalized polyplex to avoid degradation, it must
escape from the endosomal vesicle into the cytoplasm prior to reaching the lysosome. 62
Endosomal escape into the cytoplasm may be orchestrated by either biologically-inspired
or completely synthetic methods. In the former, fusogenic peptides or "smart" polymers can be
designed to undergo a conformational shift as the endosomal pH lowers from -6-7 (early
endosome) to -5-6 (late endosome), mimicking the method by which viruses, such as influenza
(via the mHA2 capsid protein), escape lysosomal trafficking. In both the case of fusogenic
peptides and "smart" polymers, the pH-triggered conformational shift results in a hydrophobic a-
helical structure capable of fusing with and disrupting the plasma membrane. 80, 81 On the other
hand, two completely synthetic methods have also been employed to direct endosomal escape.
In the first, pH-sensitive liposomes, the pH drop triggers a change in self-organizing behavior
(i.e., stable lipid bilayer at pH 7 - hexagonal-II structure at pH 5.5), which results in a structure
capable of membrane fusion and disruption. Dioleoylphosphatidyl ethanolamine (DOPE) is
perhaps the most well characterized material of this type.80 Further, the most common synthetic
method for endosomal escape is the so-called "proton sponge" mechanism. This mechanism,
first identified by Bousiff and coworkers, involves the use of condensing agents with cationic
functional groups whose pK values lie near the range of 5-6. Thus, protonation of these groups,
most commonly secondary and tertiary amines, occurs as the pH of the endosome is lowered. As
chloride counterions accumulate in the buffered vesicle, an osmotic pressure gradient is created
across the vesicle membrane. Eventually, the membrane is destabilized as a result of this
osmotic pressure gradient and the endosomal contents escape into the cytoplasm.34 See Figure
2.4.
Early endosome 1. Influx of protons and CI- counterions
pH 6.5 - 7.5 2. Sequestration of H+ by protonatable amines Endosomal rupture and
3. Osmotic pressure buildup vector escape
(a) Proton Sponge Effect
1. Influx of protons
Early endosome 2. pH-triggered peptide conformational shift Membrane disruption and
pH 6.5 - 7.5 3. Membrane penetration by hydrophobic a-helix vector escape
(b) Fusogenic Peptides
Figure 2.4. Endosomal escape mechanisms in synthetic delivery systems.
(a) Proton sponge effect. (b) Fusogenic peptides.
After entering the cytoplasm and before expression, encapsulated DNA must be partially
or fully unpackaged to allow access to the nuclear transcription apparatus. 49 In support of this
hypothesis, it has been observed that, for the case of linear polycations (i.e., poly-L-lysine
(PLL)), the transcription efficiency is inversely related to molecular weight. It has also been
demonstrated that high molecular weight (i.e., PLL 180 kDa or PEI 800 kDa)49 or strongly
charged 35 polycations result in low transfection efficiencies, probably because DNA is never
released from the tightly-bound polyplex. On the contrary, lower molecular weight systems (i.e.,
PLL 19 kDa or PEI 25 kDa) result in much faster polyplex dissociation and higher transfection
efficiencies.
It is not clear whether vector unpackaging prior to or following nuclear entry is optimal
for highest transfection efficiencies. It has, however, been demonstrated that this can occur in
either the cytoplasmic or nuclear milieu. 82 Despite this uncertainty, it is likely that partial or
complete vector unpackaging must precede transcription.83 Very little work has been devoted to
the development of systems with programmed mechanisms for vector unpackaging, but potential
solutions include degradable, swellable, or micellar systems that favor dissociation of polymers
from DNA on a physiologically relevant time scale.57-61
Once in the cytoplasm, DNA must be transported to the nucleus for transcription. The
nucleus, which contains nearly all of the cell's genetic material and transcriptional machinery, is
surrounded by two phospholipid bilayer membranes. These membranes are effectively fused at
the sites of nuclear pore complexes (NPCs), which are -125 MDa, barrel-shaped cavities
composed of 50-100 different proteins.62 Polyplexes cannot traverse the nuclear membrane and
thus must be transported through the NPCs. Further, it is known that polyplexes are too large to
enter through nuclear pore complexes by passive diffusion (diffusion limit - 9 nm).84 It has been
shown that plasmids microinjected into the cytoplasm express very poorly, while plasmids
microinjected into the nucleus are highly expressed. Taken in conjunction with the known
dimensions of the NPC, this data suggests that expression of exogenous DNA in nondividing
cells (in which passive, mitotic nuclear entry is not possible) must require an active transport
mechanism for nuclear entry.
In nature, all proteins that are found in the nucleus are synthesized in the cytoplasm.
Thus, they too require an active transport mechanism for nuclear entry. One of the most well-
characterized methods of assisted nuclear import is the importin pathway. This pathway
involves the following steps. First, a cargo protein attached to a 5-20 basic amino acid sequence
called a nuclear localization sequence (NLS) binds to importin-a and importin-P proteins (the
NLS binds directly to importin-a). The importin-P portion of the trimeric complex then interacts
with specific components of the NPC, translocating the complex into the nucleoplasm by a
poorly understood, ATP-dependent process. Once in the nucleoplasm, Ran-GTP interacts with
importin-3, triggering release of the cargo-NLS from the trimeric complex.62 See Figure 2.5 and
Table 2.4. This strategy has been mimicked in polyplex based systems, where either the cationic
polymer or DNA is bound (usually covalently) with an NLS peptide sequence for assisted
nuclear import. Great enhancements in transfection (10- to 1000-fold) have been accomplished
using these methods to date; however, this subset of gene therapy technology is still in its early
infancy and warrants further exploration."-88 Finally, it is worth noting that nuclear localization
strategies are designed for non-dividing cellular systems, the systems of interest in many clinical
applications. However, cell-cycle-dependent transfection, in which vectors or DNA are designed
for (passive) nuclear entry only during mitotic disaggregation of the nuclear membrane, may
sometimes be advantageously exploited, for instance, in the case of targeting dividing brain
tumor cells while avoiding non-dividing healthy cells.77
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Figure 2.5. The importin pathway for nuclear import and export.
Adapted from [62].
Table 2.4. Common nuclear localization peptide sequences.
Adapted from [83-86]
Name Sequencea
SV40 PKKKRKV
NF-icB VQRKRQKLMP
OCT-6 GRKRKKRT
TFIIE-P SKKKKTKV
TCFI-a GKKKKRKREKL
a: peptide sequences given as single amino acid abbreviations
A summary of the major extracellular and intracellular biological barriers discussed in
this section, along with the most prominent strategies for overcoming each barrier, is provided in
Table 2.5, below.
Table 2.5. Common strategies for overcoming major biological barriers to gene delivery.
Barrier Strategy
DNA condensation and protection Cationic materials (e.g., polymers, lipids)
Avoidance of undesired interactions Hydrophilic, flexible polymers (e.g., PEG)
Tissue targeting Targeting ligands
Passive targeting (e.g., phagocytosis or EPR effect)
Endosomal escape Buffering amines ("Proton sponge effect")
Fusogenic peptides / polymers
Vector unpackaging Hydrolytic or reductive degradation, swelling
Nuclear import Nuclear localization peptides
2.4 Next-generation synthetic vectors: The "artificial virus"
It is clear that a single delivery system with the ability to overcome the diverse biological
barriers described above must be able to perform multiple tasks. For example, such a system
must compact DNA into small particles of virus-like dimensions that can localize in targeted
regions and traverse cell membranes, protect DNA cargo from degradation, shield DNA from
undesired interactions with non-target tissues and the immune system, escape from endosomal
vesicles, and deliver DNA to the nucleus for transcription. To accomplish these tasks, it is clear
that multiple, diverse functional domains must be included in the delivery formulation, and that
each domain must be able to exert its function in a way that is unhindered by the other
components in the system. The term "artificial virus" has been used to describe such a
multifunctional synthetic system possessing the multiple, dynamic functions of a virus, yet
constructed from completely synthetic building blocks. An example of such a hypothetical
system is shown in Figure 2.6.44, 89
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Figure 2.6. Schematic of a hypothetical "artificial virus"
Reproduced with permission from [44].
Over the past fifteen years, numerous investigators have attempted to build delivery
systems with artificial virus-like properties.44 However, there are only a few examples of truly
multifunctional systems which have been designed with functionalities to overcome multiple
biological barriers, and no consensus design rules have been established for the fabrication of
such systems. One of the primary factors limiting progress in this area is the fact that multiple
functional domains in a single system rarely behave synergistically or, for that matter, additively.
The reason for this shortfall is simple: addition of new functional domains to an existing delivery
system usually changes the character of existing domains.
Figure 2.7 provides an example of such a scenario. In this case, investigators were
interested in using PEI as an in vivo delivery vehicle. However, it is well known that PEI-DNA
complexes are unstable in physiological salt concentrations, which result in aggregation of
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complexes and rapid clearance from circulation. In an attempt to remedy this situation, the
authors modified PEI with a second polymer, PEG, which is known to stabilize colloidal
suspensions by forming a dense, hydrophilic brush layer on the particle exterior, sterically
inhibiting charge shielding at the particle surface and resultant particle-particle interactions
(Figure 2.7(a)).90 As shown in Figure 2.7(b), while PEGylation indeed stabilized particles
against salt-induced aggregation, it also caused an undesired, 1000-fold drop in transfection
efficiency in vitro. The reasons for this effect are likely two-fold. First, by reacting with
secondary amines in the PEI main chain, the PEG modification may have imposed additional
steric effects on DNA binding and condensation, which in turn effect particle size, DNA
unpackaging, and direct polymer-cell membrane interactions. Second, by changing the basic
character (i.e. pKa) of secondary amines in PEI, the conjugation likely also changed their
buffering and endosomolytic properties, which are known to be central to their transfection
activity.34,35
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Figure 2.7. Effect of polyethylene glycol (PEG) modification of polyethylenimine (PEI) on
colloidal stability and transfection.
(a) Schematic showing chemical structures of PEI and PEG as well as the PEI-PEG
conjugation process (termed "PEGylation"). (b) Plots showing (i) size of polymer-DNA
complexes after 1 h incubation in 10 mM NaCI and (ii) relative gene delivery efficacy of
PEI and PEI-PEG conjugates. 90
2.5 A modular delivery system
The case described above is just one of many examples in which the modification of an
existing polymer structure with new domains encoding properties such as cell targeting, vector
unpackaging, or steric stabilization resulted in deleterious effects on existing properties. In
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response to this important limitation, we set out to design a new gene delivery system possessing
multiple functional domains arranged together in a modular fashion, such that new elements
could be added, modified, or removed without exerting a negative effect on the remaining
properties. To achieve this, we required that functional domains be physically separated from
one another. An example of such a system (possessing functional domains for DNA binding,
endosomal escape, steric stabilization, and tissue or intracellular transport) is shown in Figure
2.8. In order to make this design feasible, the following criteria must be met: (1) no elements
should possess overlapping functions; (2) various elements must be positioned appropriately
with respect to one another so as to best facilitate the function of each; and (3) elements must be
assembled using orthogonal, complementary chemistries.
Tissue or cellularDNA binding Endosomal escape Stabilization *,r. rn
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Figure 2.8. Architecture of a hypothetical modular gene delivery system.
In the following three chapters, the design and characterization of a system possessing the
above characteristics will be described. Chapter 3 begins by describing the chemical architecture
of a linear-dendritic "hybrid" polymer which was designed specifically to possess these
characteristics and continues through the synthesis of these systems, their self-assembly with
plasmid DNA, and their efficacy in in vitro DNA delivery experiments. Chapter 4 extends this
work by using the systems developed in Chapter 3 to explore a clinically-relevant model for
DNA vaccination. Finally, Chapter 5 describes a useful modification on this concept involving a
new, three-step procedure for the synthesis of hybrid polymers, the functionalization of these
systems with short peptides for solid tumor targeting, and a series of in vitro (as well as
preliminary in vivo) results demonstrating their efficacy.
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Chapter 3. Multifunctional linear-dendritic "hybrid"
polymers for non-viral gene delivery: Design, synthesis, self-
assembly with DNA, and in vitro DNA delivery
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3.1 Introduction
To fully realize the potential for new medical advances in the post-genomic era, safe and
efficient delivery systems for nucleotide-based drugs must be developed.' Ideally, such systems
will be nontoxic, non-immunogenic, and made from building blocks that are versatile to allow
for optimal delivery to a range of cells or tissues of interest. In this chapter, we describe the
design, synthesis, and testing of a unique family of hierarchically structured linear-dendritic
hybrid polymers that self-assemble with DNA to form stable nanoparticles with a series of
concentric, functional "shells" possessing independently-tunable properties necessary for
effective targeted delivery. The resultant ligand-functionalized systems demonstrate receptor-
mediated delivery to targeted cells with serum stability, transfection efficiencies exceeding the
most efficient commercially available polymer, poly(ethylenimine) (PEI), and low toxicity at
concentrations one to two orders of magnitude higher than those at which PEI is toxic. These
systems may find potential utility as targeted in vivo gene delivery systems for DNA or RNA-
based therapies.
As described in Chapter 2, the success of gene-based therapies is dependent upon the
ability to deliver genes that express key proteins when and where they are needed. As of yet, no
such therapies have been approved for clinical use, primarily because of the lack of versatile,
safe, and efficient gene delivery systems.2 , 3 A suite of electrical, mechanical, and modified viral
delivery systems have been investigated with some success, but these systems suffer from
significant drawbacks. 4-7 Notably, modified viruses often elicit severe immunogenicity, are
prone to insertional mutagenesis, and are refractory to repeated administrations. Chemical
delivery systems such as cationic linear polymers, dendrimers, or lipid-based reagents, while
generally safer than their viral counterparts, typically lack the high efficiency or multiple
functionalities required for in vivo administration. Moreover, even subtle synthetic
modifications to these systems can dramatically influence existing biological properties.8-10
In this chapter, we present a new family of multifunctional gene delivery polymers based
on dendritic poly(amidoamine) (PAMAM) and linear poly(ethylene glycol) (PEG) with an array
of properties (i.e., blood stability, cellular targeting, DNA binding, and endosomal buffering
capacity) that can be independently tuned in a modular fashion to address each of the barriers to
effective gene delivery. As a proof of concept, we demonstrate the ability to independently
modulate targeting and expression levels by choice of ligand and dendrimer species,
respectively. Further, these systems represent a platform onto which additional functionalities
may be added to impart properties such as vector unpackaging and nuclear targeting."'' 12
3.2 Experimental Methods
General Considerations. Bifunctional Fmoc-PEG-NHS (Mn = 3500) and HCI'NH2-
PEG-COOH (Mn = 3400) were purchased from Nektar Therapeutics (Birmingham, AL) and used
without further purification (both possessed substitution values > 99%). Methyl acrylate (99+%)
and ethylene diamine (99+%) were purchased from Sigma-Aldrich (St. Louis, MO) and distilled
prior to use. D-mannosamine HCl, 1-amino-1-deoxy-f3-D-galactose, and hyperbranched poly
(ethylenimine) (PEI, Mn = 25000) were purchased from Sigma-Aldrich (St. Louis, MO).
Plasmid DNA containing the firefly luciferase reporter gene and CMV promoter sequence
(pCMV-Luc) was purchased from Elim Biopharmaceuticals (San Francisco, CA) and used
without further purification. HepG2 human hepatocellular carcinoma cells and P388D1 murine
macrophages were purchased from American Type Culture Collection (Manassas, VA) and
grown at 370 C in 5% CO 2. HepG2 cells were grown in 90% Dulbecco's modified Eagle's
medium supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 jtg/mL
streptomycin. P388D1 macrophages were grown in 90% RPMI 1640 medium supplemented
with 10% fetal bovine serum, 100 units/mL penicillin, 100 jtg/mL streptomycin, 2.5 mg/mL D-
glucose, 10 mM HEPES, and 1 mM sodium pyruvate. Bright-Glo@ luciferase assay detection
kits were purchased from Promega (Madison, WI) and used according to the manufacturer's
specifications. All other materials and solvents were used as received without further
purification.
Instrumentation. 'H NMR spectra were recorded at room temperature using a Varian
Mercury 300 MHz instrument. FTIR spectra of films cast on polished KBr pellets were recorded
on a Nicolet Magna-IR 550 spectrometer. A ZetaPALS dynamic light scattering detector
(Brookhaven Instruments, 15 mW laser, incident beam 676 nm) was used for particle sizing.
Luminescence from reporter gene expression studies was measured using a Veritas Microplate
Luminometer. Optical absorbance was measured using a SpectraMax 190 microplate reader
(Molecular Devices, Sunnyvale, CA).
Synthesis. Ligand-functionalized linear-dendritic polymers were synthesized as follows.
Fmoc-PEG-NHS (3.5 g) was dissolved in 0.1M NaHCO 3 buffer (0.0375 g/mL) and pH adjusted
to pH 8.5 with 1M NaOH. Each of the two sugars were dissolved separately in 0.1M NaHCO 3
buffer (0.03 g/mL), pH adjusted to 8.5, and added to an aliquot of dissolved polymer solution at
a molar excess of 10:1 (24 h, 250 C under N2 gas). Care was taken to combine sugar and
polymer solutions immediately after dissolution of the polymer to avoid premature hydrolysis of
the NHS ester. Polymers were recovered by filtration and lyophilization, dissolved in
dimethylformamide (DMF, 0.1 g/mL) and added dropwise to a solution of piperdine in DMF to
remove the Fmoc protecting group (20% v/v, 30 min, 250 C under N2 gas). Following this step,
polymers were recovered by precipitation in ice cold diethyl ether and dried overnight under
vacuum. Dendrimer synthesis then proceeded by serial Michael addition and amidation steps via
addition of methyl acrylate and ethylene diamine, respectively, as described previously. 13 In
general, ligand functionalization and deprotection steps proceeded at 80-85%; all dendrimer
synthetic steps proceeded with conversions of 90-100% (Figures 3.2-3.4). NMR and FTIR peaks
for each of the 14 reaction products are listed below. Control polymers (no ligand) were
synthesized in parallel with ligand-functionalized species using NH 2-PEG-COOH (Mn = 3400) as
the starting material.
Sugar-Peg-Fmoc. 'H NMR in CDC13: 6PEG(CH2CH20) = 3.66 (b); 6SUGAR(CH20H) =
3.91 (m); 8SUGAR(CHCH20H) = 3.5 (m); 8Froc(-CH-) = 7.25-7.8 (m). FTIR peaks, v cm :
3336, 2885, 1687, 1468, 1344, 1279, 1245, 1111, 964, 845.
Sugar-Peg-NH 2. 1H NMR in CDC13: 8PEG(CH2CH20) = 3.62 (b); 8SUGAR(CH2OH) = 3.92
(m); 8SUGAR(CHCH2OH) = 3.51 (m). FTIR peaks, v cml': 3347, 2885, 1680, 1470, 1342, 1278,
1109, 964, 843.
Sugar-Peg-GO.5. 'H NMR in CDC13: 6PEG(CH2CH20) = 3.61 (b); 8SUGAR(CH20H) =
3.89 (m); 8SUGAR(CHCH20H) = 3.5 (m); 8PAMAM(CH2COOCH3) = 2.48 (m); 8PAMAM(next to
tertiary amines) = 2.50-2.88 (b); 6PAMAM(CH2COOCH3) = 3.3 (m). FTIR peaks, v cm-': 3351,
2885, 1735, 1679, 1467, 1342, 1282, 1112, 965, 844.
Sugar-Peg-G1.0. 1H NMR in CDC13: 6PEG(CH 2CH20) = 3.65 (b); 8SUGAR(CH20H) =
3.89 (m); 8SUGAR(CHCH20OH) = 3.52 (m); 8PAMAM(CH2CONH) = 2.43 (m); SPAMAM(next to
primary and tertiary amines) = 2.48-2.92 (b); 8PAMAM(CH2CONHCH2) = 3.33 (m). FTIR peaks,
v cm -': 3336, 2887, 1682, 1471, 1342, 1283, 1111, 962, 843.
Sugar-Peg-G1.5. 1H NMR in CDC13: 8PEG(CH2CH20) = 3.64 (b); 8SUGAR(CH20H) =
3.88 (m); 8SUGAR(CHCH20H) = 3.5 (m); 8PAMAM(CH2COOCH3) = 2.45 (m);
8PAMAM(CH2CONH) = 2.15-2.4 (m); 8PAMAM(next to tertiary amines) = 2.5-2.88 (b);
8PAMAM(CH2COOCH3) = 3.6-3.7 (m); 6PAMAM(CH2CONHCH2) = 3.32 (m). FTIR peaks, v cm -l :
3260, 2880, 1729, 1665, 1550, 1470, 1350, 1260, 1112, 960, 845.
Sugar-Peg-G2.0. 'H NMR in CDC13: 8PEG(CH2CH20) = 3.65 (b); 8SUGAR(CH20H) =
3.89 (m); 8SUGAR(CHCH20H) = 3.48 (m); 6PAMAM(CH2CONH) = 2.37 (m); 8PAMAM(next to
primary and tertiary amines) = 2.45-3.0 (b); 8PAMAM(CH2CONHCH2) = 3.3 (m). FTIR peaks, v
cm 1': 3273, 2885, 1653, 1599, 1470, 1360, 1283, 1112, 959, 841.
Sugar-Peg-G2.5. 'H NMR in CDC13: 8PEG(CH2CH20) = 3.66 (b); 8SUGAR(CH20H) =
3.87 (m); 6SUGAR(CHCH20H) = 3.52 (m); 8PAMAM(CH2COOCH3) = 2.45 (m);
8PAMAM(CH2CONH) = 2.25-2.42 (m); 6 PAMAM(next to tertiary amines) = 2.5-2.95 (b);
8 PAMAM(CH2COOCH3) = 3.6-3.7 (m); 6PAMAM(CH2CONHCH2) = 3.28 (m). FTIR peaks, v cm-1 :
3252, 2881, 1736, 1666, 1552, 1467, 1354, 1252, 1113, 957, 843.
Sugar-Peg-G3.0. 1H NMR in CDCI3: 8PEG(CH2CH20) = 3.67 (b); 6 SUGAR(CHZOH) =
3.87 (m); 8SUGAR(CHCH20H) = 3.54 (m); 8PAMAM(CH2CONH) = 2.38 (m); 8PAMAM(next to
primary and tertiary amines) = 2.5-3.1 (b); 8PAMAM(CH2CONHCH2) = 3.3 (m). FTIR peaks, v
cm-': 3253, 3065, 2875, 1662, 1551, 1470, 1354, 1302, 1252, 1107, 955, 853.
Sugar-Peg-G3.5. 'H NMR in CDC13: 8PEG(CH2CH20) = 3.65 (b); 8SUGAR(CH2OH) =
3.88 (m); 8SUGAR(CHCH20H) = 3.55 (m); 8PAMAM(CH2COOCH3) = 2.45 (m);
6PAMAM(CH2CONH) = 2.15-2.4 (m); 6 PAMAM(next to tertiary amines) = 2.5-3.0 (b);
8PAMAM(CH2COOCH3) = 3.6-3.7 (m); 8PAMAM(CH2CONHCH2) = 3.28 (m). FTIR peaks, v cm':
3268, 2870, 1737, 1666, 1552, 1466, 1360, 1256, 1201, 1187, 958, 845.
Sugar-Peg-G4.0. 'H NMR in CDC13: •PEG(CH2CH20) = 3.65 (b); 8 SUGAR(CH20H) =
3.88 (m); 8SUGAR(CHCH20H) = 3.48 (m); 8PAMAM(CH2CONH) = 2.37 (m); 8PAMAM(next to
primary and tertiary amines) = 2.45-3.1 (b); 8PAMAM(CH2CONHCH2) = 3.27 (b). FTIR peaks, v
cm-': 3260, 3068, 2881, 1660, 1552, 1470, 1357, 1300, 1260, 1113, 954, 849.
Sugar-Peg-G4.5. 'H NMR in CDC13: 8PEG(CH2CH20) = 3.67 (b); SSUGAR(CH2OH) =
3.92 (m); 8SUGAR(CHCH20H) = 3.5 (m); 8PAMAM(CH2COOCH3) = 2.45 (b); 8PAMAM(CH2CONH)
= 2.2-2.4 (m); 8PAMAM(next to tertiary amines) = 2.5-3.2 (b); 6 PAMAM(CH2COOCH3) = 3.6-3.7
(m); 8PAMAM(CH2CONHCH2) = 3.3 (m). FTIR peaks, v cml': 3272, 2873, 1740, 1665, 1556,
1469, 1362, 1260, 1200, 1184, 960, 845.
Sugar-Peg-G5.0. IH NMR in CDC13: 8PEG(CH2CH20) = 3.65 (b); 8SUGAR(CH20H) = 3.9
(m); 6SUGAR(CHCH20H) = 3.52 (m); 6 PAMAM(CH2CONH) = 2.4 (m); 8 PAMAM(next to primary
and tertiary amines) = 2.5-3.0 (b); 8PAMAM(CH2CONHCH2) = 3.32 (m). FTIR peaks, v cm-':
3262, 3073, 2880, 1664, 1555, 1472, 1360, 1301, 1264, 1111, 954, 851.
Sugar-Peg-G5.5. 'H NMR in CDC13: 8PEG(CH2CH20) = 3.65 (b); 8SUGAR(CH20H) =
3.91 (m); 8SUGAR(CHCH20H) = 3.51 (m); 8PAMAM(CH2COOCH3) = 2.45 (b);
8PAMAM(CH2CONH) = 2.2-2.4 (m); 8PAMAM(next to tertiary amines) = 2.5-3.2 (b);
8PAMAM(CH2COOCH3) = 3.6-3.7 (m); 8PAMAM(CH2CONHCH2) = 3.3 (m). FTIR peaks, v cm- :
3274, 2873, 1741, 1670, 1555, 1470, 1362, 1255, 1203, 1190, 960, 847.
Sugar-Peg-G6.0. 'H NMR in CDC13: 8PEG(CH2CH 20) = 3.66 (b); 6 SUGAR(CH20H) = 3.9
(m); 8SUGAR(CHCH20H) = 3.55 (m); 8PAMAM(CH2CONH) = 2.4 (m); 8PAMAM(next to primary
and tertiary amines) = 2.6-3.0 (b); 8PAMAM(CH2CONHCH2) = 3.2-3.4 (b). FTIR peaks, v cm-1:
3255, 3070, 2884, 1664, 1554, 1472, 1357, 1303, 1256, 1113, 960, 854.
Gel electrophoresis shift assays. Polyplexes were formed by combining 100 gL of
DNA solution (0.1 mg/mL in 25 mM acetate buffer, pH 5.1) to 100 gL of polymer solution
(concentration adjusted to reach desired concentration in 25 mM acetate buffer at pH 5.1) in an
eppendorf tube and allowing 20 min for complexation. The resultant solutions were diluted in 25
mM acetate buffer and added to gels at a concentration of 100 ng DNA per well (in 20 gL
volume) in 10% Ficoll 400 loading buffer (Amersham Pharmacia Biotech, Uppsala, Sweden).
Gels were run at 60 V for 1 h using an Embi tec RunOne Electrophoresis Cell (San Diego, CA).
Bands were visualized by ethidium bromide staining.
Dynamic light scattering (DLS). Dynamic light scattering (DLS) measurements were
used to measure the size of polymer-DNA complexes. Complexes were prepared as described
above. Correlation functions were collected at a scattering angle of 900, and the sizes of particles
were determined using the MAS option of the company's particle sizing software package
(version 2.30) assuming the refractive index and viscosity of pure water at room temperature.
Particle sizes, obtained in triplicate, are given as effective diameters assuming a log-normal
distribution.
Transmission electron microscopy (TEM). Transmission electron micrographs were
obtained using a JEOL 2000FX operating at 200kV. TEM samples were prepared on 400-mesh,
Formivar carbon-coated copper TEM grids by first depositing a small aliquot of the above
complex solution (5 gL) onto the grid and allowing 15 minutes for evaporation of the solvent. A
small drop (30 lL) of staining solution containing 0.5% RuO4 was then placed on the sample and
allowed to evaporate for 1 h prior to imaging.
Cell transfections. All transfection assays were performed in quadruplicate in
accordance with the following protocol. All materials, buffers, and media were sterilized prior to
use. HepG2 cells were grown in 96-well plates at an initial seeding density of 5000 cells/well in
150 gtL/well of growth medium (90% Dulbecco's modified Eagle's medium supplemented with
10% fetal bovine serum, 100 units/mL penicillin, and 100 gg/mL streptomycin). P388D1 cells
were grown in separate 96-well plates at an initial seeding density of 50000 cells/well in 150
LL/well of growth medium (90% RPMI 1640 medium supplemented with 10% fetal bovine
serum, 100 units/mL penicillin, 100 gLg/mL streptomycin, 2.5 mg/mL D-glucose, 10 mM
HEPES, and 1 mM sodium pyruvate). Cells were allowed to attach and proliferate for 24 h in an
incubator.
Polymers were dissolved in sterile 25 mM acetate buffer (concentrations ranging from 2-
12 mg/mL) and arrayed into a 96-well plate (25 gL/well total polymer solution with
concentrations adjusted as appropriate to yield polymer/DNA ratios ranging from 10:1 to 200:1).
Polymer/DNA complexes were formed by the addition of 25 gtL/well of 0.06 mg/mL pCMV-Luc
in 25 mM acetate buffer. Polymer and DNA solutions were vigorously mixed using a
multichannel pipettor upon addition of DNA solutions and subsequently incubated for 20 min to
allow for complexation. Thirty gL/well aliquots of the above complex solutions were then
transferred into each well of a 96-well plate containing 200 gL/well of either serum-free Opti-
MEM medium (Invitrogen Corporation, Carlsbad, CA) or 10% serum-containing growth
medium. Growth medium was removed from cells and 150 gL/well of complex-plus-medium
solution was added. Controls employing PEI were prepared exactly as above to yield polymer
DNA ratios ranging from 0.5:1 to 10:1, and in all cases optimized formulations are reported as
positive controls. Naked DNA controls were also prepared as above, and each 96-well plate
included appropriate positive and negative controls as internal standards. In all cases, wells
contained 587 ng DNA/well at indicated polymer/DNA ratios.
Following incubation of complex-containing medium solutions with cells for 4 h,
solutions were removed and replaced with 10% serum-containing growth medium. Cells were
incubated for an additional 72 h, and luciferase expression was determined using the
commercially available Bright-Glo@ luciferase assay kit (Promega, Madison, WI).
Luminescence was quantified in solid, flat-bottom, white polypropylene 96-well plates using a
bioluminescent plate reader. Luminescence was expressed in relative light units and was not
normalized to total cellular protein in this assay.
Cell viability assay. Cell viability assays were performed in quadruplicate using the
following protocol. HepG2 and P388D1 cells were seeded in 96-well clear, flat-bottom plates
and transfected according to the procedure described above. After 72 h, cell metabolic activity
was assayed using the MTT cell proliferation assay kit (ATCC, Manassas, VA). Initially, a 10
gL aliquot of MTT assay reagent was added to each well. After incubating for two hours, 100
pLL of detergent reagent was added. The plate was then covered and left in the dark for 4 h, after
which optical absorbance was measured at 570 nm using a microplate absorbance reader.
Background (media plus MTT assay reagent plus detergent reagent with no cells present) was
subtracted from the value of each well, and all values were normalized to the value of control
(untreated) cells.
3.3 Results and discussion
3.3.1 Design of linear-dendritic hybrid polymers: Modularity and
hierarchical self-assembly with DNA
Linear-dendritic hybrid polymers were designed based on the hypothesis that these
unique polymer architectures, which possess functionalities that are both chemically orthogonal
and physically separated, could self-assemble with DNA to yield nanoparticles with an outer
shell of targeting ligands accessible to cell surface receptors, a flexible, hydrophilic corona
designed to prevent protein opsonization, plasma clearance, and non-specific uptake, and an
interior of amine groups to promote DNA binding and escape from endosomal vesicles into the
cytoplasm. 14- 16 The structure of hybrid polymers, a comparison with the generic design motif
described for modular polymers in Chapter 2, and a schematic depicting the self-assembly of
these systems with plasmid DNA is provided in Figure 3.1.
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Figure 3.1. Rational design and hierarchical self-assembly of linear-dendritic polymers
with plasmid DNA.
(a) Architecture of a hypothetical modular gene delivery system described in Chapter 2.
(b) Molecular structure-function relationship in mannose-PEG-PAMAM G3.0.
(c) Structure of linear-dendritic polyplexes showing relative positions of functional
elements (not to scale).
3.3.2 Synthesis of hybrid polymers
Ligand-functionalized linear-dendritic polymers were synthesized by first conjugating an
aminated targeted ligand to PEG via an NHS ester, followed by removal of the Fmoc protecting
group on the opposite end of the bifunctional PEG and subsequent dendrimer growth by serial
¾
?
Michael additional and amidation steps (as described previously' 3; see Figure 3.2). Physical
properties of these polymers are listed in Table 3.1.
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Figure 3.2. Synthesis of linear-dendritic hybrid polymers.
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Table 3.1. Theoretical molecular weights and number of primary amines in ligand-
functionalized PEG-PAMAM hybrid polymers used in this chapter.
Polymer Mn (theoretical) # of Amine End Groups
Ligand-PEG-PAMAM-GO.0 3344 1
Ligand-PEG-PAMAM-G1.0 3572 2
Ligand-PEG-PAMAM-G2.0 4028 4
Ligand-PEG-PAMAM-G3.0 4940 8
Ligand-PEG-PAMAM-G4.0 6764 16
Ligand-PEG-PAMAM-G5.0 10412 32
Ligand-PEG-PAMAM-G6.0 17708 64
In general, ligand functionalization and deprotection steps proceeded at 80-85%; all
dendrimer synthetic steps proceeded with conversions of 90-100% (Figure 3.3). Qualitatively,
the growth of amide (3200-3400 cm'- ) and carbonyl (1600-1800 cm') peaks during dendrimer
synthesis can be seen in Figure 3.4.
A: 5•,,4A(CH20H) = 3.88
B: 6pF,(CH2CH2O) = 3.65
C: 8,PAVM(CH2CONHCH2) = 3.27
D: P.•,,(next to 1 , 30 amines) = 2.45-3.1
E: ,,,M,,(CH2CO-H) = 2.37
Figure 3.3. 'H NMR spectrum of mannose-PEG-PAMAM-G4.0 with assigned structural
peaks.
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Figure 3.4. FTIR plots of transmission (%) versus wavenumber (cm-') in sugar-PEG-
PAMAM GO.0, G2.0, and G4.0.
(a) GO.0, (b) G2.0, and (c) G4.0. Growth of amide (green) and carbonyl (red) peaks are
highlighted (Conversion of the deprotection step was approximately 80%. Conversion at
each branching step was 90-100%.). Additional NMR and FTIR structural analysis is
available in Experimental Methods.
3.3.3 Biophysical properties of polymer-DNA complexes
An array of techniques was used to probe the biophysical character of polymer/DNA
complexes, or "polyplexes" (see Figure 3.5). Gel electrophoresis demonstrates binding and
charge neutralization of DNA by linear-dendritic polymers incubated at mass ratios of greater
than 20:1, 10:1, 5:1, 1:1, and 1:1 for generations 2.0, 3.0, 4.0, 5.0, and 6.0, respectively (pH 5.1
acetate buffer was used in all cases to ensure complete protonation of primary amines on the
dendrimer periphery). The nature of this trend is consistent with intuition, as the exponentially
increasing number of amines with increasing dendrimer generation results in higher charge
density with increasing dendrimer size. Dynamic light scattering (DLS) suggests that polyplexes
of generations 3.0, 4.0, and 6.0 average around 150 nm in diameter, under the reported cutoff of
around 200 nm required for efficient cellular uptake (Figure 3.5(b)). 17 Generation 5.0 polyplexes
form larger particles with DNA, a seemingly anomalous result that was nevertheless highly
repeatable. The large size of G2.0 polyplexes reflects the fact that little DNA binding and charge
neutralization occurred in these systems. In all cases, mass ratios ranging from 0.1 to 200 were
tested and polyplex size was shown to be relatively insensitive to mass ratio above the ratio at
which complexation occurs in each system, suggesting that in all cases polyplexes consist of a
single DNA plasmid and that excess polymers remain dispersed in solution. Thus, particle
diameters given in Figure 3.5(b) represent average diameters for an evenly weighted range of
mass ratios up to 200. Finally, transmission electron micrographs (TEM) of G6.0 polyplexes
show narrowly dispersed, roughly spherical complexes with an outer corona of approximately 6-
8 nm, consistent with the expected size of PEG-PAMAM G6.0 (Figure 3.5(c)). 18 In all of the
above cases, complexes were formed prior to assay by incubating dilute solutions of plasmid
DNA encoding firefly luciferase (6.2 kb, 2.05 x 106 g/mole, 0.1 mg/mL, 25 mM acetate buffer,
pH 5.1) with equal volumes of solutions containing polymers (in 25 mM acetate buffer, pH 5.1 at
appropriate concentrations to achieve the indicated mass ratios) for 20 min at room temperature. 3
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Figure 3.5. Biophysical characterization of linear-dendritic polyplexes.
(a) 1% agarose gel electrophoresis demonstrates DNA binding at indicated mass ratios.
(b) Particle diameter measured via dynamic light scattering (DLS). (c) Transmission
Electron Microscopy (TEM) depicts narrowly dispersed, roughly spherical particles.
3.3.4 Cell targeting, transfection, and cytotoxicity
To evaluate the ability of polyplexes to transfect target cells via receptor-mediated
uptake, we transfected two cell types, P388D1 murine macrophages bearing the mannose
WNflko
receptor and HepG2 human hepatocytes bearing the asialoglycoprotein receptor (for
galactosylated ligands). 19 -22 Transfections were performed in quadruplicate in 96-well plate
format. Polymers and DNA were combined for 20 min at mass ratios ranging from 1:1 to 200:1
(polymer:DNA) in 25 mM acetate buffer, added to serum-free or 10% serum-containing
medium, and incubated with cells for 4 h (587 ng DNA/well), after which the polyplex-
containing medium was removed and replaced with growth medium. Cells were assayed for
expression of the luciferase reporter gene at 72 h.3 Figure 3.6(a) shows levels of luciferase
reporter gene expression in macrophages (in the absence of serum) with optimized formulations
of ligand-functionalized polyplexes, control polyplexes bearing no ligand, ligand-functionalized
polyplexes in the presence of excess soluble ligand, and PEI. Generation 6.0, mannose-bearing
polyplexes demonstrate transfection 1.6- to 1.8-fold higher than PEI, the most efficient
commercially available polymer for in vitro transfections. Generation 5.0 polyplexes mediate
reporter expression levels approximately 1.3-fold higher than PEI, while G4.0 polyplexes (as
well as G3.0 and G2.0, data not shown) transfect at low levels comparable to naked DNA. The
highest transfection levels were observed in polymer/DNA ratios under 50 in all systems (under
20 in G6.0), presumably owing to the effects of toxicity at high concentrations. Polyplexes with
no mannose ligand exhibited significantly lower transfection efficiencies, and competitive
inhibition of mannose receptors by an excess of soluble ligand virtually silenced reporter gene
expression without affecting expression levels in positive and negative controls (Figure 3.6(a)).
These data further support the hypothesis of cellular internalization by means of specific,
receptor-mediated endocytosis. Finally, to probe the serum stability of PEGylated polyplexes,
macrophages were transfected in the presence of 10% serum containing medium (Figure 3.6(b)).
Four-fold transfection enhancements were observed relative to PEI, most likely owing to the
"stealth" effect imparted by PEG, which is known to reduce particle agglomeration by
attenuating opsonization of serum proteins. 23
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Figure 3.6. Transfection of P388D1 macrophages bearing the mannose receptor.
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(a) Transfection by linear-dendritic polyplexes with and without the mannose ligand and in
the presence of 0.1 mg/well soluble mannose. * indicates p < 0.04; ** indicates p < 0.002
(Two-tailed, unpaired Student's T-Test). Results normalized to an optimized formulation
of PEI (2:1 PEI:DNA, serum free, no free mannose added). (b) Serum stability is
demonstrated via transfection in the presence of serum proteins. Results normalized to an
optimized formulation of PEI (2:1 PEI:DNA, 10% serum, no free mannose added). All
results are given as average +/- standard error.
Transfection of HepG2 hepatocytes by linear-dendritic polyplexes bearing the galactose
ligand is shown in Figure 3.7. In the absence of serum, optimized formulations of generation 6.0
and 4.0, ligand-functionalized polyplexes transfect significantly more efficiently (p < 0.06) than
control polymers with no ligand (Figure 3.7(a)). Moreover, generations 6.0, 5.0, and 4.0 targeted
systems mediate transfection levels within one order of magnitude of PEI in the absence of
serum, and as much as eight-fold higher than PEI in the presence of serum (Figure 3.7(a) and
(b)). Optimal polymer/DNA mass ratios were in the range of 100-200 for all systems studied.
Taken together, these data suggest that hepatocyte-targeted polyplexes are serum stable and
demonstrate enhanced transfection owing to a cell-specific, receptor-mediated process.
Interestingly, expression levels were unaffected by the presence of an excess of soluble
galactose, a finding that may owe to the multivalent nature of ligand binding by the
asialoglycoprotein receptor, suggesting that multivalent ligand presentation via synthetic,
multimeric galactose ligands may yield enhanced targeting relative to monomeric species.24' 25
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Figure 3.7. Transfection of HepG2 hepatocytes bearing the asialoglycoprotein receptor.
(a) Transfection by linear-dendritic polyplexes with and without the galactose ligand *
indicates p < 0.06; ** indicates p < 0.03 (Two-tailed, unpaired Student's T-Test). Results
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normalized to PEI (serum free, no free galactose added) = 1.0. (b) Serum stability is
demonstrated via transfection in the presence of serum proteins. Results normalized to
PEI (10% serum, no free galactose added) = 1.0. All results are given as average +/-
standard error.
To assess the cellular toxicity of linear-dendritic hybrid polymer-based systems, an MTT
assay was performed to measure the relative viability of cells treated with varying polymer/DNA
mass ratios. Cells were seeded in clear 96-well plates and transfected exactly as previously
described. A range of polymer/DNA mass ratios were studied, corresponding to concentrations
equal to and above those at which optimal transfection levels were observed. In P388D1
macrophages (Figure 3.8(a)), cells which we have found to be highly sensitive to environmental
conditions in culture, no measurable toxicity was observed in G4.0-based systems over the entire
concentration range studied. More significant toxicity was observed at high mass ratios in G5.0
(60-80% viability relative to untreated controls) and G6.0 systems (50-70%), though these
toxicities were primarily observed at concentrations higher than those optimal for transfection.
In HepG2 hepatocytes (Figure 3.8(b)), no measurable toxicity was observed in G4.0 and G5.0
systems at polymer/DNA mass ratios up to 200; in G6.0, moderate toxicity became apparent at
ratios of 150 and above. In all cases, linear-dendritic systems failed to display toxicity until
concentrations reached one to two orders of magnitude greater than those at which PEI was
toxic.
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Figure 3.8. Relative viability of cells following transfection with hybrid polymers.
(a) P388D1 macrophages and (b) HepG2 hepatocytes assayed 72 h after transfection at
indicated polymer/DNA mass ratios (control cells untreated). All results are given as
average +/- standard error.
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3.4 Summary
In this chapter, the design, synthesis, and testing of a new family of linear-dendritic
hybrid polymers for their ability to deliver DNA to two distinct mammalian cell lines has been
described. These hierarchically self-assembling polymers have functionalities that are physically
and chemically distinct and can be independently modified. The modular nature of these
systems makes them a platform from which further, serial modifications may be added to impart
additional desired characteristics without substantially altering existing properties. As a proof of
concept, we demonstrate the condensation of DNA by linear-dendritic polymers into
nanoparticle structures with small size and robust serum stability appropriate for systemic
delivery. Moreover, by presenting an outer shell of targeting ligands, these particles can
transfect cells bearing targeted surface receptors with low toxicities and efficiencies exceeding
the best commercially available polymer, PEI. Taken together, our data suggest that this new
family of materials may find use as safe and highly efficient in vivo delivery agents for plasmid
DNA and, potentially, other nucleotide-based therapeutics.
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Chapter 4: Mannose-functionalized linear-dendritic
hybrid polymers for the targeted delivery of DNA vaccines
4.1 Introduction
During the past century, vaccines have been responsible for the protection of millions of
people against devastating diseases like smallpox, poliomyelitis, and measles. As a result,
protective immunization is now recognized as the most cost-effective method for controlling and
eradicating infectious diseases. Yet, despite our rapidly advancing understanding of the
molecular and cellular underpinnings of the immune response, there remains a great need for
vaccine technologies that are effective against HIV, hepatitis B and C, malaria, cancer, and
emerging pathogens like avian influenza and weapons of bioterrorism. 1-4 In order to be useful,
these new vaccines must be safe (low risk for side effects or disease transmission), scalable, and
capable of stimulating both humoral and cellular arms of the immune system.5 7 DNA vaccines
are the only vaccine technology with the potential to offer all of these necessary attributes. 5-7
Thus, they have been the source of intense research interest in recent years. However, despite
encouraging successes in animal trials, DNA vaccines have faired only modestly in early human
clinical trials because of poor expression and adjuvancy - two problems directly related to DNA
delivery. It is clear that new delivery systems which can more effectively manipulate the
immune response will be necessary before this technology can be approved for clinical use.5-8
In order to design a better DNA vaccine, it is useful to first appreciate the mechanisms of
genetic vaccination in the complex, multicellular environment of the immune system. The
primary activators of adaptive immunity are antigen presenting cells (APC), which are most
commonly dendritic cells (DC's) and macrophages (MD's). In the immature state, APCs rapidly
sample their environment, capturing and internalizing antigens at the rate of approximately one
cell volume per hour.9 After capturing an antigen, an APC will process it through one of two
distinct pathways (Figure 4.1). If the antigen is endogenous (that is, produced intracellularly, as
in the case of viral proteins produced by an infected APC), it will be associated in the
endoplasmic reticulum with a membrane-bound molecule called Major Histocompatibility
Complex class I (MHC-I), which is then shuttled to the cell surface. Once on the APC cell
surface, the MHC-I-antigen complex is able to associate with T lymphocytes ("T cells") bearing
the CD8 surface receptor. If accompanied by appropriate "danger" signals (surfaced proteins
that are expressed by "mature" APCs), this T lymphocyte engagement will stimulate the
activation and expansion of cytotoxic T lymphocyte (CTL) clones specific for this antigen,
which will then remove cells from the body that are associated with this particular antigen (e.g.,
infected cells).5 ' 10
The second pathway for antigen presentation occurs when exogenous antigens (that is,
externally produced antigens taken up by APCs) are encountered. In this case, the antigen will
be internalized and broken down into small oligomeric fragments, associated with a molecule
called MHC-II, and presented on the APC cell surface. The MHC-II-antigen complex is able
associate with T lymphocytes bearing the CD4 surface receptor, and if accompanied by the
appropriate "danger" signals, this engagement will result in the activation and expansion of TH-
lymphocytes ("helper T cells"), which stimulate, among other things, the production of
antibodies specific to the antigen. Importantly, in addition to generating an immediate response
to the antigen, the generation of CD8+ CTL and/or CD4+ TH clones is thought to involve genetic
alterations in certain persisting T-cells that enhance the magnitude of the immune response in
future encounters with the same antigen, the basis of prophylactic vaccination.
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Figure 4.1. Antigen processing and presentation by antigen-presenting cells.
Adapted with permission from [11].
Traditional vaccines can be divided into three major categories - attenuated pathogens,
inactivated pathogens, or purified macromolecules - and the mechanism of immune stimulation
varies by vaccine category. Attenuated viral or bacterial vaccines are capable of infecting cells
but are unlikely to cause full blown infections. Because antigens can be both produced
intracellularly by infected cells or taken up exogenously, both MHC-I and MHC-II pathways can
be activated. However, while effective, attenuated vaccines are too dangerous for use against
highly dangerous pathogens such as HIV because the risk of reversion to a pathogenic state,
particularly in immunocompromised patients, is too great. On the other hand, completely
inactivated pathogens or purified macromolecular antigens are much safer, posing virtually no
risk for full-blown infection. However, they can generally only stimulate an MHC-II (TH cell
based) response, which may be insufficient for protection against certain diseases.
In contrast to these traditional vaccines, DNA vaccines instead mimic natural infection,
stimulating both arms of the immune response. Moreover, they pose no risk of pathogenic side
effects, and because both the production and delivery requirements for DNA plasmid vectors are
fairly insensitive to the particular sequence of the encoded antigen, this technology can
potentially be rapidly scaled to meet the demands of an emerging pathogen. 5' 10 See Table 4.1.
Table 4.1. Properties of traditional vaccines and DNA vaccines.
Safe? Stimulates both
Easily scalable
Type of vaccine (i.e. little or no risk for humoral and cellular
production?
infection) responses?
Attenuated pathogen No No Yes
Inactivated pathogen Yes No No
Purified
Yes Yes No
macromolecule
DNA vaccine Yes Yes Yes
A range of non-viral methods have been used to deliver DNA vaccines, including
intramuscular injections of naked DNA' 1 -13, nanoparticles formed by the complexation of DNA
with cationic lipids or polymers5' 14, and polymeric microparticles. 15-18 However, to date none of
these approaches have yielded an appropriate combination of delivery efficacy, adjuvancy, and
safety to justify clinical approval. The linear-dendritic hybrid polymer DNA delivery systems
developed in Chapter 3 represent a platform with unique promise for DNA vaccine delivery
because they can deliver DNA in a targeted, efficient manner and can potentially be
functionalized with materials to further enhance adjuvancy and expression levels. Further, it was
demonstrated that hybrid polymers functionalized with mannose can target McO cells through the
mannose receptor, which is a pattern recognition receptor expressed on a range of APC types
(including dendritic cells, the most potent APCs). 19-22
This chapter details a series of preliminary investigations conducted to gauge the ability
of mannose-functionalized hybrid polymers to deliver DNA vaccines in vivo. The receptor-
mediated transfection of a dendritic cell line is demonstrated, as well as the elicitation of antigen-
specific, primary and secondary, antibody- and cell-mediated immune responses in vivo. Finally,
a series of recommendations for future work in this area are offered. While preliminary, the
results of this study should inform and motivate future investigations on the ability of hybrid
polymers to elicit protective immune responses through DNA vaccination.
4.2 Experimental Methods
General Considerations. The synthesis and characterization of mannose-functionalized
and control hybrid polymers used in this study is described in detail in Chapter 3. D-mannose
and hyperbranched poly (ethylenimine) (PEI, Mn = 25000) were purchased from Sigma-Aldrich
(St. Louis, MO) and used without further purification. DNA plasmids encoding firefly
luciferase, f3-galactosidase, and the SIY-hsp65 fusion protein (pCMV-Luc, pBP2, and pCI-Neo,
respectively) were purchased from Elim Biopharmaceuticals (San Francisco, CA) and used
without further purification. DC2.4 dendritic cells were a generous gift from David Nguyen
(Langer lab, MIT). DC2.4 cells were grown at 370 C in 5% CO 2 in 90% Dulbecco's modified
Eagle's medium supplemented with 10% fetal bovine serum, 100 units/mL penicillin, 100 ýtg/mL
streptomycin, 10 mM HEPES, 2 mM L-glutamine, and 50 [tM 2-mercaptoethanol. Bright-Glo@
luciferase assay detection kits were purchased from Promega (Madison, WI) and used according
to the manufacturer's specifications. MTT cell proliferation assay kits were purchased from
American Type Culture Collection (ATCC, Manassas, VA) and used according to the
manufacturer's specifications. C57BL/6 (B6, H-2 Kb) mice (6-10 weeks old) were purchased
from Taconic Farms and cared for in compliance with the guidelines of the Massachusetts
Institute of Technology.
Instrumentation. Luminescence from reporter gene expression studies was measured
using a Veritas Microplate Luminometer. Optical absorbance was measured using a SpectraMax
190 microplate reader (Molecular Devices, Sunnyvale, CA). Flow cytometry was performed
using a FACScan flow cytometer (Becton Dickinson).
Cell transfections. All transfection assays were performed in quadruplicate in
accordance with the following protocol. All materials, buffers, and media were sterilized prior to
use. DC2.4 cells were grown in 96-well plates at an initial seeding density of 10000 cells/well in
150 pL/well of growth medium. Cells were allowed to attach and proliferate for 24 h in an
incubator.
Polymers were dissolved in sterile 25 mM acetate buffer (6.0 mg/mL) and arrayed into a
96-well plate (25 gL/well total polymer solution with concentrations adjusted as appropriate to
yield polymer/DNA ratios ranging from 5:1 to 100:1 (m:m)). Polymer/DNA complexes were
formed by the addition of 25 gL/well of 0.06 mg/mL pCMV-Luc in 25 mM acetate buffer.
Polymer and DNA solutions were vigorously mixed using a multichannel pipettor upon addition
of DNA solutions and subsequently incubated for 10 min to allow for complexation. Thirty
gL/well aliquots of the above complex solutions were then transferred into each well of a 96-
well plate containing 200 gL/well of serum-free Opti-MEM medium (Invitrogen Corporation,
Carlsbad, CA). Growth medium was removed from cells and 150 UL/well of complex-plus-
medium solution was added. Controls employing PEI were prepared exactly as above to yield
polymer DNA ratios ranging from 0.5:1 to 10:1 (m:m), and in all cases optimized formulations
are reported as positive controls. Naked DNA controls were also prepared as above, and each
96-well plate included appropriate positive and negative controls as internal standards. In all
cases, wells contained 587 ng DNA/well at indicated polymer/DNA ratios.
Following incubation of complex-containing medium solutions with cells for 8 h,
solutions were removed and replaced with 10% serum-containing growth medium. Cells were
incubated for an additional 24 h, and luciferase expression was determined using the
commercially available Bright-Glo@ luciferase assay kit (Promega, Madison, WI).
Luminescence was quantified in solid, flat-bottom, white polypropylene 96-well plates using a
bioluminescent plate reader. Luminescence was expressed in relative light units and was not
normalized to total cellular protein in this assay.
Cell viability assay. Cell viability assays were performed in quadruplicate using the
following protocol. DC2.4 cells were seeded in 96-well clear, flat-bottom plates and transfected
according to the procedure described above. After 24 h, cell metabolic activity was assayed
using the MTT cell proliferation assay kit (ATCC, Manassas, VA). Initially, a 15 gpL aliquot of
MTT assay reagent was added to each well. After incubating for two hours, 100 gL of detergent
reagent was added. The plate was then covered and left in the dark for 4 h, after which optical
absorbance was measured at 570 nm using a microplate absorbance reader. Background (media
plus MTT assay reagent plus detergent reagent with no cells present) was subtracted from the
value of each well, and all values were normalized to the value of control (untreated) cells.
In vivo antibody assay. Formulations containing 100 gg DNA at a 10:1 mass ratio of
polymer:DNA in 200 jtL total solution volume of 25 mM sodium acetate buffer (supplemented
with 5% glucose) were injected once intradermally in the back of each mouse. Negative controls
consisted of buffer only or naked DNA (100 gg DNA with no polymer), and the positive control
was 50 jpg recombinant P-galactosidase protein in PBS buffer. Each control was administered
exactly as described above. At indicated time points, blood samples were collected from the tail
vein. Anti--p-galactosidase IgG levels in serum were determined by ELISA, and the results were
presented as equivalents to a monoclonal anti- P-galactosidase IgG (Calbiochem, San Diego,
CA).
In vivo T-cell proliferation assay. 2C T-cells were freshly isolated from the lymph
nodes of 2C TCR transgenic mice (2C TCR transgenic mice were provided as a generous gift
from Professor Jianzhu Chen's lab at MIT). Two million naive 2C T-cells were injected
intravenously into B6 mice. On the same day, mice were injected intradermally in the back with
hybrid polymer-DNA complexes (DNA encoding SIY-hsp65, formulations prepared as described
above for antibody assays) or controls. To study primary T-cell responses, the mice were
sacrificed after 8 d and their lymph nodes and spleens were harvested and processed into single
cell suspensions. To study secondary responses, mice were challenged with 50 jgg SIY peptide
(in PBS buffer) after 28 d, then sacrificed 3 d later, after which their lymph nodes and spleens
were harvested and processed into single cell suspensions. In both cases, CD8+ cells and 2C T-
cells were assayed by immunostaining (BD Biosciences, San Jose, CA) followed by flow
cytometry (with propidium iodide gating (5 gg/mL) and collecting 100,000 total events per
sample).
4.3 Results and Discussion
4.3.1 Targeted transfection of dendritic cells in vitro
To augment our previous data on the targeting and delivery of DNA to APCs using
mannose-functionalized hybrid polymers (Chapter 3), we transfected a second type of APC:
DC2.4 dendritic cells. We chose this cell line for two reasons: First, dendritic cells are known to
be the most important and potent APCs in the body.10 Second, DC2.4 cells, like other primary
and immortalized dendritic cells, are known to be highly resistant to transfection by conventional
in vitro reagents. 23 Thus, these cells represent both an additional means of validating APC
targeting in vitro and a stringent standard for the assessment of DNA delivery potency. Figure
4.2(a) shows that an optimized formulation of mannose-functionalized polymer - DNA
complexes (20:1 polymer:DNA mass ratio) yielded transfection levels approximately 8-fold
higher than polyethylenimine (PEI). Further, mannose-mediated targeting could be observed by
comparison with either a control polymer (lacking the mannose ligand) or by transfection with a
mannose-functionalized polymer in the presence of an excess of soluble ligand to block receptor
binding. Additionally, Figure 4.2(b) shows that, in keeping with previous results using
macrophages and hepatocytes (Chapter 3), significant cytotoxicity was observed only when
hybrid polymers reached concentrations an order of magnitude higher than those at which PEI
was toxic.
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Figure 4.2. Transfection of DC2.4 dendritic cells bearing the mannose receptor.
(a) Transfection by linear-dendritic polyplexes in the presence or absence of 0.1 mg/well
soluble mannose. Results are normalized to an optimized formulation of PEI (2:1
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PEI:DNA, no free mannose added). (b) Relative viability of DC2.4 cells 72 h following
transfection at indicated polymer/DNA mass ratios (control cells untreated). All results are
given as average +/- standard error.
4.3.2 Primary and secondary humoral responses in vaccinated mice
To measure primary and secondary humoral immune responses to hybrid polymer
vaccines in vivo, we vaccinated C57BL/6 mice (n = 5) on day 0 by intradermal (ID) injection
with 100 gpg of plasmid DNA encoding P-galactosidase, a model antigen (complexed with hybrid
polymers at a 10:1 polymer:DNA mass ratio). Vaccination was repeated on day 28. All mice
(treated and untreated) were challenged on day 56 by intraperitoneal (IP) injection with 45 jlg
recombinant P-galactosidase protein in PBS buffer. Serum IgG antibody levels were measured
three weeks after the initial injection and three weeks after the challenge by ELISA (Figure
4.3(a)).
As shown in Figure 4.3(b), serum anti--0-galactosidase IgG levels were significantly
higher in vaccinated mice than in unvaccinated mice following an antigenic challenge (p = 0.11).
(Note: Mice vaccinated with naked DNA encoding P-galactosidase yielded serum anti-p-
galactosidase IgG levels that were quantitatively similar to untreated mice.) Anti-P-galactosidase
antibody levels were not significantly higher in treated versus untreated mice prior to an
antigenic challenge. Data indicating that mice vaccinated with hybrid polymer DNA vaccines
produce significantly higher levels of antibodies against an encoded antigen than unvaccinated
mice (following an antigenic challenge) suggests that mice vaccinated against a pathogen or
disease may also be better protected than unvaccinated mice.
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Figure 4.3. Humoral responses to hybrid polymer DNA vaccines.
(a) Experimental design. (b) Primary and secondary anti-p-galactosidase IgG levels in
vaccinated and unvaccinated mice (n = 5 mice per group). Pre-challenge levels were
measured three weeks after immunization. Post-challenge levels were measured three
weeks after a challenge with soluble, recombinant p-galactosidase.
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4.3.3 Primary and secondary cellular responses in vaccinated mice
To evaluate the ability of hybrid polymer formulations to elicit both primary and
secondary cell-mediated immune responses in vivo, a 2C T-cell model was used. Transgenic 2C
mice express a single, restricted T-cell receptor (referred to as a 2C T-cell receptor) which
specifically recognizes an antigenic sequence called SIY (whose full sequence is SIYRYYGL) in
complex with MHC. 24, 25 Thus, antigen-specific cellular responses in mice that have been both
vaccinated against SIY and adoptively transferred 2C T-cells can be measured by clonal
expansion of donor T-cells, up-regulation of early activation markers (for example, CD69) in
donor T-cells, or other means.18
In this study, cellular responses were measured as follows. On day 0, 2C T-cells were
freshly isolated from the lymph nodes of 2C mice and adoptively transferred to recipient
C57BL/6 mice by retro-orbital injection. On the same day, recipient mice were vaccinated by ID
injection with hybrid polymer-DNA complexes using a DNA plasmid called pCIneo-hsp65pl,
which encodes the SIY antigenic sequence fused to the carboxy-terminus of heat shock protein
65 (hsp65). To measure primary responses, vaccinated and unvaccinated mice were sacrificed
on day 8, and secondary lymphoid tissues (lymph nodes and spleen) were processed into single
cell suspensions, stained for CD8 and Thyl.1 (a 2C T-cell-specific marker), and analyzed by
flow cytometry. To measure secondary responses, vaccinated and unvaccinated mice were
challenged on day 28 with an IP injection containing 50 gg of pure SIY peptide in PBS buffer on
day 28, then sacrificed and analyzed as described above on day 31 (Figure 4.4(a)).
As shown in Figure 4.4(b), the sizes of both CD8+ and antigen-specific (donor) T-cell
populations were significantly larger in vaccinated mice than in unvaccinated mice (by 1.5- to 2-
fold) following a single vaccination. Further, following a challenge, CD8+ T cell levels were
approximately 5-fold higher than unvaccinated mice. While donor 2C T-cell levels were not
measured following a challenge, the fact that CD8+ levels were further enhanced by a challenge
(relative to primary responses) suggests that secondary responses are likely due, in part or in full,
to the selective expansion of antigen-specific CD8+ T-cells. Together, the results in Figure 4.4
suggest that mice vaccinated with hybrid polymer DNA vaccine formulations generate antigen-
specific, primary and secondary cellular responses. Moreover, these results suggest that mice
vaccinated with these formulations may be better protected against pathogens or diseases than
unvaccinated mice.
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Figure 4.4. Cellular responses to hybrid polymer DNA vaccines.
(a) Experimental design. (b) Primary and secondary, CD8+ and antigen-specific T-cell
levels in vaccinated mice. Each T-cell subset is normalized to the level of the same subset in
an unvaccinated mouse.
4.4 Recommendations for future work
The preliminary studies described above suggest that mannose-functionalized hybrid
polymers may be interesting candidates for the targeted delivery of DNA vaccines. The
following passages suggest areas of future work which should further validate and explore this
concept.
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4.4.1 Large-scale animal studies on T-cell activation and disease protection
The T-cell activation studies described above were performed using relatively small
numbers of mice (2-3 per treatment group). Follow-up studies would strongly benefit from the
use of larger cohorts of animals (5 or more per treatment group), which can allow one to generate
hypotheses and conclusions that are supported by statistically significant data sets. Further, to
better understand the dynamics of multiple types of cells involved in the immune response (e.g.,
APCs, CD4+ or CD8+ T-cells, B-cells, and natural killer cells), samples from each treatment
group should be stained for multiple, cell type-specific markers. Finally, one of the most
convincing demonstrations of a vaccine's efficacy involves protection from a disease challenge.
Established animal models exist for cancer, bacterial and viral infections, and other diseases, and
the use of these models to study the potency of immune responses elicited by hybrid polymer
DNA vaccines would be very useful.10
4.4.2 Direct observation of APC transfection in vivo
The ability to directly observe transgene expression in various cell types following
vaccination could shed light on the roles that different cells (e.g., dendritic cells, macrophages,
B-cells, etc.) play in the development of immune responses to hybrid polymer DNA vaccines. In
an initial attempt to explore this topic, C57BL/6 mice were vaccinated as described above using
hybrid polymer-DNA complexes encoding either green fluorescent protein (GFP) or luciferase
(Luc), a non-fluorescent protein (which served as a negative control). After 48 hours, lymph
nodes and spleens from all mice were processed into single cell suspensions, stained for various
cell type-specific markers (for example, CDllc for dendritic cells), and analyzed by flow
cytometry. Interestingly, CDllc+ dendritic cells showed markedly different morphological
features and autofluorescence properties in vaccinated mice as compared to unvaccinated mice
(data not shown). However, these effects were observed in both hybrid polymer-treated groups,
and as a result it was impossible to discriminate between fluorescence changes owing to GFP
expression versus those owing to non-specific changes in autofluorescence. Thus, while it is
clear that hybrid polymer-DNA complexes interacted with (and were likely taken up by)
dendritic cells, which subsequently migrated to secondary lymphoid tissues, it is impossible to
discern whether transgene expression occurred in these cells. Future experiments in this area
may potentially remedy this problem by using a reporter transgene which encodes a non-native
cell surface protein. It is possible to transfect cells with such a construct and then analyze
expression by antibody labeling using a fluorophore (such as allophycocyanin) that can be
analyzed on a fluorescence channel that yields lower levels of autofluorescence in response to
changes in cell morphology.
4.4.3 Adjuvanting effects of hybrid polymers
In addition to appropriate levels of transgene expression in APCs, up-regulation of
costimulatory factors on these cells during antigen presentation is also considered crucial to
DNA vaccine potency.10 Recent studies have shown that both natural and synthetic materials
can act as adjuvants by causing up-regulation of costimulatory factors in APCs following
exposure, an attribute which may be highly favorable for vaccine delivery systems.
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Both in vitro and in vivo approaches can be used to study the adjuvanting effects of
hybrid polymers. In vitro, immature dendritic cells may be isolated by treatment of bone marrow
progenitor cells with granulocyte/macrophage colony stimulating factor (GM-CSF) using
established protocols. 17 Treatment of these differentiated cells with polymer-DNA complexes
(or other materials), followed by antibody staining for APC cell surface markers and up-
regulated co-stimulatory factors (e.g., CD40, CD80, and CD86) can be used to measure APC
maturation in response to a given treatment. 17 In vivo, APC maturation can be studied by
immunization, APC isolation (by processing secondary lymphoid tissues into single cell
suspensions and subsequently staining for an APC marker such as CD1 c), and staining for co-
stimulatory factors.
Future work on hybrid polymer DNA vaccines is likely to benefit from the use of these
techniques to study APC maturation, as they can be instrumental in the development of
mechanistic hypotheses to explain events taking place during the vaccination process. Further,
the rational modification of hybrid polymers with elements such as Toll-like receptor ligands,
which can enhance the adjuvanting effects of biomaterials, may substantially improve the
efficacy of these systems in vaccine delivery.5' 30
4.4.4 Non-specific inflammation
In several cases, significant non-specific inflammation was observed in draining lymph
nodes following vaccination with hybrid polymer-DNA formulations. For example, total
lymphocyte counts in draining lymph nodes 8 d after a primary vaccination with hybrid polymers
were 1.5 to 3-fold higher than untreated mice (for comparison, total lymphocyte counts in mice
treated with Complete Freund's Adjuvant were six-fold higher than untreated mice). Thus, the
increases in total lymphocyte levels observed in our studies (Figure 4.4) are likely attributable to
both specific effects (as evidenced by higher fractions of antigen-specific cells in lymph nodes of
mice treated with hybrid polymer vaccine formulations as compared to untreated mice) as well as
non-specific effects. Future work in this area should focus on an in-depth characterization of the
role of both specific and non-specific effects in the immune response elicited by hybrid polymer
delivery formulations.
4.4.5 Route and frequency of administration
Vaccines can be administered by a number of routes, including ingestion, inhalation, and
injection. Within the area of injection-mediated administration alone, common routes include
intravenous (IV), intraperitoneal (IP), intramuscular (IM), subcutaneous (SC), and intradermal
(ID). The route of injection can play a powerful role in a vaccine's ultimate activity. For
example, naked DNA encoding an antigen of interest is known to elicit only very minor immune
responses if administered intravenously; however, if administered by intramuscular injection, it
can produce a significant response.1 "1-13, 17 To further complicate the situation, it is also known
that antigen persistence, or the amount of time that an antigen is accessible to the immune
system, can play an important role in a vaccine's efficacy. For example, controlled release
systems which release antigen over the course of several days, or repeated injections of small
doses of antigen, can in some cases elicit a more powerful response than a single bolus dose.' 0
Thus, when administering a new vaccine, especially one whose mechanism of action is not
entirely understood, it is important to explore a range of routes and schedules of administration.
Early work using hybrid polymer vaccine formulations has shown that: (1) intradermal
injections yield responses that are significantly stronger than intravenous injections, and
(2) repeated injections of small doses (i.e. 33 gg DNA/day for three consecutive days) can result
in stronger responses than a single equivalent dose (100 jig DNA; data not shown). On the basis
of these findings, it is clear that future efforts to systematically explore the effects of various
routes and schedules of administration on the efficacy of hybrid polymer vaccine formulations
are warranted.
4.5 Summary
In this chapter, a series of preliminary studies exploring the use of mannose-
functionalized hybrid polymers for the delivery of DNA vaccines were described. These systems
can efficiently deliver plasmid DNA to DC2.4 dendritic cells in a receptor-mediated fashion with
toxicity that is significantly lower than PEI. In vivo, these systems were shown to elicit both
primary and secondary, antibody- and cell-mediated immune responses that are specific to the
encoded transgene. The results of this study (along with the recommendations described herein)
should guide future investigations exploring the ability of hybrid polymers to elicit protective
immune responses through DNA vaccination.
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Chapter 5: Linear-dendritic hybrid polymers
functionalized with a tumor-homing peptide for targeted
gene delivery to solid tumors
5.1 Introduction
Clinical applications of gene therapies are currently limited by the lack of suitable
delivery systems capable of safely and efficiently delivering nucleic acid cargo to targeted
tissues.', 2 As described in Chapter 2, a range of barriers preventing efficient systemic delivery
exist, including the requirement that DNA be condensed into small, protected nanoparticle
structures which can be targeted to cells or tissues of interest, interact only minimally with non-
target tissues, and facilitate endosomal escape, vector unpackaging, and nuclear import.4' 5 In
recent years, strategies have been devised to overcome many of these barriers. For example,
cationic polymers can electrostatically bind and condense plasmid DNA; hydrophilic polymers
such as poly (ethylene glycol) (PEG) can be used to sterically stabilize nanoparticles, enhance
circulation times, and reduce non-specific tissue interactions; buffering amines or peptide
transduction domains (e.g., the HIV TAT peptide6) can enhance endosomal escape; and nuclear
localization sequences can direct DNA to the cell nucleus for transcription.4' 5, 7 However, an
important problem that remains is the selective targeting of gene delivery systems to tissues of
interest. 8 One potential solution involves the use of peptide targeting ligands derived from
combinatorial screening methodologies (such as phage display) which can selectively home to a
range of healthy and diseased tissues in vivo.9 Recently, these ligands have been used
successfully in the selective targeting of cytotoxic drugs, 10 pro-apoptotic peptides,"
metalloprotease inhibitors,12 imaging modalities, 13 and other agents to solid tumors.
In order to incorporate multiple functionalities into a single, integrated gene delivery
system, we developed a family of linear-dendritic "hybrid" polymers containing linear PEG and
dendritic poly(amidoamine) (PAMAM) (Chapter 3).14 These systems contain functionalities for
electrostatic DNA condensation, endosomal escape (via the proton sponge mechanism' ),
reduction of non-specific tissue interactions, and tissue targeting. Moreover, these systems have
the unique attribute of modularity: because the various functional elements are physically
separated, it is possible to add, modify, or remove functionalities independently. However,
hybrid polymers based on PAMAM are synthesized using a labor-intensive, time-consuming
process (- 30 reaction and purification steps) that requires exposure of polymer-bound ligands to
organic solvents and moderately high temperatures (> 600 C). As a result, synthesis of these
systems requires weeks to months to perform, and they cannot be modified with selective
targeting agents such as peptides or antibodies that are amenable to denaturation in organic
solvents.
In this chapter, we demonstrate an alternative means of synthesizing hybrid polymers that
is rapid (three reaction steps, two days), takes place in aqueous media at room temperature, and
requires no purification steps. We use this approach to synthesize hybrid polymers modified
with a peptide ligand (peptide 1, sequence = WIFPWIQL) capable of selectively targeting
glucose-regulated protein 78 kDa (GRP78) (Figure 5.1). GRP78 is a functional tumor antigen
that is selectively expressed in a range of human cancers, and peptides binding to GRP78 have
been used to selectively target tumors in mouse models of breast and prostate cancer and in
human patient-derived tumor samples. 16 24 Here, we demonstrate that peptide 1-modified hybrid
polymer systems can condense DNA into small nanoparticle structures and transfect cells
expressing GRP78 more efficiently than branched polyethylenimine (bPEI), one of the best
commercially available polymers for in vitro transfections. The GRP78-targeted polymers
developed in this study may have direct clinical applications in cancer gene therapy. More
broadly, the new synthetic approach described in this chapter may be used as a general means to
rapidly synthesize high efficiency, multifunctional polymers bearing a variety of protein or
peptide-based functionalities (e.g., targeting ligands, protein transduction domains, and/or
nuclear localization sequences).
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Figure 5.1. Peptide-modified hybrid polymer-DNA complexes.
5.2 Experimental Methods
General Considerations. Bifunctional Maleimide-PEG-NHS (Mn = 5278 Da, PDI =
1.0) and monofunctional mPEG-Maleimide (Mn = 5840 Da, PDI = 1.0) were purchased from
Nektar Therapeutics (Birmingham, AL) and used without further purification. Cystamine-core,
generation 4.0 poly (amidoamine) (G4.0 PAMAM) dendrimers (Mn = 14308 Da, 64 primary
amines per dendrimer) were obtained from Dendritic Nanotechnologies, Inc. (Mt. Pleasant, MI)
and used without further purification. Peptide 1 (sequence HOOC-WIFPWIQL-NH 2) was
synthesized by the MIT Biopolymers Laboratory and purified by high performance liquid
chromatography (HPLC) prior to use. Hyperbranched poly (ethylenimine) (PEI, Mn = 25000),
dithiothreitol (DTT), and 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB or Ellman's reagent) were
purchased from Sigma-Aldrich (St. Louis, MO). Fluoraldehyde was obtained from Pierce
Biotechnology, Inc. (Rockford, IL). Plasmid DNA containing the firefly luciferase reporter gene
and CMV promoter sequence (pCMV-Luc) was purchased from Elim Biopharmaceuticals (San
Francisco, CA) and used without further purification. A polyclonal rabbit anti-GRP78 antibody
was obtained from Stressgen Biotechnologies (Victoria, British Columbia). DU145 human
prostate cancer-derived cells were purchased from American Type Culture Collection (ATCC,
Manassas, VA) and grown at 370 C in 5% CO 2 in 90% ATCC Eagle's minimum essential
medium (with 2 mM L-glutamine and Earle's BSS adjusted to contain 1.5 g/L sodium
bicarbonate, 0.1 mM non-essential amino acids, and 1.0 mM sodium pyruvate) supplemented
with 10% fetal bovine serum, 100 units/mL penicillin, and 100 gg/mL streptomycin. MTT cell
proliferation assay kits were also obtained from ATCC. Bright-Glo@ luciferase assay detection
kits were purchased from Promega (Madison, WI) and used according to the manufacturer's
specifications. All other materials and solvents were used as received without further
purification.
Instrumentation. 1H NMR spectra were recorded at room temperature using a Varian
Mercury 300 MHz instrument. Gel electrophoresis was performed using an Embi tec RunOne
Electrophoresis Cell (San Diego, CA), and gel imaging was performed using a Kodak
Electrophoresis Documentation and Analysis System 120. A ZetaPALS dynamic light scattering
detector (Brookhaven Instruments, Holtsville, NY; 15 mW laser, 676 nm incident beam, 900
scattering angle) was used to measure particle size and zeta potential of polymer-DNA
complexes. Luminescence from reporter gene expression studies was measured using a Veritas
Microplate Luminometer. Optical absorbance was measured using a SpectraMax 190 microplate
reader (Molecular Devices, Sunnyvale, CA).
Synthesis. Peptide-functionalized linear-dendritic polymers were synthesized as follows.
(1) Generation 4.0 (G4.0), cystamine-core PAMAM dendrimers were dissolved in 1X TAE
buffer (pH 8.3), combined with a 10-fold molar excess of DTT, and stirred for 48 h under N2 gas
at room temperature. After reduction, solutions were dialyzed against pure water using a 1000
MWCO SpectraPor 7 dialysis membrane (Spectrum Laboratories, Rancho Dominguez, CA) to
remove all DTT. Ellman's assay (see below) was used to verify that > 95% of dendrimers were
reduced. (2) In a separate flask, Maleimide-PEG-NHS was dissolved in 1X PBS buffer (pH 7.4,
137 mM NaC1, 2.7 mM KC1, 10 mM Na2HPO4) and added to a solution of peptide 1 in dimethyl
sulfoxide (DMSO, 99+% pure, Sigma-Aldrich) such that the reaction mixture contained equal
volumes of PBS and DMSO and a 1:1 molar ratio of Maleimide-PEG-NHS and peptide 1. The
solution was stirred under N2 gas at room temperature for 90 min. (Note: Care was taken to
combine peptide and polymer solutions immediately after dissolution of the polymer to avoid
premature hydrolysis of the NHS ester.) (3) Next, a solution of reduced, G4.0 PAMAM dendron
in pure water was adjusted to IX PBS buffer concentration using 10X concentrated PBS stock
and added to the solution from (2) to achieve a final molar ratio of peptide:PEG:G4.0 dendron of
1:1:1. This reaction was stirred under N2 gas at room temperature for 48 h. Following synthesis,
hybrid polymers were dialyzed against pure water to remove buffers and trace amounts of
DMSO (MWCO 1000). Control polymers (no ligand) were synthesized in parallel with ligand-
functionalized species using an analogous protocol and mPEG-Maleimide (Mn = 5800) as the
starting material.
Structural characterization. Ellman's assay was used to quantify free thiols in
solution.25 Briefly, Ellman's reagent (DTNB) was dissolved in IX TAE buffer at 1 mg/mL. In
each well of a clear, 96-well plate, 7.1 [tL of DTNB solution was combined with 75 [LL of pure
TAE buffer and 17.9 pLL of the thiol-containing solution to be measured. The solutions were
allowed to incubate for 20 min in the dark at room temperature before measuring absorbance at
412 nm. A standard curve was generated using cysteine at concentrations ranging from 0 to 1.5
mM. All conditions were measured in triplicate, averaged, and compared with the standard
curve to determine free thiol concentrations.
The fluoraldehyde assay was used to quantify free amines in solution. 26 In each assay,
200 gtL of amine-containing solution was added to 2.0 mL of fluoraldehyde reagent. After 5 min
of dark incubation, the absorbance was measured at 338 nm. A standard curve was generated
using solutions containing known concentrations of the species to be detected (peptide 1) in a
50/50 mixture of DMSO and PBS buffer (v/v).
NMR was used to further characterize reactants and products. Results are as follows:
1H NMR of peptide 1 in DMSO-d6 : 8.65 (s), 8.4 (s), 8.2 (s), 8.05 (s), 7.9 (s), 7.75 (s), 7.5
(s), 7.3 (s), 6.8-7.2 (m), 4.8 (s), 4.2-4.6 (s), 3.75 (s), 3.5 (m), 3.3 (s), 3.0 (m), 2.8 (s), 2.2 (s), 1.8
(s), 1.7 (m), 1.5 (s), 1.3 (s), 0.6-1.2 (m).
1H NMR of Maleimide-PEG-NHS in DMSO-d6 : 8PEG(CH2CH20) = 3.73 (s);
6PEG(CH2CH20) = 3.60 (b); 6PEG(CH2CH20) = 3.4 (s); 6 MALEIMIDE(COCHCHCO) = 3.26 (s),
8NHs(COCH2CH 2CO) = 2.8-2.92 (s).
'H NMR of Maleimide-PEG-Peptide in DMSO-d6 : 8PEG(CH2CH20) = 3.73 (s);
8PEG(CH2CH20) = 3.59 (b); 8PEG(CH2CH20) = 3.39 (s); 6 MALEIMIDE(COCHCHCO) = 3.26 (s);
8PEPTIDE = 8.05 (s), 7.9 (s), 7.75 (s), 7.5 (s), 7.3 (s), 6.8-7.2 (m), 4.8 (s), 4.2-4.6 (s), 3.0 (m), 2.8
(s), 2.2 (s), 1.8 (s), 1.7 (m), 1.5 (s), 1.3 (s), 0.6-1.2 (m).
'H NMR of G4.0 PAMAM in CD30D: 8PAMAM(-CH 2CONHCH 2CH2NR2-) = 3.27 (b);
6PAMAM(-CH2CONHCH2CH2NH 2) = 3.24 (b); 8PAMAM(-NCH2CH2CONH-) = 2.75 (b); 8 PAMAM(-
CH2CONHCH 2CH2NH 2) = 2.7 (m); 8PAMAM(-CH 2CONHCH 2CH2NR 2-) = 2.53 (m); 8PAMAM(-
NCH2CH2CONH-) = 2.32 (m).
'H NMR of final conjugate (peptide-PEG-PAMAM G4.0) in D20: 6 PEPTIDE = 3.8-4.2 (s),
3.45-3.55 (s), 3.04-3.12 (s), 1.0-2.3 (s); 8PEG(CH2CH20) = 3.55-3.78 (b); SPAMAM(-
CH 2CONHCH 2CH 2NR2-) = 3.36 (b); 8PAMAM(-CH2CONHCH2CH 2NH2) = 3.25 (b); 8PAMAM(-
NCH 2CH 2CONH-) = 2.95 (b); SPAMAM(-CH2CONHCH 2CH2NH 2) = 2.77 (m); 8PAMAM(-
CH 2CONHCH 2CH 2NR2-) = 2.57 (m); 8PAMAM(-NCH2CH2CONH-) = 2.4 (b).
Gel electrophoresis shift assays. Polyplexes were formed by combining 100 glL of
DNA solution (0.1 mg/mL in 25 mM acetate buffer, pH 5.1) to 100 gL of polymer solution
(concentration adjusted to reach desired concentration in 25 mM acetate buffer at pH 5.1) in an
eppendorf tube and allowing 20 min for complexation. The resultant solutions were diluted in 25
mM acetate buffer and added to gels at a concentration of 100 ng DNA per well (in 20 gL
volume) in 10% Ficoll 400 loading buffer (Amersham Pharmacia Biotech, Uppsala, Sweden).
Gels were run at 65 V for 2 h. Bands were visualized by ethidium bromide staining.
Dynamic light scattering (DLS). Dynamic light scattering (DLS) was used to measure
the size and zeta potential of polymer-DNA complexes. Complexes were prepared as described
above. Correlation functions were collected at a scattering angle of 900, and the sizes of particles
were determined using the MAS option of the BIC particle sizing software package (version
2.30) assuming the refractive index and viscosity of pure water at room temperature. Particle
sizes are given as effective diameters assuming a log-normal distribution. Zeta potentials were
calculated from electrophoretic mobilities of complexes using the BIC PALS zeta potential
analysis software incorporating the Smoluchowsky model for aqueous colloidal dispersions.
Cell transfections. All transfection assays were performed in quadruplicate in
accordance with the following protocol. All materials, buffers, and media were sterilized prior to
use. DU145 cells were grown in 96-well plates at an initial seeding density of 10000 cells/well
in 150 gL/well of growth medium. Cells were allowed to attach and proliferate for 24 h in an
incubator.
Polymers were dissolved in sterile 25 mM acetate buffer (6.0 mg/mL) and arrayed into a
96-well plate (25 gL/well total polymer solution with concentrations adjusted as appropriate to
yield polymer/DNA ratios ranging from 5:1 to 100:1 (m:m)). Polymer/DNA complexes were
formed by the addition of 25 iL/well of 0.06 mg/mL pCMV-Luc in 25 mM acetate buffer.
Polymer and DNA solutions were vigorously mixed using a multichannel pipettor upon addition
of DNA solutions and subsequently incubated for 10 min to allow for complexation. Thirty
pL/well aliquots of the above complex solutions were then transferred into each well of a 96-
well plate containing 200 tgL/well of serum-free Opti-MEM medium (Invitrogen Corporation,
Carlsbad, CA). Growth medium was removed from cells and 150 pL/well of complex-plus-
medium solution was added. Controls employing PEI were prepared exactly as above to yield
polymer DNA ratios ranging from 0.5:1 to 10:1 (m:m), and in all cases optimized formulations
are reported as positive controls. Naked DNA controls were also prepared as above, and each
96-well plate included appropriate positive and negative controls as internal standards. In all
cases, wells contained 587 ng DNA/well at indicated polymer/DNA ratios.
Following incubation of complex-containing medium solutions with cells for 4 h,
solutions were removed and replaced with 10% serum-containing growth medium. Cells were
incubated for an additional 72 h, and luciferase expression was determined using the
commercially available Bright-Glo@ luciferase assay kit (Promega, Madison, WI).
Luminescence was quantified in solid, flat-bottom, white polypropylene 96-well plates using a
bioluminescent plate reader. Luminescence was expressed in relative light units and was not
normalized to total cellular protein in this assay.
Cell viability assay. Cell viability assays were performed in quadruplicate using the
following protocol. DU145 cells were seeded in 96-well clear, flat-bottom plates and transfected
according to the procedure described above. After 72 h, cell metabolic activity was assayed
using the MTT cell proliferation assay kit (ATCC, Manassas, VA). Initially, a 10 gL aliquot of
MTT assay reagent was added to each well. After incubating for two hours, 100 AL of detergent
reagent was added. The plate was then covered and left in the dark for 4 h, after which optical
absorbance was measured at 570 nm using a microplate absorbance reader. Background (media
plus MTT assay reagent plus detergent reagent with no cells present) was subtracted from the
value of each well, and all values were normalized to the value of control (untreated) cells.
In vivo tumor targeting and transgene expression assay. Tumor-bearing mice were
established and bioluminescence imaging performed as previously described. 13,24,27,28 Mice were
anesthetized by intraperitoneal administration of Avertin or by gas (2% isoflurane and 98%
oxygen) inhalation. The EF43-FGF4 mouse mammary tumor cells (5 x 104 ) expressing GRP78
were implanted subcutaneously into 6-week-old female BALB/c immunocompetent mice.' 3
When tumors reached a size in excess of 150 mm3, mice received a single intravenous polymer-
DNA complexes or pure saline (negative control). Polymer-DNA complexes consisted of 100
gLg DNA (pCMV-Luc) complexed with 2.0 mg of peptide-PEG-G4.0 in 200 gLL of 25 mM
sodium acetate buffer supplemented with 5% glucose. To image reporter gene expression,
tumor-bearing mice received a single dose (150 mg/kg, intraperitoneal) of the substrate D-
luciferin (Xenogen). Photonic emission was imaged using an IVIS 200 In Vivo Imaging System
(Xenogen). Imaging parameters included image acquisition time: I min; binning: 2; no filter;
f/stop: 1; field of view: 10 cm. Regions of interest were defined manually over the tumors for
measuring signal intensities. All mice were cared for in compliance with the standards and
practices of the University of Texas-M.D. Anderson Cancer Center.
5.3 Results and Discussion
5.3.1 Synthesis of hybrid polymers
The synthesis of hybrid polymers bearing peptide- or protein-based ligands requires that
the synthesis be performed in aqueous solution at moderate temperature and pH. The synthetic
approach developed in this work is shown in Figure 5.2, and makes use of the commercial
availability of cystamine-core PAMAM dendrimers, which can be reduced to yield dendrons
with a single, free thiol in the interior. Briefly, dendrimers were first reduced by addition to a
molar excess of dithiothreitol (DTT) followed by dialysis against pure water to remove the
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reducing agent. Ellman's assay was used to quantify the fraction of dendrimers reduced prior to
the PEG conjugation (see Experimental Methods). In a separate vessel, peptide 1 was added to a
bifunctional Maleimide-PEG-NHS ester for 90 minutes, followed by addition to a molar
equivalent of reduced dendrimer at pH 7.4 (phosphate buffered saline) with stirring for 24-48
hours to yield the final conjugate. Note that peptide 1 was dissolved in dimethylsulfoxide prior
to the PEG conjugation reaction because it is insoluble in water.
(1) DTT
H20-TAE (pH 8.2)
250 C, N2, 48 h
-MA1 HS
(2) Dialysis against
PBS
(1000 MWCO)
(1)
PAMAM G4.0 Dendron
32 Terminal Primary Amines
M,= 7153.5 Da
Wit WRl.1-rin 2PBSIDMSO (pH 7.4)
25- C, N2, 1 h
1:1 PEG:Peptide
fm o r,
NHS-PEG-Maleimide
IM,= 5278 Da (1)
PDI - 1.00 PBSIDMSO (pH 7.4)
250 C, N2 , 48 h
1:1 PEG:PAMAM
NH2  (molar)
NH2
*. NH 2
WFPWQL N N S NH2
H
NH2
Peptide-Peg-G4.0 -NH 2
NH2
Figure 5.2. Synthesis of peptide-functionalized hybrid polymers.
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Table 5.1 provides a quantitative analysis of the conversions achieved in each step of the
hybrid polymer synthesis. All PAMAM reduction reactions proceeded at conversions of 95-
100% (based on total thiol concentration as measured by Ellman's method). The peptide-PEG
conjugation reaction proceeded at 78% conversion (Figure 5.3), and the final PEG-PAMAM
conjugation step went at 74% conversion (based on the disappearance of thiols). To ensure that
the disappearance of free thiol groups during the PEG-PAMAM conjugation step was a result of
a reaction with the maleimide group instead of reformation dendritic disulfides, a sample of the
final product was incubated overnight with a 10-fold molar excess of DTT, dialyzed, and
analyzed again for thiol content. No additional thiols were observed, suggesting that the
disappearance of free thiols during the PEG-PAMAM conjugation reaction was due exclusively
to the formation of stable thioether linkages with the maleimide group. Additionally, each
conjugation step was also verified using NMR (see Experimental Methods).
Table 5.1. Conversions of reduction and conjugation reactions.
Reaction Percent Conversion (%)
Dendrimer reduction >9 5 a
Peptide-PEG conjugation 78 b
PAMAM-PEG conjugation 74a
a: Ellman's method. b: Fluoraldehyde method.
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Figure 5.3. Conjugation of peptide 1 to NHS-PEG-Maleimide as monitored by
fluoraldehyde assay. Peptide contains only one primary amine (N-terminus).
5.3.2 Physical properties of hybrid polymer-DNA complexes
A range of techniques was used to measure the physical properties of polymer-DNA
complexes. In Figure 5.4(a), gel electrophoresis demonstrates binding and charge neutralization
of plasmid DNA (pCMV-Luciferase) by hybrid polymers at polymer:DNA mass ratios of greater
than 1:1, with complete charge neutralization occurring at mass ratios equal to or greater than
5:1. Zeta potential measurements indicate that complexes formed at polymer:DNA ratios of up
to 40:1 have low, positive zeta potentials (Figure 5.4(b)), and dynamic light scattering shows that
small particles (<210 nm) are formed with diameters equal to or less than the reported cutoff of -
200 nm for efficient cellular uptake (Figure 5.4(c)). 29 Particle size showed some sensitivity to
the polymer:DNA mass ratio, with small ratios yielding smaller (- 140-150 nm) particles and
larger ratios yielding slightly larger particles (180-210 nm), likely due to increased steric or
charge repulsion in complexes formed at high mass ratios. All general, the physical properties of
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hybrid polymer-DNA complexes described here were in close agreement with those of hybrid
polymers synthesized by divergent growth (Chapter 3).
Naked
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Ratio (m:m) Potential (my)
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i
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Figure 5.4. Physical properties of hybrid polymer-DNA complexes.
(a) 1% agarose gel electrophoresis demonstrates DNA binding at indicated mass ratios. (b)
Zeta potential and (c) particle diameter measured by dynamic light scattering (DLS).
5.3.3 Targeted DNA delivery by peptide-functionalized hybrid polymers
Hybrid polymers developed in this study were functionalized with a peptide that
selectively targets GRP78, a functional tumor antigen identified through epitope mapping of the
humoral immune response in human cancer patients.22 GRP78 confers a protective cellular
response against stress conditions in solid tumors, and GRP78 expressed at the cell surface of
cancer cells has been used to target peptide ligands to both mouse models of human cancers as
well as human patient-derived samples. 16-24 To test for the ability of peptide-functionalized
hybrid polymers to target and deliver plasmid DNA to cells expressing GRP78, we transfected
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DU145 cells, which have been shown to bind and internalize peptide 1 in a GRP78-dependent
manner. 24 Our results show that peptide-functionalized hybrid polymers can transfect DU145
cells at levels nearly 10-fold higher than an optimized formulation of branched, 25 kDa PEI.
Moreover, this process is receptor-mediated, as evidenced by the fact that cells transfected using
polymers lacking a peptide ligand, as well as cells transfected with peptide-functionalized
polymers in the presence of polyclonal anti-GRP78 antiserum (to block receptor-ligand binding),
yielded significantly lower levels of transfection (Figure 5.5).
12 -
o 10
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Z%MOO
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Peptide-PEG- PEG-PAMAM Peptide-PEG-
PAMAM (no ligand) PAMAM + anti-
GRP78 Ab
PEI PEI + anti-
GRP78 Ab
Figure 5.5. Transfection of DU145 prostate carcinoma cells expressing GRP78 with
peptide-modified hybrid polymers.
Polymers with and without the peptide ligand, and peptide-modified polymers transfecting
in the presence of polyclonal anti-GRP78 antiserum to block receptor binding, are shown. 2
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* indicates p < 0.1. Results normalized to an optimized formulation of PEI (2:1 PEI:DNA
ratio (m:m)). All results are given as average +/- standard error.
5.3.4 In vivo bioluminescence imaging of transgene expression in tumor
xenografts
To investigate the delivery of DNA to solid tumors following systemic administration of
peptide-PEG-G4.0-DNA complexes, we used an established model based on EF43-FGF4 mouse
mammary tumors (expressing GRP-78) established in immunocompetent BALB/c mice,
combined with bioluminescence imaging of luciferase transgene expression. 13 Briefly, tumors
were established by subcutaneous injection of 5 x 104 EF43-FGF4 tumor cells. When tumors
reached sizes greater than 150 mm3, mice were administered a single, intravenous injection of
either saline (negative control) or hybrid polymer-DNA (pCMV-Luc) complexes at a mass ratio
of 20:1 (polymer:DNA). Forty-eight hours following administration, mice were anesthetized,
injected with D-luciferin, and imaged using a Xenogen IVIS 200 In Vivo Imaging System.
Preliminary results demonstrate that, in comparison with controls, mice treated with peptide-
functionalized hybrid polymers show significant transgene expression in regions surrounding the
exterior of the tumor while showing lower expression in non-target tissues as well as the central,
necrotic core of tumors. A representative image is shown in Figure 5.6.
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Figure 5.6. In vivo bioluminescence imaging of luciferase expression in EF43-FGF4 mouse
mammary tumors established in immunocompetent BALB/c mice.
Mice were treated with a single, intravenous injection of either saline (control) or peptide-
PEG-G4.0-pCMV-Luc polymer-DNA complexes (20:1 polymer:DNA mass ratio) 48 h prior
to imaging. Intensity scale at right indicates relative light units (RLU). The absence of
signal in the core of the tumor is a result of the fact that large tumors have developed
necrotic cores.
5.4 Summary
In this chapter, a new synthetic approach yielding hybrid polymers is described. This
approach is rapid (three reaction steps, two days), takes place in near-neutral pH, room
temperature, aqueous conditions which are compatible with the use of sensitive biological
agents, and in some cases can be performed without the need for additional purification steps.
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Using this approach, we synthesized hybrid polymers functionalized with short peptides which
bind to glucose-regulated protein-78 kDa (GRP-78), a tumor associated antigen that is
selectively expressed by a range of human cancers. These peptide-functionalized hybrid
polymer systems form small, electrostatic complexes with DNA and can efficiently transfect
cells expressing GRP-78 in a receptor-mediated fashion. Finally, preliminary in vivo
bioluminescence imaging experiments performed using mice bearing EF43-FGF4 tumors
demonstrate that a single, intravenous injection of peptide-functionalized hybrid polymer
systems can lead to transient, tumor-specific transgene expression. Future work in this area will
focus on bioluminescence imaging of targeted gene delivery to metastatic tumors as well as the
delivery of "suicide" transgenes to solid tumors.
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Chapter 6: Local drug delivery and drug-medical device
combinations
6.1 Local drug delivery
In clinical settings, drugs are administered through a range of diverse routes, including
oral, intravenous, subcutaneous, intramuscular, sublingual, topical (nasal, cutaneous, aural, and
ocular), and other local routes.' While the goal of many approaches is to achieve systemic drug
bioavailability, local administration seeks instead to provide therapeutic drug concentrations only
to discrete target sites for times sufficient to achieve a desired pharmacological outcome.2 In
some cases, local delivery strategies can have important advantages over systemic drug therapy
(see Table 6.1). As a result, local drug delivery strategies have found use in treatments for
conditions such as thrombosis, ocular diseases, infection, inflammation, osteomyelitis, and
cancer.2-5
Table 6.1 Advantages of local drug administration strategies over systemic approaches
(adapted from [2])
1 Lower doses required
2 Greater control over toxicity and bioavailability of dose
3 Lower risk of promoting antibiotic resistance
4 Longer duration of drug release
5 Potential for combining local and systemic drugs with differing kinetics
6 Applicability to drug-medical device combinations
7 Avoidance of systemic exposure and undesired systemic side effects
8 Direct treatment for device-related problems (e.g. tissue integration, infection, etc.)
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6.2 Drug-medical device combinations
A prominent example of the utility of local drug administration involves the recent
development of drug-medical device combinations as implantable therapeutics. Combining
drugs with medical devices has been demonstrated as a means for overcoming several long-
standing clinical hurdles related to complications associated with device implantation such as
infection and poor tissue integration. In particular, several early applications have demonstrated
that drug-medical device combinations can achieve mutually reinforcing effects that are superior
to the administration of the same drug and device in their conventional, separate forms.2, 6-10 For
example, drug-eluting stents have demonstrated dramatically reduced rates of restenosis
compared to conventional, bare metal stents in several large clinical trials, ', 8, 11 and central
venous catheters coated with antimicrobial agents have led to significantly reduced risk of
catheter-related bloodstream infections in both preclinical and clinical studies. '10,1 2-15 Both the
European Union and United States Food and Drug Administration have established new
guidelines governing the approval of such combination products for human clinical
administration, and the market for such products is expected to reach $9.5 billion USD by
2009.2,6 Examples of drug-device combinations approved by the US FDA are listed in Table 6.2,
below.
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Table 6.2. Examples of recent FDA-approved drug-medical device combinations (ref. [2])
Name Company Device Type
Cordis CYPHERTM Johnson & Johnson DES
TAXUS Express 2TM Boston Scientific DES
ARROWgardTM Arrow International CVC
BioGuard SpectrumTM  Cook Critical Care CVC
LubriSil I.C.TM  C.R. Bard UC
Simplex PTM Stryker Osteonics BC
DES: Drug-eluting stent; CVC: Central venous catheter; UC: Urinary catheter; BC: Bone cement
6.3 Traditional fabrication of drug-medical device combinations
Local drug delivery systems, including those used in drug-medical device combinations,
are most frequently fabricated using one of three approaches: (1) simple coating of a device or
substrate with a drug by ab- or adsorption; 9' 12, 16 (2) incorporation of a drug into a bulk polymer
matrix either alone or in combination with a device;"' 17 (3) direct incorporation of a drug into a
device during or after fabrication. 2' 4, 13
While each method has shown promise in certain applications, each also has drawbacks.
For example, simple drug coating typically requires derivatization of drug molecules with ionic
functional groups prior to surface coating to promote surface adsorption, which may alter drug
activity and bioavailability. 9, 16 Additionally, this method allows for little control over drug
loading and release kinetics, particularly when long-term release is desired.2' 9, 16 Incorporation
of drugs into bulk polymer matrices, on the other hand, can allow for much greater control over
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release kinetics. However, uniformly depositing bulk polymeric coatings onto medical devices,
which commonly possess small features (on the micrometer length scale) and non-planar
geometries, can be challenging.2, 11, 17 As a result, achieving uniformity of coating and drug
release while preserving the properties of the underlying device can be challenging. Finally,
direct incorporation of drugs into devices or substrates places limits on total mass loading
because of gross effects on the device's physical properties, and also frequently requires that
drugs be stable in the non-aqueous or high temperature environments used in materials
fabrication. 2 As a result, there is currently a significant amount of research and commercial
interest in the development of drug delivery approaches which can allow for extended release,
encapsulation and release of biological drugs (e.g., proteins, antibodies, and nucleic acids),
release of multi-drug or multi-dose schedules, responsiveness to a variety of environmental
stimuli, and integration with existing medical device technologies.4' 5, 18-20
The following three chapters describe our initial attempts to develop a set of general
strategies for fabricating systems with the properties described above. Specifically, we sought to
develop controlled release systems that can be applied to existing implantable devices without
placing restrictions on the size, shape, or surface chemistry of the device, that can allow for the
delivery of drugs with varying chemical structures (e.g., small molecules, nucleic acids, and
proteins), and that are amenable to the controlled release of multiple agents with well-controlled
kinetics. The layer-by-layer (LbL) directed self-assembly technique was chosen as the primary
tool for this work. The scientific basis for this technique, our rationale for using it for these
applications, and a preview of our work in this area will be described in the following section.
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6.4 Drug-device combinations using layer-by-layer self-assembly
6.4.1 Layer-by-layer self assembly
Since their introduction in 1992, self-assembled layer-by-layer (LbL) thin films have
been the source of an extraordinary amount of interest in the materials science and engineering
community because of their well-controlled physicochemical properties, ease of processing, and
versatility (particularly with regard to materials selection and applications).21' 22 Compared with
other techniques for fabricating nanoscale coatings and thin films (e.g., Langmuir-Blodgett and
chemisorption techniques), the LbL technique allows for significantly greater flexibility with
regard to materials selection, substrate chemistry, and resultant bulk and surface properties.
22-24
LbL films are formed by the sequential adsorption of materials containing complementary
functional groups onto a solid substrate, as illustrated in Figure 6.1 for the specific case of
oppositely charged polymers.21 22 Complementary interactions driving LbL assembly are most
commonly ionic in nature (using polyanionic and polycationic materials), but can also be
extended to include hydrogen bonding25-28, van der Waals forces29, and biomolecular
recognition. 30 Layer-by-layer assemblies can be deposited onto substrates ranging from large
area surfaces to nanoscopic colloidal materials using processes such as dip coating21' 22, colloidal
adsorption , and spin coating.32 As described in Figure 6.1 for a typical dip coating process, a
substrate (e.g., glass or silicon) is first dipped into a solution containing a charged species, rinsed
to remove purely physically bound species, dipped again into a solution containing the
oppositely charged species (e.g., polyanion), and rinsed again. This process is repeated as
desired to build up a film one molecular layer at a time, resulting in composite assemblies whose
composition, thickness, surface, and other properties can be precisely manipulated.22 -2 4 As a
result of this versatility, LbL systems have been constructed using materials that extend beyond
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simple polyelectrolytes to include anything that either possesses, or can be encapsulated in a
"carrier" species that possesses, the appropriate charged or functional group (e.g., dendrimers,
micelles, nanoparticles). Thus, materials such as inorganics 24, uncharged small molecules 33,
proteins34, polysaccharides35, 36, and enzymes 37 have all been used in LbL assemblies, with the
latter three examples demonstrating little to no loss of functional activity. Because of their
versatility, LbL systems have been used in applications which include sensors, semi-permeable
membranes, electrochromic devices, solid-state electrolytes, patterned arrays, and biological
interfaces. 22-24
1. Polycation 1. Polyanion
Substrate Substrate
2. Rinse 2. Rinse
Repeat
Figure 6.1. Layer-by-layer deposition.
6.4.2 Layer-by-layer systems in drug delivery
LbL thin films have also been investigated extensively for drug delivery applications in
recent years based on the hypothesis that their highly tunable properties may lead to controllable
drug release behavior. In early work, Sukhishvili, et al. demonstrated the release of fluorescent
dyes from hydrogen bonded films containing weak poly(acids), which dissolve immediately in
response to changes in environmental pH.27, 38 Similarly, Schfiler and coworkers demonstrated
the NaCl-induced degradation of LBL thin films at very high ionic strengths.39
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Later, Caruso and others pioneered the use of core-shell architectures for the
encapsulation and release of various drugs. In these studies, LBL thin films were first deposited
onto colloids followed by extraction of the colloidal template to yield hollow microcapsules. 40
The resultant systems can be loaded with enzymes 41' 42, dyes 33, ions 43, or small molecules 33,44 , 45
for controlled release applications.
In an alternative approach, Rubner and coworkers developed porous LBL thin films for
encapsulation and pH-triggered release of poorly water soluble small molecules.46, 47 In these
studies, two general strategies were employed. In the first, small, charged molecules such as
dyes were loaded into films via electrostatic interactions with unbound, oppositely charged
functional groups within the films. In this arrangement, a subsequent pH change results in the
release of the entrapped small molecule.46 In the second strategy, uniform pores with high
affinity for small organic molecules were formed throughout the film via a simple, post-
deposition process. Pore affinity was shown to be effectively reversed by a second pH-induced
conformational shift, resulting in release of the entrapped drug.47
While the approaches outlined above represent the first steps toward the realization of
LBL drug delivery systems, each possesses drawbacks. For example, hydrogen bonded LBL
systems are often highly unstable at near neutral pH and degrade on time scales that are too rapid
for most controlled release applications. Salt-induced multilayer degradation requires salt
concentrations (0.6-5.0 M) which are considerably higher than most physiological environments.
Most colloidal core-shell structures are not amenable to device or materials coatings and rely on
diffusion of drugs through the shell as the primary release mechanism, thus limiting their ability
to respond rapidly to physiological triggers such as pH. Finally, while porous LBL systems are
strong candidates for the delivery of small organic molecules, they are not suitable for the
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delivery of larger protein- and polysaccharide-based drugs. Perhaps most importantly, none of
the above mentioned technologies offers a clear mechanism for controlling the sequence by
which incorporated species are released.
6.4.3 Programmable disassembly of layer-by-layer films
The focus of our work in this area is on the development of LbL films capable of
disassembling to release their components in controlled ways (Figure 6.2). This new approach
could possess the following unique attributes relative to the approaches described previously:
1. Broad applicability to existing implantable devices. LbL films can be conformally
deposited onto a range of substrates without regard to substrate geometry, size, or surface
chemistry. 22-24 As such, these materials may be use in the coating of materials ranging from
large area, implantable devices (i.e., prosthetics, sutures, stints, and tissue engineering scaffolds)
to circulating micro- or nanoscopic colloids.
2. Compatibility with a range of chemical and drug structures. LbL films can be
used to encapsulate a diverse range of molecular species, from uncharged small molecules to
large proteins, thus making them attractive candidates for a wide range of delivery
applications. 33,34,48-50 Moreover, these films are constructed using all-aqueous processing
conditions, and as a result can be used to encapsulate functional proteins with little to no loss of
functional activity.34' 37, 51,52
3. Potential utility in multi-drug or multi-dose release applications. The fabrication
of LbL structures through "bottom-up" assembly suggests that it may be possible to build LbL
architectures containing multiple, physically separated components (i.e. drugs). Combining such
architectural control with top-down film disassembly could result in films capable of releasing
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complex schedules of drugs, a highly desirable technology that is only currently available in a
very limited spectrum of materials." ' ", Moreover, the ability to exert fine-scale control over
the nature and relative abundance of different chemical components in a single film suggests an
additional means for controlling disassembly kinetics.
+
S~imlllla ~c C~r·4.
(e.g., pH, redox,
electrical, etc.)
Drug-loaded, Disassembly and
degradable LbL film drug release
Figure 6.2. Concept of controlled disassembly of LbL thin films for controlled release
applications.
Our initial efforts in this area focused on (1) the development and use of different
chemical stimuli to trigger disassembly of LbL films, and (2) control over architectural features
and resultant release behavior in single- and multi-drug containing films. In Chapter 7, a proof-
of-concept study demonstrating the passive, pH-dependent, hydrolytic degradation of LbL films
built using a degradable poly (13 amino ester) will be discussed.53 In Chapter 8, this work will be
extended to include both the extended release of a single drug as well as the development of
films capable of releasing multiple drugs either in series or in parallel. 54 Finally, Chapter 9 will
describe the development of a similar class of degradable LbL films which, instead of degrading
by passive hydrolysis, make use of a remotely-controllable, electrochemical stimulus to trigger
degradation and drug release.55
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Chapter 7: Hydrolytically degradable layer-by-layer thin
films: Assembly, degradation, and release of a single drug
Reproduced in part with permission from Wood, K.C.; Boedicker, J.Q.; Lynn, D.M.; Hammond,
P.T. Tunable drug release from hydrolytically degradable layer-by-layer thin films. Langmuir 21,
1603-1609 (2005). Copyright 2005 American Chemical Society.
7.1 Introduction
Over the past several years, the field of drug delivery has advanced considerably,
resulting in new controlled and sustained release systems. These systems allow for enhanced
targeting, improved pharmacokinetics, lower toxicity, and improved patient convenience. In
sum, these advances have led to both entirely new disease treatments and great improvements on
traditional therapies.' However, many challenges still exist, notably the development of
improved systems which are versatile, highly responsive, and capable of encapsulating an ever-
increasing range of drug types.
As reviewed in Chapter 6, self-assembled polyelectrolyte layer-by-layer (LbL) thin film
technology has been extensively developed over the past decade. These multilayer systems,
formed by the sequential adsorption of oppositely charged polyelectrolytes onto a solid substrate,
can be constructed with nanometer scale control over morphology, molecular architecture, and
surface properties. 2-4 In the area of biomaterials alone, these versatile systems have been used to
create novel biosensors5, membranes6, arrays7 , and bioactive or biocompatible coatings 8 12,
among other things. Further, these films have been shown to effectively encapsulate a range of
functional biomolecules, including uncharged small molecules1 3, proteins 14, polysaccharides 15' 16,
and enzymes , without substantial loss in activity.
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LbL thin films have been investigated extensively for drug delivery applications in recent
years based on the hypothesis that their highly tunable properties may lead to controllable drug
release behavior. Despite significant progress on several fronts, there has been very little
progress in the development of systems which can be engineered to disassemble and release their
contents in response to physiologically-relevant environmental conditions. Such systems, if
developed, could potentially be used to deliver drugs from the surfaces of a range of
biomaterials, including those with both large and small area surfaces (e.g., prosthetic devices and
nanoscopic colloids, respectively), diverse surface chemistries, and non-planar geometries.
Additionally, the all-aqueous construction of LbL films makes them amenable to the
encapsulation of a wide range of therapeutics, from small molecules to proteins. Finally, and
perhaps most significantly, the ability to build complex spatial architectures into these self-
contained, biodegradable systems could potentially render them useful for the timed release of
complex schedules of drugs.
As an initial step toward the creation of films which degrade passively under
physiologically-relevant environmental conditions, the focus of this chapter is to examine the
hydrolytic degradation of, and associated drug release from, LbL thin films formed by the
alternating deposition of a degradable, cationic poly (P amino ester) 18 (polymer 1, Figure 7.1)
and a series of model polysaccharide therapeutics, including heparin, low molecular weight
heparin, and chondroitin sulfate. Polymer 1, which possesses the dual requisite functionalities of
charge (via tertiary amine groups) and hydrolytic lability (via main chain ester groups), was
chosen on the basis of its relatively slow degradation rate at acidic pH (tl/2 > 10 h at pH 5.1, 370
C). 18  Further, it is known to form electrostatic complexes with both free and adsorbed
polyanions, and both the polymer and its degradation products have been shown to cause low
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cytotoxicity relative to poly(ethylenimine) (PEI), a common synthetic polymer used in biological
applications.'8, 19 In a previous work2o, Lynn, Hammond and colleagues demonstrated that
polymer 1 can be incorporated into LbL thin films, which then degrade in a manner that appears
to be top-down at pH 7.4 (the desired behavior for most sustained release applications). 21 In this
chapter, we examine the incorporation of a spectrum of model polysaccharide drugs, including
heparin, low molecular weight heparins, and chondroitin sulfate, into polymer 1-based LbL thin
films. The degradation of drug-loaded films at a range of pH values is studied, and we observe
highly consistent, pseudo-first-order degradation kinetics. Finally, the controlled release of 3H-
labeled heparin from these degradable systems is demonstrated.
O O
0 0
Polymer I
Figure 7.1. Chemical structure of a repeat unit of the degradable poly (P amino ester)
(polymer 1) used in this work.
(Mn = 10,000, PDI = 2.0).18
7.2 Experimental Methods
General Considerations. Silicon substrates (3 cm x 2 cm) were rinsed with methanol
and deionized water, dried under a stream of dry nitrogen, and plasma etched prior to use using a
Harrick PDC-32G plasma cleaner. Thin film deposition was performed using a Carl Zeiss HMS
Series Programmable Slide Stainer. Ellipsometric measurements were conducted using a
Gaertner Variable Angle Ellipsometer (6328 nm, 700 incident angle) and accompanying Gaertner
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Ellipsometer Measurement Program (GEMP) Version 1.2 software interface. Fourier Transform
Infrared Spectroscopy (FTIR) spectra were recorded using a Nicolet Magna IR 550 Series II
Spectrometer. Zinc selenide substrates were used for transmission FTIR analysis, and were
prepared using the same method employed for silicon substrates. Radiolabeled 3H-heparin used
in drug release experiments was quantified using a Tri-carb liquid scintillation counter (Model
U2200). The amount of radiolabel in each sample vial was measured using a 3H counting
protocol which was shown to be highly accurate over a broad concentration range (30-100,000
DPM/mL) in calibration experiments performed prior to drug release.
Materials. Polymer 1 (Mn = 10000) was synthesized as previously described. 18 Heparin
sodium salt (Mn = 12500) and low molecular weight heparin (Centaxarin@, Mn = 6000) were
obtained from Celsus Laboratories (Cincinnati, OH). Chondroitin sulfate sodium salt (Mn =
60000) was obtained from VWR Scientific (Edison, NJ). Silicon wafers (test grade n-type) were
purchased from Silicon Quest (Santa Clara, CA). Linear poly(ethylenimine) (LPEI, Mn = 25000)
was received from Polysciences, Inc. Poly (sodium 4-styrenesulfonate) (PSS, Mn = 1000000)
was purchased from Sigma-Aldrich (St. Louis, MO). 3H-heparin sodium salt was obtained from
American Radiolabeled Chemicals, Inc (1 mCi total, 0.30 mCi/mg, Mn = 12500). All materials
and solvents were used as received without further purification.
Preparation of Polyelectrolyte Solutions. Dipping solutions containing polymer 1 were
made at a concentration of 5 mM with respect to the polymer repeat unit in acetate buffer (100
mM, pH 5.1). Heparin, low molecular weight heparin, and chondroitin sulfate dipping solutions
were prepared in acetate buffer (100 mM, pH 5.1) at concentrations of 10 mM with respect to the
polymer repeat unit of interest. Nondegradable base layers were deposited from dipping
solutions of LPEI and PSS in deionized water pH adjusted to 4.25 and 4.75, respectively.
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Deionized water used to prepare all solutions was obtained using a Milli-Q Plus (Bedford, MA)
at 18.2 MQ. For degradation experiments, PBS buffer (pH 7.4, 137 mM NaCI, 2.7 mM KC1, 10
mM Na 2HPO4) and sodium acetate buffer (pH 5.1, 100 mM) were used. For degradation
experiments conducted at pH 6.2, sodium acetate buffer was pH adjusted by dropwise addition of
NaOH (1 N), yielding a final salt concentration of approximately 200 mM.
Polyelectrolyte Deposition. All polyelectrolyte LbL thin films were constructed as
follows according to the alternate dipping method.2, 22 A ten bilayer nondegradable base film
((LPEI/PSS)10 ) was deposited by submerging plasma treated silicon substrates in an LPEI
dipping solution for 5 minutes, then a cascade rinse cycle consisting of three deionized water
rinsing baths (15, 30, and 45 seconds, respectively). Substrates were then submerged in a PSS
dipping solution for 5 minutes followed by the same cascade rinsing cycle, and the entire process
was repeated ten times. Next, degradable films were deposited on the existing polyanion-
terminated base layer by repeating the above procedure 20 times using polymer 1 as the
polycationic species and either heparin, low molecular weight heparin, or chondroitin sulfate as
the polyanionic species. Following deposition, films were immediately removed from the final
rinsing bath and dried thoroughly under a stream of dry nitrogen gas. Film thickness was
determined by ellipsometry at ten different predetermined locations on the film surface after
deposition of both the nondegradable base layer and the degradable layer. All measurements
were performed in triplicate.
Fourier transform infrared spectroscopy (FTIR). LbL thin films were removed
following the deposition of every second bilayer (and subsequent cascade rinse), dried under a
stream of dry nitrogen, and FTIR spectra were recorded between 4000 and 500 cm -1 (baseline
subtraction mode).
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Measurement of Thin Film Degradation. All film degradation studies were performed
as follows. Films were immersed in 20 mL of the appropriate buffer solution in a screw top
glass vial and tightly sealed. At designated times, films were removed, dried thoroughly under a
stream of dry nitrogen, and thickness was measured using ellipsometry at ten predetermined
locations on the film surface (measurements were performed in triplicate). Following
measurements, films were reimmersed in buffer solutions and resealed.
Measurement of Drug Release. Radiolabeled 3H-heparin sodium salt (2.48 g, 0.32
mCi/mg) was reconstituted in deionized water to form a stock solution containing 172 pCi/mL.
In the drug release experiment, a 3H-heparin labeled dipping solution was prepared by dissolving
1 mL of radiolabeled stock solution in 30 mL of heparin sodium salt solution (10 mM in sodium
acetate buffer, as above). The LbL deposition procedure was then performed, also as above.
Following deposition, 3H-heparin labeled films were immersed in 50 mL PBS buffer for 1000
minutes. A 1 mL sample was extracted every 30 minutes and analyzed by adding 5 mL of
ScintiSafe Plus 50% (Fisher Scientific, Atlanta, GA) prior to measurement. Degradation vials
were tightly capped between sample extractions to prevent evaporation of the buffer solution.
Raw data (disintegrations per minute, DPM) were converted to micrograms (pg) of heparin using
the conversion factor 2.2 x 106 DPM = 1 pCi = 3.3 ýpg 3H-heparin. Finally, the total heparin
release from a single film was calculated according to the following equation:
M = (C, x V, ) + (lmL)- C j(345)
j=(1)
where Mi (ýpg) is the total cumulative mass released from the film as of measurement i, Ci
(pg/mL) is the concentration of sample i, Vi (mL) is the total volume of the degradation bath
i-1
(lmL)_ Cj
prior to measurement i, j1= is the total mass in previously extracted samples, and 345 is
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equal to the mass ratio of total heparin to 3H-labeled heparin in the dipping solution (i.e., in the
degradable film).
7.3 Results and Discussion
7.3.1 Analysis of Thin Film Construction
Films were constructed on planar silicon substrates using the alternate dipping method.2'
22 In all cases, degradable films were assembled on 10 bilayers of nondegradable (LPEI/PSS)
(terminating in PSS) to ensure a uniform surface charge for the deposition of polymer 1. Dilute
aqueous solutions of polymer 1 and model polyanions in acetate buffer (100 mM, pH 5.1) were
used for the construction of degradable thin films. Films were dried immediately after
completion of the dipping process to avoid premature degradation. All dipping conditions were
chosen judiciously to avoid the range of conditions for which degradation of polymer 1 occurs
rapidly.
As shown in Figure 7.2(a), (LPEI/PSS)lo base layers formed smooth films on the surface
of the substrate (ca. 400 A), and as such contributed little to the roughness of the final films.
Degradable multilayers were constructed from 20 bilayers of (polymer 1/X), where X is a model
polyanion (e.g., heparin, low molecular weight heparin, or chondroitin sulfate). Degradable
multilayers were observed to form an even, conformal coating on the substrate, as evidenced by
their modest roughness (error bars represent one standard deviation in film thickness
measurements) and a lack of defects observable by ellipsometry. Degradable multilayers could
be reproducibly fabricated, as multiple films constructed under similar deposition conditions
(e.g., dipping solution pH and ionic strength) were observed to possess nearly identical thickness
and surface roughness values. Finally, it is worth noting that each of the three model polyanions
used in this study formed degradable multilayer films with similar thickness and roughness
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values, an effect that is attributable to their similarities with respect to chemical structure and
relative number of strong and weak acid groups.
It should be noted that error bars depicted in Figure 7.2(a) (as well as Figure 7.3(a-b))
represent one standard deviation in film thickness based on measurements taken at ten
predetermined locations on the film surface. In contrast, the standard deviation of multiple
thickness measurements taken at a single location was less than 10 A. Thus, error bars can be
interpreted as a measure of the roughness of films rather than an indication of the intrinsic error
of the analytical device.
As shown in Figure 7.2(b), the LbL deposition process was monitored using FTIR for the
case of (polymer 1/heparin) 20 films. Specifically, the absorbance from sulfonic acid groups
(heparin) at 1035 cm l' and carbonyl groups at 1730 cm-1 (heparin, polymer 1) was measured
after the deposition of every second bilayer. All measurements were taken from the same spot
on the surface of the film in transmission mode on IR-transparent, zinc selenide substrates. FTIR
absorbance was used to measure film growth because it is known to scale approximately linearly
with mass in the low wavenumber regime, and while it can only give a relative measure of film
thickness, it is not as sensitive to variations in the surface roughness and refractive index of the
film as ellipsometry. The observed increase in absorbance with increasing number of bilayers is
indicative of the LbL deposition process. The exponential nature of this trend suggests
exponential growth behavior, a commonly observed phenomenon.23 -25 (Note that each data set in
Figure 7.2(b) can be fit to an exponential regression with R2 > 0.96.) This behavior seems to be
especially prevalent in systems comprised of biologically-derived polyanions. 26-29 Explanations
of the exact mechanism responsible for exponential growth vary. One explanation, offered for
the case of deposition from high ionic strength solutions, states that exponential growth is due to
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increasing surface roughness, which in turn presents increasing surface area that permits the
deposition of greater amounts of material at each step.23 In a second explanation, diffusion into
and out of the film is cited.26-29 In our studies, the second mechanism is most likely to be the
major contributor to the exponential growth behavior observed, namely because (1) roughness
does not increase with increasing number of bilayers (data not shown), (2) the multivalent nature
of heparin repeat units contributes to strong electrostatic repulsion along the polymer backbone
and an extended (non-globular) conformation in solution, (3) deposition is performed at low
ionic strengths, and (4) exponential growth behavior owing to diffusion has been rigorously
verified in systems containing hyaluronan 26-29, and other polysaccharides with chemical
structures highly similar to that of heparin. Further investigation and verification of the
phenomenon of exponential growth in degradable LbL films is warranted, as this may have
important ramifications for drug loading and release behavior from these constructs.
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Figure 7.2. Construction of degradable layer-by-layer thin films.
(a) Average film thickness. (LPEI/PSS)lo base layers are represented by dark gray and
(polymer 1/X)20 degradable layers by light gray. Five representative films were used to
determine the average in each case. Error bars represent the average standard deviation
of the measured thickness values at ten predetermined locations on the surface of the films.
(b) Measured FTIR absorbance versus number of bilayers for sulfonic acid (triangle,
heparin, 1035 cm "') and carbonyl (square, polymer 1/heparin, 1730 cm 1') functional groups
in the (polymer 1/heparin) system. Measurements were performed in duplicate
(discrepancies were within 0.005 absorbance units). The (LPEIIPSS)10 base layer spectrum
was taken as a baseline and subtracted in all cases.
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7.3.2 Analysis of Thin Film Degradation
All thin film degradation studies were performed by immersing a single film-coated
substrate in a sealed vial containing 20 mL of buffered solution. At indicated time points, films
were removed and dried under a stream of dry nitrogen. Film thickness was then measured by
ellipsometry, followed by reimmersion of the film in the appropriate buffer solution. The pH of
buffered solutions was checked throughout the degradation process to ensure that it remained
constant.
Figure 7.3(a) shows the change in film thickness in (polymer 1/X)20 films with time
following immersion in phosphate buffered saline at pH 7.4. All films demonstrate swelling to
2-8% above their original thickness during the first 0.5-2.0 hours following submersion. Most
likely, this behavior reflects a balance between hydrolysis and swelling immediately following
immersion of the dry films. Following this brief swelling period, films reach saturation and
hydrolysis begins to act as the dominant factor effecting film thickness. Accordingly, film
thickness decreases at a constant rate (approximately 0.8, 0.7, and 1.0 A/min for heparin, low
molecular weight heparin, and chondroitin sulfate-based systems, respectively). Finally, film
degradation was observed to cease in all cases when the degradable (polymer 1/X)20 film had
degraded completely, leaving only the nondegradable (LPEI/PSS)10 base layer. Base layers were
stable in all pH environments for at least 200 days.
Figure 7.3(b) shows the degradation of (polymer 1/X)20 films at pH 6.2. As in the case of
degradation at pH 7.4, films initially swell up to 10% above their original thickness.
Interestingly, this swelling period occurs during the first 10-30 hours following submersion in
the pH 6.2 environment, a significantly longer swelling time (by approximately 10-fold) than
was observed in the pH 7.4 environment. Most likely, this is a reflection of slower hydrolysis in
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this less basic environment. After this period of initial swelling, films degrade again at a
constant, measurable rate (approximately 0.05, and 0.04 A/min for heparin and chondroitin
sulfate-based systems, respectively). As in the case above, film degradation ceased in all cases
following complete degradation of the polymer 1/X film, leaving behind only the nondegradable
(LPEI/PSS)10 base layer. Interestingly, polymer 1-based films were completely stable (no
measurable degradation) for over one to two weeks when immersed in 0.1 M acetate buffer at pH
5.1. Further, degradation rates of 0.004 - 0.005 A/min were observed in both polymer 1/heparin
and polymer 1/low molecular weight heparin systems, and complete degradation of 1000 A films
occurred after 140 - 160 days at pH 5.1 (data not shown).
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Figure 7.3. Total film thickness versus degradation time for degradable films as a function
of pH.
(LPEIIPSS)o1  + (polymer 1/X)20 systems at (a) pH 7.4 and (b) pH 6.2. Model
polysaccharides represented by X include heparin (triangle), low molecular weight heparin
(diamond), and chondroitin sulfate (x). Dashed lines represent the approximate thickness
(t 20 A) of nondegradable base layers. Error bars represent one standard deviation of the
measured thickness values at ten predetermined locations on the surface of the film. As
such, error bars provide an indication of the surface roughness of films (standard deviation
of multiple thickness measurements taken at a single location was less than 10 A).
7.3.3 Pseudo-First-Order Degradation Behavior
Polymer 1 and other amine-containing polyesters are known to degrade more rapidly in
basic environments than acidic environments. Consistent with this, degradation half-times for
polymer 1 in solution have been reported to range from less than 2 h at pH 7.4 to 7 h at pH 5.1.18
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It has been speculated that the exact mechanism of hydrolysis of poly (amino esters) may involve
attack by both the free hydroxyl ion and intramolecular nucleophilic amines, though the latter
effect is most likely less significant in polymer 1 because of the hindered reactivity of tertiary
amines in the polymer backbone.30, 31 The degradation rate of polymer 1-based LbL thin films,
also more rapid in basic environments, is influenced by the rate of diffusion of the reactant
hydroxyl species from the bulk aqueous phase to the film surface, the rate of hydrolysis of the
immobilized species on the film surface, and the rate of diffusion of the hydrolysis products from
the film surface into the bulk. Further, degradation of polymer 1-based films may also be
influenced by diffusion and reaction within the bulk of the film. However, despite these
complexities film degradation behavior at all pH conditions was observed to be linearly
proportional to the concentration of hydroxyl ion species in the aqueous (bulk) environment,
suggesting that the degradation behavior may be modeled as pseudo-first-order. A pseudo-first-
order reaction rate constant, kobs, relating the film degradation rate to the concentration of free
hydroxyl ions, can be calculated from the degradation data at any pH. Using the degradation at
pH 7.4 as a basis, kobs was found to be equal to 3.3(5) x 106 A min M- . Further, using this
reaction rate constant, the degradation behavior at pH 6.2 and 5.1 can be accurately predicted to
within 10%. Utilitizing the highly tunable and predictable rate of degradation and drug release
from LbL thin films as a basis, we are currently working to develop constructs capable of more
complex, timed drug release profiles.
7.3.4 Drug Release from Degradable LbL Thin Films
To measure drug release from degradable LbL thin films, 3H-heparin loaded films were
constructed by adding of a known quantity of radiolabeled heparin to the deposition solution,
then constructing films as described above. 3H-heparin with the same molecular weight and
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chemical composition as the unlabeled heparin was chosen so as to most closely reflect the
deposition of the unlabeled species studied in all previous figures. 3H-heparin loaded films were
then immersed in 50 mL of buffer solution in a 200 mL sealed flask. At indicated time points, 1
mL samples of the buffer solution were extracted and analyzed for 3H-heparin content, and total
heparin release was determined by multiplying by the ratio of total to 3H-labeled heparin in the
original dipping solution. All release experiments were performed at least in duplicate, and
highly reproducible results were obtained (i.e., release profiles from multiple film samples were
quantitatively and qualitatively similar).
Figure 7.4(a) shows the heparin release profile at pH 7.4. Unlike the film degradation
profile, the drug release profile is nonlinear. During the first 100 minutes, a period of rapid drug
release is observed, most likely owing to the rapid release of material on the outermost layer of
the film (the terminal layer in all films is composed of the polyanion species). Following the
first 100 minutes, the drug release rate was observed to gradually decline until effectively
approaching zero over the final 150 minutes of degradation. Figure 7.4(b) shows the heparin
release profile at pH 6.2. Again, a period of rapid drug release from the outermost layer of the
film was initially observed, followed by steadily declining drug release rates over the final 70-
80% of the degradation period. Taken together with Figures 7.2(b) and 7.3, these data suggest an
interesting hypothesis with respect to the composition and drug release properties of degradable
heparin-loaded thin films. The quantity of heparin in each layer of the progressively growing
film appears to increase exponentially with the number of bilayers. As a result, we postulate that
the films are heavily loaded with heparin in the outermost layers and only sparsely loaded in the
innermost layers (Figure 7.2(b)). The exposure of heparin-loaded films to the degradation buffer
solution appears to result in the rapid release of the thick, outermost heparin layer, followed by
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the steady release of heparin from adjacent, underlying layers as the film degrades from the top-
down. After 40-50% of the film has degraded, the remaining intact film is composed of
increasingly thinner layers, which release decreasing amounts of drug with time.
For a more complete description of the composition and drug release properties of these
systems, one must also consider that, despite nonlinear growth and drug release properties, film
thickness was observed to decrease linearly with time. This suggests that polymer 1 is evenly
dispersed throughout the films, without regard to the thickness of a particular bilayer. This may
be attributable to the ability of polymer 1 to diffuse substantially during the film construction
process, effectively suppressing any variations in its concentration with respect to position within
the film. Interestingly, this observed behavior closely reflects the mechanistic hypothesis first
postulated by Voegel, Schaaf, and coworkers. In systems containing biologically-derived
polyanions (e.g., hyaluronan) similar in structure to heparin, they observed film growth behavior
that can be briefly described as follows. Upon each dipping step, the polycation was observed to
diffuse into and throughout the entire film. The polycation could then diffuse out toward the
surface of the film during each successive rinsing step. As the polycation continues to diffuse
out of the film during the polyanion dipping step, it encounters the incoming polyanion, forming
a new layer. The amount of material in each successive layer is proportional to the amount of
polycation diffusing out of the film during the build-up step, and thus the thickness of each
successive layer grows "exponentially". 26-29 Interestingly, dye-labeling experiments performed
on these systems suggest that the polyanion is not able to diffuse throughout the film as the
polycation does, resulting in films composed of stratified layers of polyanion of increasing layer
thickness and a homogeneous concentration of diffuse polycation. 29
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Our analysis of the polymer 1/heparin system appears to support this mechanistic
hypothesis of exponential growth and interlayer diffusion. Namely, the combination of nonlinear
growth and release with linear degradation suggests that the quantity of heparin increases with
increasing numbers of bilayers while the concentration of the degradable polycation does not
vary with position. Further, our previous atomic force microscopy (AFM) studies involving the
polymer 1/PSS system indicate that surface roughness values of partially eroded films (RMS
roughness = 6.9 nm) were less than the thickness of a single bilayer (-10 nm) and were
consistent over 1 glm 2 portions of the films. 20  Nevertheless, it remains possible that an
alternative degradation mechanism may be controlling the observed behavior. In light of this, we
are currently exploring the deposition and degradation of polymer 1-based thin films, as well as
the possible interlayer diffusion of various species within these constructs, in greater detail with
the aim of better understanding and possibly augmenting the mechanistic hypothesis described
above.
In summary, the data presented in Figure 7.4 provide interesting clues about the
architecture of polymer 1/heparin LbL films and a tool for improving the design and drug release
profiles from these constructs.
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Figure 7.4. 3H-Heparin release from degradable thin films as a function of pH.
Results show release from (polymer 1/heparin)20 thin films at (a) pH 7.4 and (b) pH 6.2.
One milliliter samples were extracted from the degradation buffer solution every thirty
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minutes and DPM (disintegrations per minute) values were converted to cumulative
micrograms of heparin released using equation (1). Error bars indicate one standard
deviation in the measured DPM values.
7.4 Summary
In this chapter, we have examined the construction, degradation, and drug release
properties of degradable LbL thin films containing a series of model therapeutic polysaccharides
alternately deposited with a degradable, cationic poly (P3 amino ester) (polymer 1). Twenty
bilayer degradable films, deposited on nondegradable (LPEI/PSS)lo base films to promote
uniform adhesion, appear to grow exponentially during the deposition process, with the resultant
films exhibiting consistent thickness and surface roughness. Films exhibited linear degradation
profiles following an initial swelling period, where both the rate of degradation and the duration
of the swelling period were proportional to the concentration of hydroxyl ions in the degradation
environment. Degradation kinetics of these polymer 1-based films can be predicted (±10%) at
various pH conditions using a highly simplified, pseudo-first-order kinetic model. Finally,
heparin release from degradable LbL thin films was nonlinear, instead exhibiting distinct
regimes which we believe may correspond to the degradation of layers of decreasing thickness
from the top-down. Our data provide interesting information about the morphology and
architecture of these degradable LbL systems and represents a platform from which we may
explore the controlled release of other drug types (i.e., proteins or small molecules). Further, as
the LbL technique allows for a high degree of control over film thickness and spatial
composition, we may eventually be able to use this technique for the fabrication of controlled
release systems capable of administering complex, multi-dose or multi-drug schedules from
systems ranging from implantable devices to circulating particles.
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Chapter 8: Hydrolytically degradable layer-by-layer thin
films: Controlling interlayer diffusion to achieve sustained,
multi-agent release
Reproduced in part with permission from Wood, K.C.; Chuang, H.F.; Batten, R.D.; Lynn, D.M.;
Hammond, P.T. Controlling interlayer diffusion to achieve sustained, multi-agent delivery from
layer-by-layer thin films. Proc. Natl. Acad. Sci. USA 103, 10207-10212 (2006). Copyright 2006
National Academy of Sciences USA.
8.1 Introduction
The ability to engineer surfaces which present multiple functionalities when and where
they are needed could lead to important advances in electro-optical devices, separations, and
biomaterials. 1, 2 For example, in the area of drug delivery there is a need for low-cost "smart"
coatings that balance the ability to release complex drug profiles with the flexibility of
incorporation into a range of biomaterials, including those with large area sizes or non-planar
geometries such as pins, sutures, prosthetic bones, devices, and microparticles. The layer-by-
layer (LbL) electrostatic assembly technique is ideally suited for such applications because it
allows for absolute control over the order in which multiple functional elements are incorporated
into a growing film.3 However, the development of truly stratified, multicompartment LbL films
has been largely unsuccessful with many biomacromolecules because of the phenomenon of
interlayer diffusion, which results in blended structures lacking regular, controlled order.4 In this
chapter, we systematically probe a range of strategies designed to solve this problem by placing
physical barriers between various components within a single film to control interlayer diffusion.
We measure the effect of each type of barrier using a novel system consisting of a hydrolytically
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degradable polymer (Polymer 1, Figure 8.2) alternately deposited with a series of radiolabeled
polyelectrolytes. Top-down film degradation results in the release of components in a sequence
which reflects their relative positions in the film; thus, we can quantify the effects of various
barrier strategies aimed at limiting diffusion behavior. Using this approach, we uncover for the
first time a set of strategies which allow for the production of compartmentalized films capable
of passively releasing complex, tuned release profiles. In addition to uncovering fundamental
strategies to control interlayer diffusion in LbL films, this work may lead to important
applications in drug delivery by allowing for the fabrication of nanoscale materials coatings
capable of releasing sustained, multi-drug schedules from surfaces of virtually any composition
or geometry under physiological conditions.
As described in Chapter 6, the layer-by-layer (LbL) electrostatic assembly technique
entails the sequential adsorption of monolayers of oppositely charged polymers, colloids, or
other materials onto a solid substrate to form a cohesive, ionically crosslinked thin film.3
Multilayers can be deposited rapidly and inexpensively atop large area surfaces of any geometry
while allowing for nanometer scale control over a range of physical properties. 3, 5 Further, the
all-aqueous processing of LbL systems allows for the incorporation of sensitive biomolecules
such as proteins and DNA.6-10 More broadly, the technique can also be extended to include any
molecular species that is either charged or that can be encapsulated in a charged "carrier" (i.e.,
dendrimer, micelle, chaperone, or nanoparticle), thus making it possible to incorporate a wide
range of species without regard to molecular weight or intrinsic charge. On the basis of these
attributes, we hypothesized that degradable LbL systems based on a hydrolytically degradable
polyion such as Polymer 1 might be useful for a range of drug delivery applications, particularly
those which involve the release of complex schedules of drugs (Figure 8.1). 11-13 However,
146
though promising, this technology has been limited because of the inability to control the relative
positions and distributions of multiple species residing within a single film, resulting in highly
disorganized architectures. 14 The phenomenon responsible for this lack of control is referred to
as interlayer diffusion, the tendency of some species to diffuse throughout LbL systems during
the deposition process. All polyelectrolytes fall into one of two broad classes with respect to
interlayer diffusion: diffusing polyelectrolytes (for example, many polypeptides and
polysaccharides) are able to rapidly diffuse throughout LbL architectures during assembly,
resulting in poorly organized, blended structures, while non-diffusing polyelectrolytes (for
example, many synthetic, strong polyelectrolytes) cannot, resulting in spatially organized
structures wherein each deposited species is only able to interact with neighboring layers in close
proximity (usually 2-3 layers).4
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Figure 8.1. Schematic depicting hypothetical drug release profiles from hydrolytically
degradable LbL thin films with controlled architectures.
In this chapter, we examine the effects of various physical barrier strategies on both
diffusing and non-diffusing systems by tracking the release of radiolabeled polyelectrolytes
which exhibit either extensive diffusing behavior (heparin, HEP) or non-diffusing behavior
(dextran sulfate, DS) when incorporated into LbL structures. We show that covalently cross-
linked barriers deposited between the two labeled components can effectively block interlayer
diffusion, leading to compartmentalized structures. In contrast, even very large numbers of
ionically cross-linked (degradable or non-degradable) barrier layers cannot block interlayer
diffusion. By connecting interlayer diffusion with ultimate film architecture and release
properties, and by further studying the fabrication parameters which allow us to control
interlayer diffusion, we uncover a set of guiding principles which should significantly aid future
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attempts to build highly organized LbL structures. Further, the demonstration that these films
can release multiple agents either in parallel or in series may have important implications for
drug delivery and controlled release materials.
8.2 Experimental Methods
Materials. Polymer 1 (Mn = 10000) was synthesized as previously described.15 Heparin
sodium salt (Mn = 12500) was obtained from Celsus Laboratories (Cincinnati, OH). Dextran
sulfate sodium salt (Mn = 8000), poly (sodium 4-styrenesulfonate) (SPS, Mn = 1000000), poly
(allylamine hydrochloride) (PAH, Mn = 70000), and poly (diallyldimethylammonium chloride)
(PDAC, Mn = 100000) were obtained from Sigma-Aldrich (St. Louis, MO). Linear
poly(ethylenimine) (LPEI, Mn = 25000) and poly (acrylic acid) (PAA, Mn = 90000) were
purchased from Polysciences, Inc (Warrington, PA). Silicon wafers (test grade n-type) were
purchased from Silicon Quest (Santa Clara, CA). 3H-heparin sodium salt (1 mCi, 0.30 mCi/mg,
Mn = 12500) and 14C-dextran sulfate sodium salt (100 jtCi, 1.5 mCi/g, Mn = 8000) were obtained
from American Radiolabeled Chemicals, Inc. Radiolabeled and corresponding unlabeled
polymers were chosen with similar molecular weights and polydispersities in order to mimic the
behavior of the unlabeled species as closely as possible. All materials and solvents were used as
received without further purification.
General Considerations. A Harrick PDC-32G plasma cleaner was used to etch silicon
substrates (3 cm x 2 cm) following rinsing with methanol and deionized water and drying under
a stream of dry nitrogen. Layer-by-layer thin films were deposited using an automated Carl
Zeiss HMS Series Programmable Slide Stainer. Absorbances from growing films were
measured using Fourier Transform Infrared Spectroscopy (FTIR) using a Nicolet Magna IR 550
Series II Spectrometer. Zinc selenide substrates used for transmission FTIR analysis were
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prepared using the same method employed for silicon substrates. Ellipsometric measurements
for film thickness were conducted using a Gaertner Variable Angle Ellipsometer (6328 nm, 70'
incident angle) and Gaertner Ellipsometer Measurement Program (GEMP) Version 1.2 software
interface. The release of radiolabeled polymers was quantified using a Tri-carb liquid
scintillation counter (Model U2200). The amount of radiolabel in each sample vial was
measured using 3H, 14C, and dual counting protocols, each of which were shown to be both
consistent and highly accurate over a broad concentration range (30-100,000 DPM/mL) in
calibration experiments performed prior to drug release. Thermal cross-linking of (PAH/PAA)
films was performed by incubating films in a Yamoto DVS400 gravity convection oven at 2150
C for indicated time intervals.
Thin Film Fabrication. All films were constructed from dilute aqueous solutions (2-10
mM) using the alternating dipping method.3 All polymers used in degradable thin films were
prepared in 100 mM acetate buffer at pH 5.1 to avoid the conditions under which polymer 1
degrades rapidly (tl/2 > 10 h at pH 5.1, 370 C). 15 Nondegradable base layers were deposited from
dipping solutions of LPEI and SPS in deionized water pH adjusted to 4.25 and 4.75, respectively.
Deionized water used to prepare all solutions was obtained using a Milli-Q Plus (Bedford, MA)
at 18.2 MQ. For degradation experiments, 1X PBS buffer (pH 7.4, 137 mM NaC1, 2.7 mM KC1,
10 mM Na2HPO4) was used. Films used in this study were constructed on either silicon (for
ellipsometry and degradation studies) or zinc selenide (for transmission mode FTIR) planar
substrates. In all cases, degradable, polymer 1-based films were constructed directly on top of
ten bilayer, nondegradable base films containing linear poly(ethylenimine) (LPEI) and
sulfonated poly(styrene) (SPS) to ensure uniform adhesion to the substrate. Following
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deposition, films were removed from rinsing baths and dried thoroughly under a stream of dry
nitrogen to avoid premature degradation.
Thin Film Degradation Studies. All film degradation studies were performed as
follows. Films were immersed in 20 mL of the appropriate buffer solution in a screw top glass
vial and tightly sealed. At designated times, films were removed, dried thoroughly under a
stream of dry nitrogen, and thickness was measured using ellipsometry at ten predetermined
locations on the film surface (measurements were performed in triplicate). Following
measurements, films were reimmersed in buffer solutions and resealed.
Release Studies. For drug release experiments, radiolabeled LbL thin films were first
constructed by alternately depositing polymer 1 and the indicated radiolabeled drug(s).
Radiolabled deposition solutions containing 3H-heparin were prepared by combining 1 mL of 50
jiCi/mL 3H-heparin (0.30 mCi/mg, Mn = 12500) with 35 mL of 100 mM acetate buffer.
Unlabeled heparin (Mn = 12500) was added to bring the total concentration of heparin (unlabeled
plus labeled) to 2 mg/mL (1.5-2 giCi/mL 3H). Radiolabled deposition solutions containing 14 C-
dextran sulfate were similarly prepared by combining 14C-dextran sulfate (1.5 mCi/g, Mn =
8000), unlabeled dextran sulfate (Mn = 8000), and 100 mM acetate buffer to yield a total
concentration of dextran sulfate (unlabeled plus labeled) to 2 mg/mL (1 gCi/mL 14C). After
fabrication of the indicated films, drug release experiments were performed by immersing each
film in 50 mL LX PBS buffer in a 200 mL screw top vial. A 1 mL sample was extracted at
indicated time points and analyzed by adding 5 mL of ScintiSafe Plus 50% (Fisher Scientific,
Atlanta, GA) prior to measurement. Degradation vials were tightly capped between sample
extractions to prevent evaporation of the buffer solution. Raw data (disintegrations per minute,
DPM) were converted to micrograms (jig) of drug released using the conversion factor 2.2 x 106
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DPM = 1 gLCi, the specific radioactivity of the drug, and our knowledge of the ratio of total drug
to labeled drug in the deposition solution. 13
8.3 Results and Discussion
8.3.1 Build up and release properties of single component films
As a basis for these studies, we selected two radiolabeled polysaccharides, heparin (HEP)
and dextran sulfate (DS), which exhibit growth behavior associated with diffusive and non-
diffusive species, respectively.4 Figure 8.2(a) is a plot of the transmission mode FTIR
absorbance recorded from films containing either (polymer 1/Hep) or (polymer 1/DS).
Specifically, the absorbances from sulfonic acid groups at 1035 cm-1 (heparin) and 1017 cm'
(dextran sulfate) were measured after the deposition of indicated bilayers. All measurements
were taken from the same spot on the surface of the film in transmission mode on IR-transparent,
zinc selenide substrates. The inset shows the film thickness versus number of deposited bilayers
for a (polymer 1/DS) film. Both FTIR and ellipsometry demonstrate that the quantity of DS
incorporated into the film is linearly proportional to the number of adsorption cycles, a
commonly observed characteristic of many LbL systems. Linear build-up behavior is
characteristic of films whose constituent polyions adsorb directly onto the film surface during
each deposition step. Interlayer diffusion does not occur in these systems, which as a result form
spatially organized structures wherein species deposited at a given step are only able to interact
with neighboring species that are in close proximity (e.g., 2-3 layers). 3' 16,17 On the other hand,
heparin-based films exhibit an exponential increase in absorbance with increasing numbers of
adsorbed layers. Exponentially growing films, which are most commonly composed of
hydrophilic polyelectrolytes or biologically-derived materials (i.e., peptides and
polysaccharides), are poorly organized, blended architectures characterized by the complete "in"
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and "out" diffusion of adsorbing species throughout the growing film during the film's assembly
process.4, 18-20 A series of recent studies offer mechanistic explanations 20, 21 and direct evidence4
for this process, wherein a species deposited at a given step can reside in any position throughout
the film.
Figure 8.2(b) depicts the chemical structures of the repeat units of polymer 1, HEP, and
DS, the three polymers used in this study. Polymer 1 is a cationic, degradable poly (0 amino
ester) synthesized by the conjugate addition-step polymerization of a diamine and a diacrylate; it
represents one member of a library of over 2350 degradable poly (P amino esters) recently
synthesized and screened for their abilities to deliver DNA to cells in culture.2 2 Both model drug
compounds, HEP and DS, are polysaccharides that possess similar structural attributes, including
strong (sulfonic) acid groups on each repeat unit and relatively low molecular weights.
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Figure 8.2. Assembly of LbL films exhibiting linear or exponential growth.
(a) A plot of FTIR absorbance versus number of thin film bilayers demonstrates layer-by-
layer assembly of (polymer 1/heparin) (diamond) and (polymer 1/dextran sulfate) (triangle)
films exhibiting exponential and linear growth, respectively. (Inset: Thickness versus
number of bilayers for (polymer 1/dextran sulfate) films.) (b) Chemical structures of
degradable polymer and model drugs used in this chapter.
To better understand the degradation and release behavior exhibited by the two model
polyelectrolytes, we simultaneously measured release and degradation of single component films
containing each species. Figures 8.3(a) and 8.3(b) show degradation and release from 20 bilayer
(polymer 1/HEP) and (polymer 1/DS) systems, respectively, following immersion in PBS buffer
at pH 7.4. As previously documented, complete degradation and consequent release from
(polymer 1/HEP) systems occurred within 20 hours. Film thickness was observed to decrease
linearly following a brief swelling period of 0.5-2.0 h on first exposure to aqueous solution. 13
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DS-based films exhibited similar degradation and release behavior, though with kinetics
approximately five-fold slower than their HEP-based counterparts. The initial release observed
in both cases within the first few hours of degradation likely reflects passive release from the
surface, as the outermost layer of each film consists of the labeled compound. The fact that this
effect is more pronounced in the case of heparin likely reflects the presence of interlayer
diffusion, which results in a thick outer layer of diffusible material at the film surface.4
Interestingly, in both cases film thickness was observed to decrease linearly with time; further,
the apparent roughness of the film surface, taken from the standard deviation in film thickness
measured at 10 predetermined spots on the surface, was observed to remain constant, or even
decrease, with time. Taken together, these data suggest top-down surface erosion of the films;
one would anticipate that patchy or bulk degradation would result in a much larger standard
deviation and nonlinear degradation behavior. (Recent AFM investigations also provide further
physical support to the mechanism of top-down degradation. 11' 23) Given the linear degradation
and surface erosion observed in both sets of thin films, the vastly different kinetics of
degradation and release exhibited by these two systems reflect differences in film organization,
wherein the diffusive character of HEP contributes to loose gradient films with larger quantities
of HEP in the top layers, in comparison to their relatively more stratified, and more densely ion-
crosslinked DS counterparts that have a constant distribution of DS throughout the film.
155
1200
1000
C,
u. 800
IZ-
E 400
200
0
25
Time (h)
(a)
1000
900
800
700
600
500
400
300
200
100
0
50 100
Time (h)
9
8
7
a6 D
CD
30
2 
-,2 •
1
0
150
(b)
Figure 8.3. Degradation (square) and drug release (triangle) from single component films.
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To further verify that release occurs by means of surface erosion, and to explore the
relationship between interlayer diffusion and release properties of degradable LbL constructs, we
constructed a series of 20, 50, and 80 bilayer films containing either (polymer 1/HEP) (Figure
8.4(a)) or (polymer 1/DS) (Figure 8.4(b)). For the case of (polymer 1/HEP) systems, the release
behavior reflects intuition for the case of an exponentially growing system with top-down
degradation behavior. The slope of the release curve differs dramatically between films of
varying thickness, a reflection of the fact that exponentially growing systems result in the
formation of disorganized films with increasing amounts of the diffusible species (HEP) at each
deposition step (initial release rates of 0.4, 3.7, and 7.9 pgg/cm2 h were observed for 20, 50, and
80 bilayer films, respectively). Moreover, each HEP-based system was observed to release its
contents rapidly (in less than 20 h) without regard to its thickness, again a likely reflection of the
fact that the majority of the model polyelectrolyte is contained in the upper layers following
multiple deposition cycles.4 In sharp contrast, release from (polymer 1/DS) films of increasing
thickness results in all cases in an initial phase of linear release followed by a "leveling off' as
degradation is completed. Interestingly, as might be expected for the case of top-down release
from a series of linearly growing films, we observed that all three films released DS at a
relatively equivalent rate during the linear release phase (release rates of 0.07, 0.06, and 0.08
gtg/cm2 h were observed for 20, 50, and 80 bilayer films, respectively), and that the duration of
this linear release phase was proportional to the number of deposited bilayers (20 h, 49 h, and 97
h for 20, 50, and 80 bilayer films, respectively). The slow release kinetics of these systems
likely reflects the higher effective ionic crosslink density of the thin films and much lower
interlayer diffusivity of the model polyelectrolyte within the multilayer matrix. Importantly,
these data suggest that the hydrolytic degradation of LbL systems can provide quantitative new
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insights into the architecture and organization of these films. Moreover, this demonstration
suggests that the duration of time over which release occurs can be broadly tuned in linearly
growing (non-diffusing) systems simply by changing the number of deposited layers.
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Figure 8.4 Release from 20 (diamond), 50 (square), and 80 (triangle) bilayer films versus
time.
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exhibiting linear growth (release is surface area normalized; error bars are small).
8.3.2 Controlling interlayer diffusion to modulate multi-agent release profiles
Having demonstrated the ability of hydrolytically degradable LbL thin films to act as a
probe to gain quantitative insight into film organization and architecture, we next sought to
evaluate a range of strategies to control the relative positions of multiple, labeled species within a
single film by constructing physical barriers to separate the two components. We constructed
films containing first 20-40 base layers of polymer 1/HEP, followed by a set of "barrier" layers
consisting of either polymer 1/SPS (degradable), PDAC/SPS (non-degradable), thermally cross-
linked PAH/PAA, or nothing at all, and finally a set of 20-40 surface layers of polymer 1/DS. In
similar fashion, we also constructed films identical to these, only with the order of the labeled
components reversed (DS base layers and HEP surface layers). See Figure 8.5.
Polymer l/DS Polymer 1/HEP
(Poly IISPS) ,ar
"warier" layers (PDAC/SPS)Ma,,t "r~ layers
(PAHPA A)~,Vr I
Polymer 1/HEP Polymer 1/DS
Figure 8.5. Schematic depicting strategies used to construct physical barriers to control
interlayer diffusion in multi-component films.
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As shown in Figure 8.6, when a base layer of polymer 1/DS was coated with a single
bilayer of PAH/PAA (covalently cross-linked for 20 min at 2150 C), followed by the deposition
of polymer 1/HEP, we observed a multi-stage, serial release of first the surface heparin followed
by the underlying DS. Thus, the use of a single covalently cross-linked PAH/PAA layer was
sufficient to separate the two components when deposited onto the surface of the linearly
growing polymer 1/DS system, as evidenced by the two-stage release profile. Following the
approximately 25 h time delay, underlying DS was released with a linear profile. Interestingly,
the average rate of DS release was approximately 60% slower than that observed in
corresponding films without covalently cross-linked barrier layers. This work constitutes the
first observation of such a two-part release profile from fully electrostatically assembled thin
film constructs; moreover, to our knowledge, this is the first demonstration of the use of
covalently cross-linked barrier layers to physically separate the constituents in a multi-
component degradable thin film. Additional experiments using single and multiple cross-linked
PAHIPAA barrier layers show that both the duration of the release delay and the rate of release
following this delay can be broadly controlled using this approach. For example, multiple layers
of (PAH/PAA) cross-linked for longer than 1.5 h (at 2150 C) virtually halted the release of all
underlying DS (no release of DS was observed for up to 45 days). This result may have
important and direct applications in drug delivery, as it suggests that both the timing and rate of
release of an underlying species can be broadly controlled using as little as a single cross-linked
bilayer. Interestingly, we also found that when the order of the two labeled components was
reversed (HEP as the base layer and DS as the surface layer) it was no longer possible to achieve
serial release of the two components using cross-linked spacer layers, suggesting that the nature
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of the base film onto which the cross-linked barrier layer is absorbed influences the final
properties of the barrier layer (Figure 8.7).
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Figure 8.6. Dextran sulfate (base layer, triangle) and heparin (surface layer, diamond)-
loaded layers separated by a single, cross-linked layer of (PAHIPAA) exhibit sequential
release.
(a) Fraction of mass released versus degradation time. (b) Fractional release rate versus
time.
0 5 10 15 20 25
Time (h)
Figure 8.7. A single cross-linked layer
release of underlying heparin.
30
of (PAHIPAA) does not significantly delay the
161
I
I 1
100
* Hep
+ Hep + (PAA/PAH)1
It i I i
Release of heparin-loaded films coated with a single layer of (PAH/PAA) cross-linked for
45 min at 2150 C (filled diamond) is compared with untreated heparin-loaded films (open
diamonds).
Remarkably, all of the non-covalent (noncrosslinked) barrier layers designed to
physically separate the HEP and DS systems (Figure 8.5) resulted in simultaneous release of
both components (see Figures 8.9-8.16). In most cases the barrier layers failed to even slow the
release of the initially deposited base layers (Figure 8.8). To further verify these findings, the
above series of films was repeated at a range of fabrication conditions (pH, ionic strength,
number of deposited barrier layers), yet all resulted in simultaneous, rapid release in every case
studied (data not shown). These data suggest that noncovalent, electrostatically-assembled
barrier layers cannot block interlayer diffusion and thus cannot be used to create
compartmentalized structures involving diffusive polyelectrolytes. This finding is particularly
interesting in light of a recent study which showed that compartmentalized films containing
linearly and exponentially growing regions could be constructed simply by depositing different
films directly on top of one other.24 The incongruities between this study and ours could be a
result of a number of factors, including different polymer systems, molecular weights, and
deposition conditions; moreover, they suggest that factors outside of the nature of growth that a
given system exhibits may powerfully influence the final film architecture.
To more clearly demonstrate the effect of barrier layers on the average release rate from
the aforementioned two-component systems, release rate is normalized and charted versus the
type of barrier layer used in Figure 8.8. In Figure 8.8(a), it is apparent that the average release
rate (taken as the average slope of the initial, linear portion of the release curve) of systems
composed of an underlying layer of linearly-growing DS can be broadly controlled using both
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multiple layers of a nondegradable system PDAC/SPS or as little as a single layer of cross-linked
PAH/PAA. Further, by tuning any of the parameters affecting the degree of cross-linking (e.g.,
cross-linking time, temperature, number of cross-linked layers), the release rate can be
dramatically altered (cross-linking times of greater than 1.5 h at 2150 C, as well as barriers
containing more than five cross-linked layers, resulted in one to two order of magnitude
decreases in release rate) (data not shown). Thus, milder cross-linking conditions (such as lower
temperatures) may allow for a greater degree of flexibility in tailoring release profiles. Further,
aqueous, chemical cross-linking techniques using common biochemical reagents such as
carbodiimides may represent a suitable alternative to thermal cross-linking when low
temperature fabrication is required. Nevertheless, these proof-of-principle studies suggest that
sampling a range of approaches to control the release of underlying species can yield effective
results, particularly when the underlying species lacks the ability to diffuse throughout the film.
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Figure 8.8. Normalized release rates from films coated with various blocking layers.
Normalized initial average release rate (pg/h-cm 2) from base films containing (a) dextran
sulfate and (b) heparin coated with no separation layers (control), or with a single layer of
(PAH/PAA) cross-linked at 2150 C for variable times, non-degradable (PDAC/SPS), or
degradable (Polyl/SPS). Initial average release rates were calculated from the average
slope of the linear portion of the mass released versus time curve during the first 50 h
(dextran sulfate) or 10 h (heparin) of degradation.
Taken together, the data in Figures 8.6-8.8 yield a set of interesting hypotheses with
respect to diffusion and release from multi-component, hydrolytically degradable LbL films.
First, when initially deposited layers contain a highly diffusible species such as HEP, subsequent
deposition of additional layers has little to no effect on its release, as the diffusible species is
likely able to migrate through even tightly interacting networks within the film, effectively
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ensuring that it always resides near the film surface.4 However, when initially deposited layers
contain a linearly growing species such as DS, subsequent deposition of new species can have a
significant impact on its release, as the linearly growing system provides a structural substratum
on which a tightly interacting network of barrier layers can be formed (which can then serve to
hinder its release during degradation by physically separating it from subsequently adsorbed
species). We demonstrate that a relatively simple understanding of the nature of build up and
diffusion within a given system can allow one to engineer stratified, multicompartment
architectures with complex release profiles, and that these profiles can be broadly controlled to
suit the demands of a particular application.
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Figure 8.9. Heparin (base layer, diamond) and dextran sulfate (surface layer, triangle)-
loaded layers, without dividing layers, sustain simultaneous release.
(a) Fraction of mass released versus degradation time (error bars are small). (b) Fractional
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Figure 8.11. Heparin (base layer, diamond) and dextran sulfate (surface layer, triangle)-
loaded layers, separated by (PDAC/SPS)so non-degradable dividing layers, sustain
simultaneous release.
166
1
C 0.8
0 .6
S0.4
LL 0.2
0
150 200
u
I L i
(a) Fraction of mass released versus degradation time (error bars are small). (b) Fractional
release rate versus time.
* Hep 4
ADS **44 * *O·
AILiA •
* 
A A
A
A
W
4)0
oU_
LL
40
Time (h)
25 50 75
Time (h)
(a) (b)
Figure 8.12. Dextran sulfate (base layer, triangle) and heparin (surface layer, diamond)-
loaded layers, without dividing layers, sustain simultaneous release.
(a) Fraction of mass released versus degradation time (error bars are small). (b) Fractional
release rate versus time.
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(a) Fraction of mass released versus degradation time (error bars are small). (b) Fractional
release rate versus time.
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Figure 8.14. Dextran sulfate (base layer, triangle) and heparin (surface layer, diamond)-
loaded layers, separated by 50 (PDAC/SPS) non-degradable dividing layers, sustain
simultaneous release.
(a) Fraction of mass released versus degradation time. (b) Fractional release rate versus
time.
8.4 Conclusions
In this chapter, we systematically probe a series of strategies designed to physically
separate multiple components within a layer-by-layer film by blocking interlayer diffusion. We
measure the effect of each type of barrier using a novel experimental system consisting of a
hydrolytically degradable polymer alternately deposited with a series of radiolabeled
polyelectrolytes. Using this approach, we uncover for the first time a set of strategies which
allow for the production of compartmentalized, or stratified, films capable of releasing complex,
tuned release profiles. In particular, we show covalently cross-linked barriers can effectively
block interlayer diffusion, leading to compartmentalized structures, while even very large
168
numbers of ionically cross-linked (degradable or non-degradable) barrier layers cannot block
interlayer diffusion. Perhaps most interestingly, we demonstrate that wide ranging materials
properties can be obtained from a single, relatively simple set of materials by judiciously
applying strategies to control interlayer diffusion. Combining the attributes of the LbL
processing technique - which allows for the rapid, all-aqueous, conformal, highly uniform and
tunable fabrication of nanoscale coatings - with the ability to spatially order active agents and
control release kinetics for multiple species may yield significant new opportunities in drug
delivery, separations, electro-optical materials, and other fields.
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Chapter 9: Electroactive controlled release thin films
9.1 Introduction
Recently, great interest has centered on the development of 'smart' controlled release
systems capable of administering drugs in response to external stimuli such as electric or
magnetic fields for use in applications such as controlled release implants ('pharmacy-on-a-
chip'). 1-3 Toward these goals, microfabricated devices have been developed which make use of
micrometer-scale pumps, channels, and wells to deliver drugs on demand.1-5 However, while
these technologies have resulted in encouraging new treatment possibilities, several challenges
still remain. For example, the direct integration into non-planar, functional or structural implants
such as arterial stents, medical sutures, and bone prostheses is challenging, as photolithographic
and micromachining techniques are primarily developed for planar, silicon-based substrates. 6
Further, the multi-step processing of these devices can be both time consuming and expensive. 7
In this chapter, we extend the concept of layer-by-layer (LbL) thin films for controlled
release applications to include a new class of films which degrade to release their contents in
response to a small applied voltage (1.25 V). These "active" controlled release systems possess
many of the benefits of LbL films described in Chapters 6-8 (e.g., ability to conformally coat a
range of substrates, nanoscale control over various architectural features, and all-aqueous
processing); moreover, they also allow for external control of drug release through
electrochemical modulation of film stability using an electroactive component that is both non-
toxic and approved by the US FDA for use in humans.
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Electroactive thin films are constructed using the layer-by-layer (LbL) directed self-
assembly technique which, as previously described, utilizes the alternating adsorption of
materials containing complementary charged or functional groups onto a solid substrate to form
thin films. 8 This method can be used to create highly tunable, conformal thin films with
nanometer-scale control over film composition and structure. The only criteria for inclusion in
an LbL thin film is that the species of interest either possess, or that it be encapsulated in a
'carrier' species (i.e., nanoparticle, micelle, dendrimer, etc.) that possesses the desired
complementary functional group. Thus, a wide range of components including polymers,
proteins, nucleic acids, small molecules, and nanoparticles have been incorporated into these
assemblies, which can further be constructed in a range of interesting geometries and patterns. 9'
10 As a result of this versatility, LbL thin films have been used in a variety of drug delivery
applications, most notably as coatings that can release drugs passively 1-13 or in response to
environmental changes such as pH or ionic strength.14-
22
The electroactive component of films described in this chapter is Prussian Blue (PB), a
non-toxic, FDA-approved inorganic iron hexacyanoferrate compound that is well known for its
electrochromic,23 electrochemical, 24 and magnetic properties. 25 PB exhibits a number of stable
oxidation states known colloquially as Prussian White (PW), Prussian Blue (PB), Berlin Green
(BG), and Prussian Brown (PX), in order of increasing oxidation state. These states are all
negatively charged with the exception of PX, which is neutral. 26 PB can be synthesized in the
form of polydisperse, anionic nanoparticles (median size 4-5 nm) which are stable in aqueous
solution. 27 Applying a potential of +1.25 V (compared to SCE) switches these materials between
the PB (negative) and PX (neutral) states.26
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Here, we demonstrate that by applying a low voltage to PB nanoparticle-based LbL thin
films, and thus changing the PB oxidation state from negative to zero-valent, we can induce
rapid film destabilization and controlled release of the film's components. This destabilization is
believed to be based on the loss of electroneutrality occurring within the film following the PB to
PX transition, resulting in the repulsion of adjacent, like-charged layers. Destabilization is
associated with swelling and then release of the film's components into solution, and we quantify
this controlled release using a model, radiolabeled drug (14C-dextran sulfate). We further show
that this release is well-controlled; that is, removal of the oxidizing potential results in
restabilization of the remaining film. Finally, as a measure of biocompatibility we demonstrate
that PB particles exhibit no measurable toxicity on a panel of mammalian cell lines at
concentrations up to 1.0 mg/mL. Together, this technology represents a new robust, inexpensive,
and versatile platform for the fabrication of nanostructured, field-activated (remote-controlled)
drug delivery systems.
9.2 Experimental Methods
Materials. Dextran sulfate sodium salt (Mn = 8000) was obtained from Sigma-Aldrich
(St. Louis, MO). 14C-dextran sulfate sodium salt (100 gCi, 1.5 mCi/g, Mn = 8000) was obtained
from American Radiolabeled Chemicals, Inc (St. Louis, MO). Radiolabeled and corresponding
unlabeled polymers were chosen with similar molecular weights and polydispersities in order to
mimic the behavior of the unlabeled species as closely as possible. Linear poly(ethylenimine)
(LPEI, Mn = 25000) was received from Polysciences, Inc. FeC12, potassium ferricyanide, and
KCI were purchased from Aldrich. All materials and solvents were used as received without
further purification.
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Synthesis of PB nanoparticles. Briefly, 35 mL of 10 mM aqueous FeC12 (Aldrich) was
added dropwise to an equivalent volume of 50 mM potassium ferricyanide (Aldrich) and 50 mM
KC1, agitated for 1 min, and filtered continuously with deionized water (with magnetic stirring)
against a 3000 Da MWCO regenerated cellulose membrane. Permeate solutions (containing ten
or more equivalent volumes) were yellow, suggesting that only the excess potassium ferricyanide
along with a trivial amount of PB may have passed through the membrane. The retentate
solution was collected, pH adjusted to 4 by addition of potassium hydrogen phthalate buffer, and
used immediately in LbL assembly. 27
Preparation of electrolyte solutions. LbL films were assembled on conducting ITO-
coated glass substrates (Delta Technologies, 0.7 cm x 5 cm, 6 U/square) for profilometry,
deconstruction, and drug release studies. ITO-glass substrates were cleaned via ultrasonication
in dicholormethane, acetone, methanol, and deionized water for 15 min each, followed by a 5
min oxygen plasma etch (Harrick PCD 32G) to ensure that the surfaces were clean and abundant
in hydroxyl groups. Dextran sulfate and LPEI dipping solutions were prepared at concentrations
of 10 mM with respect to the polymer repeat unit in acetate buffer (100 mM, pH 5.1) and
deionized water (pH 4.25 by addition of HC1), respectively. Deionized water used to prepare all
solutions was obtained using a Milli-Q Plus (Bedford, MA) at 18.2 MO.
Thin film deposition. LBL films were constructed as follows according to the alternate
dipping method using an automated Carl Zeiss HMS Series Programmable Slide Stainer.8
Briefly, pretreated substrates were submerged in an LPEI dipping solution for 10 minutes
followed by a cascade rinse cycle consisting of three deionized water rinsing baths (15, 30, and
45 seconds, respectively). Substrates were then submerged in a PB dispersion for 10 minutes
followed by the same cascade rinsing cycle, and the entire process was repeated as desired to
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construct (LPEI/PB) films with desired numbers of layer pairs. Tetralayer films containing
LPEI/dextran sulfate/LPEI/PB were constructed using the same general protocol; however, in
this case, the PB dipping step alternated with a dextran sulfate dipping step (10 min with cascade
rinse cycle). Following deposition, films were immediately removed from the final rinsing bath
and dried thoroughly under a stream of dry nitrogen gas. Film thickness and deconstruction
experiments on conducting ITO-glass substrates were conducted using a Tencor P10
profilometer by scoring the film and profiling the score. A tip force of 5 mg was used to avoid
penetrating the underlying ITO film.
Electrochemical degradation of thin films. Electrochemical deconstruction studies
were performed using an EG&G 263 A potentiostat/galvanostat. The electrolyte was a 10 mM
KCI solution. Approximately 0.3 cm 2 was used, the reference electrode was a K-type saturated
calomel electrode, and the counter electrode was a piece of Pt foil (2.5 cm x 2.5 cm).
Drug release. For drug release experiments, films were formed using a radiolabeled 14 C-
dextran sulfate sodium salt (100 gCi, 1.5 gCi/mg) dipping solution at a concentration of 4
lgCi/mL. The LBL deposition procedure was then performed as described above. Following
deposition, 14C-dextran sulfate labeled films were immersed in 100 mL of 10 mM KC1, and
electrochemical deconstruction was performed by applying square wave potentials, also as
described above. In all cases, films were first immersed for 10 min prior to application of
potential, and no passive release was observed. A 1 mL sample was extracted at indicated time
points and analyzed for radioactive 14C content by adding 5 mL of ScintiSafe Plus 50% (Fisher
Scientific, Atlanta, GA) prior to measurement. Raw data (disintegrations per minute per mL,
DPM/mL) were converted to micrograms per mL (gtg/mL) of 14C-dextran sulfate using the
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conversion factor 2.2 x 106 DPM = 1 jiCi = 0.67 mg 14C-dextran sulfate. Finally, the total
dextran sulfate release from a single film was calculated according to the following equation:
i-1
M, = Ci xVi + (lmL)Z Cj (1)
j=1
where Mi ([tg) is the total cumulative mass released from the film as of measurement i, Ci
(ptg/mL) is the concentration of sample i, Vi (mL) is the total volume of the deconstruction bath
i-I
prior to measurement i, and (1mL)Z Cj is the total mass in previously extracted samples.
j=I
Cell viability. Cell viability assays were performed in triplicate using the following
protocol. All materials, buffers, and reagents were sterilized prior to use. Cell culture reagents
were purchased from Invitrogen Corporation (Carlsbad, CA) and MTT viability assay kits were
obtained from American Type Culture Collection (Manassas, VA). Focus HCC cells were
grown in 96-well plates at an initial seeding density of 5000 cells/well in 150 gL/well of growth
medium (90% modified Eagle's medium supplemented with 10% fetal bovine serum, 100
units/mL penicillin, and 100 gLg/mL streptomycin, 0.1 mM non-essential amino acids, 1 mM
sodium pyruvate, and 2 mM L-glutamine). HeLa cells were grown in 96-well plates at an initial
seeding density of 10000 cells/well in 150 tL/well of growth medium (90% modified Eagle's
medium supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 jig/mL
streptomycin, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, and 2 mM L-
glutamine). Cos-7 cells were grown in 96-well plates at an initial seeding density of 15000
cells/well in 150 LL/well of growth medium (90% Dulbecco's modified Eagle's medium
supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 gLg/mL
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streptomycin). After seeding, cells were allowed to attach and proliferate for 24 h in an
incubator (370 C, 5% CO2). A sterile, 10X concentrated PBS buffer solution was added to an
aqueous suspension of PB nanoparticles to yield a final solution containing 1.125 mg/mL PB,
137 mM NaCl, 2.7 mM KC1, and 10 mM Na2HPO4 at pH 7.4. Growth media were removed
from cells and replaced with the above suspension of PB particles diluted in Opti-MEM
(Invitrogen) at concentrations ranging from 0 mg/mL to 1.0 mg/mL PB. In parallel, cells were
also incubated with carrier solutions alone (Opti-MEM plus an equivalent concentration of PBS
without PB particles) to account for toxicity associated with the carrier solution only. Cells were
incubated with the solutions for 4 h, after which solutions were removed and replaced with
growth media. After 72 h, cell metabolic activity was assayed using the MTT cell proliferation
assay kit (ATCC, Manassas, VA). Initially, a 10 gL aliquot of MTT assay reagent was added to
each well. After incubating for two hours, 100 gL of detergent reagent was added. The plate
was then covered and left in the dark for 4 h, after which optical absorbance was measured at
570 nm using a SpectraMax 190 microplate reader (Molecular Devices, Sunnyvale, CA).
Background (media plus MTT assay reagent plus detergent reagent with no cells present) was
subtracted from the value of each well, and all values were normalized to the value of control
(untreated) cells. In similar fashion, the toxicity of an equivalent amount of PBS buffer in Opti-
MEM (with no PB) was calculated. Values reported in Figure 9.8 represent the normalized
viability of PB-treated cells divided by the normalized viability of cells treated with equivalent
amounts of pure PBS (to account for the toxicity of PBS itself).
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9.3 Results and discussion
9.3.1 Fabrication of electroactive thin films
Figure 9.1(a) outlines the process for constructing electroactive LbL thin films based on
PB. A glass substrate coated with a conducting film of indium tin oxide (ITO) is first dipped in a
solution containing a cationic drug or drug-containing 'carrier' species, then rinsed in deionized
water. Next, the substrate is dipped into an aqueous PB solution at pH 4 and rinsed again in
deionized water. The process is repeated to build up a multilayer nanocomposite film with
desired properties (see Experimental Methods). Controlled film deconstruction occurs upon the
application of an electrochemical potential of 1.25 V, "switching" PB to the neutral PX state and
releasing the encapsulated species. Removing the potential reduces the particles back to the
anionic PB state, allowing one the ability to switch the assembly back and forth between stable
and unstable states.
Figure 9.1(b) depicts the structure of 'soluble' PB, KFe"'[Fe"(CN) 6]. Potassium
inclusions in this form of PB can dissociate in aqueous solutions, resulting in a net negative
charge on the particle surface which renders nanoparticles stable in solution. PB nanoparticles
are formed via the room temperature, aqueous-phase reaction that occurs upon the addition of a
molar excess of potassium ferricyanide to iron(II) chloride (see Methods). This synthesis and
purification procedure yielded dark blue, aqueous suspensions that were stable in the absence of
sonication or chemical stabilizers.
Figure 9.1(c) shows the linear build-up of the tetralayer system containing linear
poly(ethylenimine) (LPEI)/dextran sulfate/LPEI/PB used in this study (measured by profilometry
and UV-Visual spectroscopy). Tetralayer systems, rather than traditional bilayer systems, were
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used in order to encapsulate and release 14C-dextran sulfate (DS), our negatively charged model
drug species. The thickness of an average tetralayer was 4.2 ± 0.6 nm. (This value reflects the
average of five data points taken at various positions on the surface of the film.) Films were
observed to grow linearly in thickness with increasing numbers of layers. The linear growth
behavior observed in these systems may have important implications for the controlled delivery
of precise quantities of drugs, as the thickness (and mass) of a given layer can be precisely
predicted with no dependence on the thickness of the underlying film, resulting in facile control
over drug payloads.
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Figure 9.1. Fabrication of LbL nanocomposite thin films based on PB.
(a) Generalized schematic detailing the assembly and deconstruction of drug-containing PB
nanocomposites. (b) Structure of PB. (c) Absorbance at 700 nm versus number of
deposited tetralayers for the (PBILPEIIDSILPEI) system as determined by UV-Visual
spectroscopy. (Insert: Film thickness versus number of deposited tetralayers for the
(PB/LPEI/DS/LPEI) system as determined by profilometry. Measurements were
performed at five predetermined spots on the surface of the films, and error bars represent
one standard deviation in measured values.)
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9.3.2 Electroactive degradation of films
Figure 9.2 shows the deconstruction of (LPEI/DS/LPEI/PB) 30 tetralayer films under the
influence of an applied voltage held constant at 1.25 V, as monitored by UV-Visual spectroscopy
(PB exhibits an absorbance maximum at - 700 nm). Absorbance from PB-containing films was
observed to decrease with increasing amounts of time at 1.25 V (Figure 9.2(a)). Quantitatively,
absorbance at 700 nm was observed to decline rapidly during the first 5-10 minutes, reaching a
value equal to 54% of that of the original film by 10 minutes (see Figure 9.2(b)). Thereafter,
absorbance continued to decrease, reaching a value of 38.5% of the original film by 20 min,
18.2% by 60 min, and 10.4% by 90 min. Absorbance measurements taken from a control film (0
V) showed no decrease in color, suggesting that PB loss is directly related to film instabilities
that are stimulated by the applied potential. Further, control experiments using films containing
only LPEI and DS show that no degradation or drug release occurs in the presence of an applied
potential when PB is absent from the system, suggesting that film destabilization is mediated by
voltage-induced switching of PB (data not shown).
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Figure 9.2. Electrochemical deconstruction of PB-containing thin films.
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(a) Absorbance spectrum showing decreasing PB absorbance with increasing time at 1.25
V. (b) Absorbance (700 nm) versus time for films with (filled triangles) and without (open
triangles) an applied potential.
To measure the effect of an applied potential on film thickness, and specifically to
determine if PB loss correlated with deconstruction of the film, PB-containing films were
exposed to a constant potential of 1.25 V and thickness was measured with respect to time using
profilometry (Figure 9.3). In all PB-containing films studies, film thickness was observed to
decrease rapidly at early times (1-5 min) followed by a more gradual decrease at later times (5 -
60 min), kinetics which reflect the time scales for PB loss described above. Further, in all
systems, thickness was observed to decay until reaching 10-20% of the original film thickness,
suggesting that some residual material was remaining on the surface of the substrate. In
(LPEI/DS/LPEI/PB)30 tetralayer films, thickness decayed to 80% of the original film after 1 min
at 1.25 V, 50% after 5 min, and 20% after 60 min (not shown). In (LPEI/PB) 20 systems,
destabilization occurred on a more rapid time scale, reaching 43% in under 1 min and 20% in
under 4 min. The shorter time scales required for destabilization in (LPEI/PB)20 systems likely
reflects the fact that these films lose all cohesive electrostatic interactions following the PB to
PX transition, resulting in rapid deconstruction relative to (LPEI/PB/LPEI/DS)30 systems, which
retain some stable electrostatic interactions (from LPEI and DS) in the presence of an applied
potential.
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Figure 9.3. Normalized thickness of PB-containing films versus time at a constant potential
of 1.25 V.
(a) Total film thickness versus time with constant potential held at 1.25 V. (a)
(LPEI/DS/LPEI/PB)30 films; (b) (LPEI/PB)20 films. Error bars represent one standard
184
deviation of the measured thickness values at five predetermined locations on the surface of
the film. As such, error bars provide an indication of the surface roughness of films
(standard deviation of multiple thickness measurements taken at a single location was less
than 10 A).
9.3.3 Single and multi-film drug release
To determine if the electrochemical destabilization of PB-containing films causes drug
release into solution, we built films containing a radiolabled, model drug compound, 14C-DS.
Figure 9.4 shows that these systems release the drug rapidly following the application of
potential, with kinetics that are in agreement with film degradation. It appears on the basis of
this data that PB-containing films are quickly destabilized by an applied potential, resulting in
rapid film deconstruction and drug release. To verify that release occurs only in the presence of
an applied potential, we soaked films in a solution identical to those used in the deconstruction
experiments (10 mM KC1) and observed no significant drug release.
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Figure 9.4. Drug release from a single film held at a constant potential of 1.25 V.
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14C-Dextran sulfate release from (LPEI/DSILPEI/PB) 30 films. Films held constant at 1.25 V
(closed diamonds) or no applied potential (open diamonds; error bars are small) are
shown. All error bars represent one standard deviation in measured values.
The ability of PB-containing thin films to release their contents only in response to a
small applied potential suggests that these systems might be interesting materials for implantable
pharmacy-on-a-chip applications.' For example, existing patterning and machining techniques
could be used to array multiple films onto individually addressable electrodes on a single
substrate, and the application of a potential to individual films could result in the release of an
active species from one film at a time. As a simple proof of this concept, we placed two
(LPEI/DS/LPEI/PB) 30 films in a release bath, then applied a potential of 1.25 V to each film
individually. As shown in Figure 9.5, this results in the release of the contents of the first film
followed by the contents of the second film.
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Figure 9.5. Serial release from multiple films in a single solution.
(a) 14 C-Dextran sulfate release from two (LPEI/DS/LPEI/PB)3 0 films. A potential was
applied to one film for 10 min, followed by 10 min with no applied potential. Next, the
process was repeated with a second film in the same degradation bath. Periods during
which a potential was applied are shaded. All error bars represent one standard deviation
in measured values. (b) Release rate versus time for the films in part (a).
9.3.4 Reversible destabilization of a single film
To more closely examine the kinetics of film deconstruction, we measured drug release
from representative 30 tetralayer LPEI/ 14C-dextran sulfate/LPI/PB systems under the influence
of a square wave potential of 1.25 V for varying amounts of time. All films used in these studies
were deposited onto identical 2.45 cm 2, ITO-coated glass substrates from the same dipping
solutions in order to ensure uniform thickness and drug loading. Figure 9.6(a) shows the release
due to 10 s and 1 min square wave intervals at 1.25 V. Application of the oxidizing potential for
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very short intervals (10 s) is not sufficient to significantly destabilize the film, likely because
diffusion of polyelectrolytes out of the destabilized structure is the rate-limiting process (PB
redox switching times are less than 1 s). 27 Thus, only a relatively small amount of 14C-dextran
sulfate was released. A longer interval (1 min) at the oxidizing potential results in significantly
greater total drug release. Further, in both cases the drug release was observed to stop shortly
after removing the potential, suggesting that films can become restabilized. In Figure 9.6(b) the
drug release in response to differing time intervals at 1.25 V is shown. Films release
significantly more drug following 10 min and 30 min intervals than shorter 10 s or 1 min
intervals, an indication of the reversible nature of film destabilization. Further, 10 min and 30
min intervals result in similar quantities of drug release with similar kinetics (data not shown),
suggesting that all of the available drug was released within the first 10 min. This is in
agreement with the data in Figure 9.4, which shows that -10 min at a 1.25 V potential is
sufficient to achieve complete release from 30 tetralayer systems used in this study. To examine
the reversible nature of film destabilization in response to an applied potential, a single film was
exposed to two 1 min intervals at 1.25 V, separated by a 14 min interval with no applied
potential (Figure 9.6(c) and (d)). From this data, it is apparent that films are rapidly destabilized
in the presence of an applied potential, then restabilized when the potential is removed. This
process is reversible, as reapplication of a potential can again destabilize the film. Thus, the
stability (and drug release properties) of PB-based films can be precisely controlled
electrochemically. In drug delivery applications, this reversible stability may allow for fine-
tuned control over doses administered from implanted films.
Together, the data in Figure 9.6 suggests the following conclusions: (1) the process of
destabilization can be reversed by removing the oxidizing potential and reactivated by re-
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applying the oxidizing potential so long as each occurs prior to complete film deconstruction;
(2) diffusion of the film's components out of the destabilized film structure is a rate-limiting step
in drug release; and (3) deconstruction and release from 30 tetralayer systems studied in this
chapter is completed in fewer than 10 min when held at constant potential.
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Figure 9.6. Reversible destabilization of PB-containing thin films.
(a) 14C-Dextran sulfate release after applying potential for 10 s and 1 min intervals. (b)
Total 14C-dextran sulfate release from equivalent samples held at the oxidizing potential for
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varying times. (c) 14C-dextran sulfate release from a single film held at 1.25 V for 1 min
intervals at t = 0 and t = 15 min. (d) Release rate from film shown in (c). In all cases, error
bars indicate one standard deviation.
9.3.5 Surface analysis
An interesting phenomenon that we observed in all cases is that film thickness decreased
by only -80%, leaving behind a fraction of the film on the substrate surface even after holding
the oxidizing potential constant for long amounts of time (e.g., 1-2 h). We hypothesize that the
remaining material is composed of oxidized hydrophobic PX particles which aggregate at the
substrate-liquid interface. To investigate this phenomenon, we used Atomic Force Microscopy
(AFM). Before degradation, the film surface exhibits small, regular surface features that likely
reflect a monolayer of nanoparticles on the film surface. Following degradation, the film surface
becomes rougher, and larger aggregates become visible (data not shown). This data supports the
hypothesis that oxidized hydrophobic PX particles aggregate at the substrate surface following
degradation.
9.3.6 Toxicity of Prussian Blue
Finally, as a measure of the biocompatibility of PB nanoparticles, we measured their
toxicity on a panel of mammalian cell lines, including hepatocellular carcinoma (HCC), ovarian
cancer (HeLa), and kidney fibroblast (Cos-7) cells, using a conventional MTT assay. The MTT
assay measures the effect of added substances on cell growth and metabolism, and is commonly
used as an in vitro measure of toxicity.28 Interestingly, PB particles caused no observable
toxicity at all concentrations tested (up to 1.0 mg/mL) (Figure 9.7). These findings are not
entirely surprising, as PB is known to cause no adverse health effects in humans and was
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approved by the US FDA in 2003 for the treatment of radiation contamination and heavy metal
poisoning. 29
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Figure 9.7. MTT assay for cellular toxicity indicates that PB nanoparticles exhibit no
toxicity on three different cell lines at concentrations up to 1.0 mg/mL.
Error bars represent one standard deviation in measured values.
9.4 Summary
We have demonstrated a new approach for constructing nanostructured thin films capable
of releasing precise quantities of chemicals on demand in response to a small electrochemical
stimulus. Further, we have shown that the films are stable enough to release a fraction of their
contents, then restabilize upon removal of the applied potential. The LbL technique is
sufficiently general to allow for the incorporation of chemicals of any structure (small molecules,
macromolecules, charged and uncharged species, etc.) into these systems, alone or in conjunction
with a 'carrier' species.s8-1 As a simple proof of principle, we have studied the (LPEI/dextran
sulfate/LPEI/PB) system, in which the model chemical species of interest (dextran sulfate) is
alternately deposited (in conjunction with a 'carrier' species, LPEI) with the electroactive
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component, PB. Similar model drug species that are currently under study include heparin
sulfate and a range of charged proteins. 17 , 30 Finally, we have outlined a mechanistic hypothesis
to explain the deconstruction process occurring in these systems, whereby an electrochemical
signal oxidizes the nanoparticles to the PX state, resulting in loss of particle charge and
destabilization of the film through self-repulsion of the polycation species. We expect that these
electroactive controlled release thin films may find interesting applications in fields including
drug delivery, tissue engineering, medical diagnostics, analytical chemistry, and chemical
detection. Further, using the various thin film patterning techniques developed in recent years,
we suggest that these materials may eventually be arrayed to produce multi-drug or multi-dose
'smart' devices.'
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Chapter 10: Summary and future work
10.1 Summary
The main objective of the work in this thesis was to design new polymeric structures for
gene and drug delivery applications. An emphasis was placed on controlling both molecular
structure and supramolecular self-assembly behavior in these systems based on the hypothesis
that fine control over architectural features could yield superior properties as compared to
conventional, bulk materials.
In the first part of this thesis (Chapters 2-5), the design and synthesis of a family of
linear-dendritic "hybrid" polymers for gene delivery applications was described. These systems
are unique in that they possess multiple, complimentary functional domains which are assembled
in a modular fashion. Chapters 2-3 describe the initial design and characterization of these
systems, including: the divergent synthesis of hybrid polymers; hierarchical self-assembly of
polymers with plasmid DNA to yield small (. 150 nm), spherical, electrostatic complexes; the
targeted transfection of cells in culture; and the low cytotoxicity of hybrid polymers in vitro.1
Chapter 4 described a series of initial experiments toward the use of hybrid polymers for the
delivery of DNA vaccines, including the targeted, efficient transfection of dendritic cells in
culture as well as the elicitation of both primary and secondary, cellular and humoral responses
specific to an encoded transgene. Finally, Chapter 5 described an alternative synthetic approach
for hybrid polymers which is rapid (three steps, two days) and takes place at room temperature in
neutral pH, aqueous solutions. As a result, unlike the original divergent synthesis of hybrid
polymers, this new approach allows for the use of biological targeting ligands such as peptides,
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proteins, and antibodies. This method was utilized to synthesize hybrid polymers functionalized
with a tumor-homing peptide which can efficiently target and transfect cells expressing glucose-
regulated protein-78 kDa (GRP-78), a known tumor-associated antigen. Further, preliminary
results demonstrating the potential utility of these systems for targeted gene delivery to solid
tumors in vivo was shown.2
In the second part of this thesis (Chapters 6-9), the development of degradable layer-by-
layer (LbL) thin films was described. These systems, formed by the directed self-assembly of
systems containing charged or complementary functional groups onto a solid substrate, were of
interest for two major reasons. First, they are conformal and have the ability to coat virtually any
surface without regard to size, shape, or chemical composition. Second, the LbL technique
allows for absolute control over the order in which multiple components are deposited onto a
growing film, suggesting that the film composition and resultant release properties of one or
more species can be controlled. Following a brief overview of the LbL technique in Chapter 6,
Chapter 7 described an initial attempt to construct degradable LbL films using a hydrolytically-
labile poly (P3 amino ester). The thickness of these nanoscale thin films decreases linearly with
time at a rate that is proportional to the concentration of hydroxyl ions in solution, suggesting
that hydrolysis (rather than dissolution or decomplexation) controls film degradation. Further,
drug release occurs on time scales which are in quantitative agreement with film degradation. 3
In Chapter 8, the concept of drug release from hydrolytically degradable LbL films was extended
in several ways. First, it was demonstrated that the amount of drug incorporated into a film and,
in some cases, the duration of time over which a drug is released are proportional to the number
of adsorbed layers. Second, the effects of interlayer diffusion of drugs were explored in detail;
namely, a connection between interlayer diffusion, final film architecture, and drug release
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behavior was established. Third, the release of multiple drugs from a single film, both in series
and in parallel, was demonstrated. In particular, it was shown that the serial release of multiple
drugs requires that drug-containing layers be physically separated, a property which can be
controlled using cross-linked blocking layers.4 Finally, Chapter 9 explored an alternative means
of destabilizing LbL films based on an active, electrochemical stimulus. LbL films containing
Prussian Blue, an iron hexacyanoferrate material, can undergo reversible destabilization in the
presence of a small applied potential (1.25 V), resulting in drug release which can be precisely
controlled. The process of destabilization is reversible in these systems, and they are made from
active components which are both non-toxic and FDA approved for use in humans. 5 Together,
LbL systems which degrade by both hydrolytic and electrochemical means represent exciting
candidates for a host of drug delivery applications.
10.2 Future Work
The materials and methodologies developed in this thesis warrant further investigation in
several ways. In the area of hybrid polymer gene delivery systems, the new synthesis technique
described in Chapter 5 (linear dendritic coupling) should enable a range of new opportunities,
particularly involving the use of biologically-derived functional domains such as targeting
ligands. Four areas for future exploration are proposed below.
1. Pre-clinical animal studies. Preliminary studies demonstrating the promise of hybrid
polymer systems for both the in vivo delivery of DNA vaccines and direct tumor targeting should
be augmented with more comprehensive, large scale animal studies. In the former area, a more
thorough study of the activation of cell-based immune responses using hybrid polymers, an
investigation of the adjuvanting effects of these systems, and a study involving the use of these
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systems for protective vaccination against a robust, clinically-relevant disease challenge are each
warranted. In the area of direct tumor targeting, a large animal study exploring the use of
peptide-functionalized hybrid polymers for the delivery of both reporter (i.e. luciferase) and
"suicide" (i.e. Herpes simplex virus-thymidine kinase, HSVtk6) transgenes to solid tumors is also
warranted.
2. Engineering new functionalities. Hybrid polymers provide an excellent platform for
the testing of additional or modified functional domains, such as nuclear localization peptides,
membrane destabilizing peptides, and degradable polymer chemistries, which may significantly
enhance the activity of these delivery systems.7' Mechanistic studies on the effect of such
additions on targeting and intracellular trafficking of complexes, and ultimately on transgene
expression, would provide important insight into the behavior and engineering of these systems.
3. Toxin potentiation. A series of preliminary experiments conducted in collaboration
with the Wittrup group at MIT have explored the conjugation of hybrid polymers to single chain
variable fragments (scFv) that were engineered to bind to tumor-associated antigens. 9 These
conjugates will be used for the targeted delivery of both DNA and protein-based toxins to solid
tumors. In the former area, targeted gene delivery will be explored in a manner analogous to the
work described in Chapter 5. In the latter area, we will be studying the ability of hybrid
polymers to potentiate the toxicity of gelonin, a naturally-occurring toxin found in plants which
functions by cleaving ribosomal RNA. Gelonin is highly toxic in the cytosolic compartment of
cells, where studies have shown that even a single molecule of toxin can destroy an entire cell.
However, it is non-toxic in the extracellular environment and lacks a mechanism for cellular
entry. Thus, its use as a therapeutic requires that it be actively transported to the cytosol.10' 1 As
described in Part I, PAMAM dendrimers are known to be effective intracellular delivery agents
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because of their ability to promote endosomal escape via the proton sponge mechanism. 12 By
conjugating PAMAM dendrimers to an scFv that is selectively internalized by cells expressing
tumor-associated antigens, it may be possible to selectively potentiate the toxicity of co-
administered gelonin in tumors (using co-administration with either free gelonin or a gelonin-
scFv fusion protein). Preliminary experiments examining the synthesis and purification of scFv-
hybrid polymer conjugates and their ability to potentiate gelonin toxicity in vitro have yielded
promising results and warrant further exploration.
4. Product purification. Each of areas described above will benefit from the continued
development of purification protocols which allow for the isolation of pure samples of hybrid
polymers. In some cases, the products of linear-dendritic coupling reactions can be relatively
pure, obviating the need for extensive purification. However, it is clear that the isolation of pure
samples would allow for a more clear inference of structure-property relationships in these
materials, as well as potentially improved properties.
In the area of degradable LbL thin films, the studies described in Chapters 6-9
demonstrate the use of these systems for the controlled release of one or more species in
response to both passive (hydrolytic) and active (electrochemical) stimuli. A range of additional
studies are warranted, including investigations aimed at better understanding and manipulating
physicochemical properties of these systems as well as studies involving distinct therapeutic
applications. Three areas of primary emphasis are described below:
1. Approaching therapeutic applications. The studies described in this thesis shed light
on the fact that even subtle changes in drug or polymer structure and film assembly or
degradation conditions can significantly alter release properties of degradable LbL systems.
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Thus, future studies aimed at therapeutic applications of these systems should focus largely (if
not exclusively) on the encapsulation and release of relevant drug compounds in environments
that mimic physiological conditions, rather than model drug compounds in "unnatural"
environments (for example, buffered saline at room temperature). After studying the properties
of drug-containing film systems in vitro (with an emphasis on establishing desired drug release
kinetics and efficacy), studies should progress as rapidly as possible toward in vivo studies which
can both provide a more realistic appraisal of a system's therapeutic efficacy and also shed light
on important issues related to biocompatibility.
2. Understanding and manipulating physicochemical properties of degradable films. As
described above, we have observed that subtle factors regarding polymer structure, assembly
conditions, and other parameters can strongly influence final film properties.4  A large,
systematic study of the effects of a range of fabrication conditions on resultant film properties
should be undertaken in conjunction with quantitative analysis and physical/mathematical
modeling to better understand these phenomena. In addition to leading to a better understanding
of the film assembly process, these studies could reveal important factors which can be
manipulated to improve film stability and release behavior.
3. Multi-drug or multi-dose release from "stacked" or arrayed films. The LbL
technique allows for precise control over the order in which multiple components are
incorporated into a growing film. Thus, it may be possible to exploit this process to construct
multicompartment, striated structures comprised of "stacked" layers, each containing a different
drug component.13-15 The surface-mediated degradation of such a film could then lead to the
release of multiple drugs or doses in a predefined manner.16, 17 However, despite the simplicity
of this concept, it has been difficult to experimentally engineer systems with such properties.
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This is most likely attributable to the phenomenon of interlayer diffusion, a phenomenon which
results in the migration of one or more components throughout a film structure. In Chapter 8, a
strategy for controlling interlayer diffusion based on thermally cross-linked blocking layers was
discussed. However, the development of additional strategies to create striated film structures by
blocking interlayer diffusion is warranted, as the approach used in Chapter 8 involves high
temperatures and chemistries which are not compatible with a large number of drugs. An
alternative approach to "stacked" multicompartment films involves the patterning of surfaces
with multiple features possessing differential drug release properties.' 18 19 Such an approach
could also be used to achieve complex, multi-drug or multi-dose release profiles. Thus,
additional research exploring (1) techniques for controlling interlayer diffusion to create
multicompartment film structures capable of releasing multiple components, and (2) two-
dimensional patterning of multiple films with differential release properties are both warranted.
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